{"DataElement":{"publicId":"3914955","version":"1","preferredName":"Off-Treatment Study Follow-Up Therapeutic Procedure Discontinued Reason","preferredDefinition":"information related to the study follow-up during off-treatment._The reason for the discontinuation of protocol therapy.","longName":"PtOffStudyReasons","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"2195103","version":"1","preferredName":"Off-Treatment Study Follow-Up","preferredDefinition":"information related to the study follow-up during off-treatment.","longName":"OTX_STUDY_FU","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2206580","version":"1","preferredName":"Off-Treatment Study","preferredDefinition":"Off-Treatment; the phase of a protocol during which a patient does not receive treatment.:A type of research study that tests how well new medical treatments or other interventions work in people.  Such studies test new methods of screening, prevention, diagnosis, or treatment of a disease.  The study may be carried out in a clinic or other medical facility.  Also called a clinical trial.","longName":"C25601:C15206","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Off Treatment","conceptCode":"C25601","definition":"When a patient is not receiving therapy they are considered off treatment.  In clinical trials, a dosing schedule may require a patient to stop medication for a period of time, then resume, such as 28 days on and 7 days off.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Study","conceptCode":"C15206","definition":"Research conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects; includes development of new technologies, study of mechanisms of human diseases, therapy, clinical trials, epidemiologic, behavior, and health services research.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0428-FADE-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2177513","version":"1","preferredName":"Follow-up","preferredDefinition":"Monitoring a person's health over time after treatment.  This includes keeping track of the health of people who participate in a clinical study or clinical trial for a period of time, both during the study and after the study ends.","longName":"Follow-up","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Follow-Up","conceptCode":"C16033","definition":"The process by which information about the health status of an individual is obtained after a study has officially closed; an activity that continues something that has already begun or that repeats something that has already been done.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE29A78C-51FA-3A05-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":"Updated Concept Code AA","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008554","version":"1","preferredName":"Treatment/Off-treatment Reasons","preferredDefinition":"justification for or explanation of the administration or cessation of therapy.","longName":"TX_OTX_RSNS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2C9BE32-8BDB-649C-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ECF1FD80-8F8D-58A4-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3389970","version":"1","preferredName":"Therapeutic Procedure Discontinued Reason","preferredDefinition":"The reason for the discontinuation of protocol therapy.","longName":"Disc_Reas","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"176","valueDescription":"Patient experiences Grade 2 or greater SOS","ValueMeaning":{"publicId":"6144268","version":"1","preferredName":"Patient experiences Grade 2 or greater SOS","longName":"6144268","preferredDefinition":"Patient experiences Grade 2 or greater SOS","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"67DE9F08-0330-4E2A-E053-F662850A53D1","latestVersionIndicator":"Yes","beginDate":"2018-03-20","endDate":null,"createdBy":"LEEW","dateCreated":"2018-03-20","modifiedBy":"ONEDATA","dateModified":"2018-03-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"67DE9F08-0349-4E2A-E053-F662850A53D1","beginDate":"2018-03-20","endDate":null,"createdBy":"LEEW","dateCreated":"2018-03-20","modifiedBy":"ONEDATA","dateModified":"2018-03-20","deletedIndicator":"No"},{"value":"10","valueDescription":"Germinoma (Stratum 2) patients with PD and positive markers at the end of Induction chemotherapy.","ValueMeaning":{"publicId":"3422309","version":"1","preferredName":"Germinoma (Stratum 2) patients with PD and positive markers at the end of Induction chemotherapy.","longName":"3422309","preferredDefinition":"Germinoma (Stratum 2) patients with PD and positive markers at the end of Induction chemotherapy.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC3DFD79-2286-AE2F-E040-BB89AD4349B0","latestVersionIndicator":"Yes","beginDate":"2012-03-27","endDate":null,"createdBy":"WONGW","dateCreated":"2012-03-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BC3DFD79-229F-AE2F-E040-BB89AD4349B0","beginDate":"2012-03-26","endDate":null,"createdBy":"WONGW","dateCreated":"2012-03-27","modifiedBy":"ONEDATA","dateModified":"2012-03-27","deletedIndicator":"No"},{"value":"12","valueDescription":"Germinoma (Stratum 2) patients with any viable tumor (except mature teratoma) after second look surgery.","ValueMeaning":{"publicId":"3422310","version":"1","preferredName":"Germinoma (Stratum 2) patients with any viable tumor (except mature teratoma) after second look surgery.","longName":"3422310","preferredDefinition":"Germinoma (Stratum 2) patients with any viable tumor (except mature teratoma) after second look surgery.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC3DFD79-22A9-AE2F-E040-BB89AD4349B0","latestVersionIndicator":"Yes","beginDate":"2012-03-27","endDate":null,"createdBy":"WONGW","dateCreated":"2012-03-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BC3DFD79-22C2-AE2F-E040-BB89AD4349B0","beginDate":"2012-03-26","endDate":null,"createdBy":"WONGW","dateCreated":"2012-03-27","modifiedBy":"ONEDATA","dateModified":"2012-03-27","deletedIndicator":"No"},{"value":"13","valueDescription":"Radiotherapy cannot be initiated within 6 weeks after completion of Induction chemotherapy or within 31 days after second look surgery. (See Sections 15.2.3 and 15.2.4).","ValueMeaning":{"publicId":"3422311","version":"1","preferredName":"Radiotherapy cannot be initiated within 6 weeks after completion of Induction chemotherapy or within 31 days after second look surgery. (See Sections 15.2.3 and 15.2.4).","longName":"3422311","preferredDefinition":"Radiotherapy cannot be initiated within 6 weeks after completion of Induction chemotherapy or within 31 days after second look surgery. (See Sections 15.2.3 and 15.2.4).","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC3DFD79-22CC-AE2F-E040-BB89AD4349B0","latestVersionIndicator":"Yes","beginDate":"2012-03-27","endDate":null,"createdBy":"WONGW","dateCreated":"2012-03-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BC3DFD79-22E5-AE2F-E040-BB89AD4349B0","beginDate":"2012-02-28","endDate":null,"createdBy":"WONGW","dateCreated":"2012-03-27","modifiedBy":"ONEDATA","dateModified":"2012-03-27","deletedIndicator":"No"},{"value":"6","valueDescription":"Progressive disease and/or increasing markers at the end of Induction chemotherapy, following second look surgery or during radiation therapy.","ValueMeaning":{"publicId":"3422312","version":"1","preferredName":"Progressive disease and/or increasing markers at the end of Induction chemotherapy, following second look surgery or during radiation therapy.","longName":"3422312","preferredDefinition":"Progressive disease and/or increasing markers at the end of Induction chemotherapy, following second look surgery or during radiation therapy.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC3DFD79-22EF-AE2F-E040-BB89AD4349B0","latestVersionIndicator":"Yes","beginDate":"2012-03-27","endDate":null,"createdBy":"WONGW","dateCreated":"2012-03-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BC3DFD79-2308-AE2F-E040-BB89AD4349B0","beginDate":"2012-03-26","endDate":null,"createdBy":"WONGW","dateCreated":"2012-03-27","modifiedBy":"ONEDATA","dateModified":"2012-03-27","deletedIndicator":"No"},{"value":"8","valueDescription":"NGGCT (Stratum 1) patients with < PR after second look surgery or any viable tumor after second look surgery.","ValueMeaning":{"publicId":"3421708","version":"1","preferredName":"NGGCT (Stratum 1) patients with < PR after second look surgery or any viable tumor after second look surgery.","longName":"3421708","preferredDefinition":"NGGCT (Stratum 1) patients with < PR after second look surgery or any viable tumor after second look surgery.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC2DFBD3-1ED4-8513-E040-BB89AD4309ED","latestVersionIndicator":"Yes","beginDate":"2012-03-26","endDate":null,"createdBy":"WONGW","dateCreated":"2012-03-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BC2DFBD3-1EED-8513-E040-BB89AD4309ED","beginDate":"2012-03-26","endDate":null,"createdBy":"WONGW","dateCreated":"2012-03-26","modifiedBy":"ONEDATA","dateModified":"2012-03-26","deletedIndicator":"No"},{"value":"9","valueDescription":"NGGCT (Stratum 1) patients with positive markers at the end of Induction chemotherapy or who have < PR after Induction chemotherapy.","ValueMeaning":{"publicId":"3421710","version":"1","preferredName":"NGGCT (Stratum 1) patients with positive markers at the end of Induction chemotherapy or who have < PR after Induction chemotherapy.","longName":"3421710","preferredDefinition":"NGGCT (Stratum 1) patients with positive markers at the end of Induction chemotherapy or who have < PR after Induction chemotherapy.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC2DFBD3-1F1A-8513-E040-BB89AD4309ED","latestVersionIndicator":"Yes","beginDate":"2012-03-26","endDate":null,"createdBy":"WONGW","dateCreated":"2012-03-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BC2DFBD3-1F33-8513-E040-BB89AD4309ED","beginDate":"2012-03-26","endDate":null,"createdBy":"WONGW","dateCreated":"2012-03-26","modifiedBy":"ONEDATA","dateModified":"2012-03-26","deletedIndicator":"No"},{"value":"15","valueDescription":"Death","ValueMeaning":{"publicId":"3141242","version":"1","preferredName":"Death","longName":"3141242","preferredDefinition":"The cessation of life.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dead","conceptCode":"C28554","definition":"The cessation of life.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"90DEC4CC-5E17-3212-E040-BB89AD436EBB","latestVersionIndicator":"Yes","beginDate":"2010-09-22","endDate":null,"createdBy":"LUY","dateCreated":"2010-09-22","modifiedBy":"GDEEN","dateModified":"2023-12-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BC2DFBD3-1F6A-8513-E040-BB89AD4309ED","beginDate":"2012-02-28","endDate":null,"createdBy":"WONGW","dateCreated":"2012-03-26","modifiedBy":"ONEDATA","dateModified":"2012-03-26","deletedIndicator":"No"},{"value":"16","valueDescription":"Withdrawal of consent for any further data submissions","ValueMeaning":{"publicId":"3389971","version":"1","preferredName":"Withdrawal of consent for any further data submissions","longName":"3389971","preferredDefinition":"Withdrawal of consent for any further data submissions","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA09DDE8-2B2B-B133-E040-BB89AD431578","latestVersionIndicator":"Yes","beginDate":"2012-02-28","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2012-02-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BC2DFBD3-1F7E-8513-E040-BB89AD4309ED","beginDate":"2012-02-28","endDate":null,"createdBy":"WONGW","dateCreated":"2012-03-26","modifiedBy":"ONEDATA","dateModified":"2012-03-26","deletedIndicator":"No"},{"value":"17","valueDescription":"Patient enrollment onto another COG study with tumor therapeutic intent","ValueMeaning":{"publicId":"3389972","version":"1","preferredName":"Patient enrollment onto another COG study with tumor therapeutic intent","longName":"3389972","preferredDefinition":"Patient enrollment onto another COG study with tumor therapeutic intent","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA09DDE8-2B4E-B133-E040-BB89AD431578","latestVersionIndicator":"Yes","beginDate":"2012-02-28","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2012-02-28","modifiedBy":"KUMMEROA","dateModified":"2022-07-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BC2DFBD3-1F92-8513-E040-BB89AD4309ED","beginDate":"2012-02-28","endDate":null,"createdBy":"WONGW","dateCreated":"2012-03-26","modifiedBy":"ONEDATA","dateModified":"2012-03-26","deletedIndicator":"No"},{"value":"18","valueDescription":"Patient is enrolled but rechecked labs are outside the limits of eligibility prior to starting therapy","ValueMeaning":{"publicId":"3389974","version":"1","preferredName":"Patient is enrolled but rechecked labs are outside the limits of eligibility prior to starting therapy","longName":"3389974","preferredDefinition":"Patient is enrolled but rechecked labs are outside the limits of eligibility prior to starting therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA09DDE8-2BB4-B133-E040-BB89AD431578","latestVersionIndicator":"Yes","beginDate":"2012-02-28","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2012-02-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BC2DFBD3-1FA6-8513-E040-BB89AD4309ED","beginDate":"2012-02-28","endDate":null,"createdBy":"WONGW","dateCreated":"2012-03-26","modifiedBy":"ONEDATA","dateModified":"2012-03-26","deletedIndicator":"No"},{"value":"19","valueDescription":"Completion of protocol therapy","ValueMeaning":{"publicId":"3389977","version":"1","preferredName":"Completion of protocol therapy","longName":"3389977","preferredDefinition":"Completion of protocol therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA09DDE8-2C1D-B133-E040-BB89AD431578","latestVersionIndicator":"Yes","beginDate":"2012-02-28","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2012-02-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BC2DFBD3-1FBA-8513-E040-BB89AD4309ED","beginDate":"2012-02-28","endDate":null,"createdBy":"WONGW","dateCreated":"2012-03-26","modifiedBy":"ONEDATA","dateModified":"2012-03-26","deletedIndicator":"No"},{"value":"20","valueDescription":"None","ValueMeaning":{"publicId":"3030997","version":"1","preferredName":"None","longName":"3030997","preferredDefinition":"No person or thing, nobody, not any.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"None","conceptCode":"C41132","definition":"No person or thing, nobody, not any.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"82DD865C-2FEA-9DF4-E040-BB89AD434EAA","latestVersionIndicator":"Yes","beginDate":"2010-03-28","endDate":null,"createdBy":"CURTIST","dateCreated":"2010-03-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BC2DFBD3-1FCE-8513-E040-BB89AD4309ED","beginDate":"2012-02-28","endDate":null,"createdBy":"WONGW","dateCreated":"2012-03-26","modifiedBy":"ONEDATA","dateModified":"2012-03-26","deletedIndicator":"No"},{"value":"7","valueDescription":"Progressive Disease","ValueMeaning":{"publicId":"2559908","version":"1","preferredName":"Progressive Disease","longName":"2559908","preferredDefinition":"Cancer that is increasing in scope or severity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Progressive Disease","conceptCode":"C35571","definition":"A clinical, pathologic, and/or molecular finding indicating that the course of a disease is worsening in terms of extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B711-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"HARTLEYG","dateModified":"2014-10-10","changeDescription":"Manually Curated for OHSU 10262","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BC2DFBD3-1FE2-8513-E040-BB89AD4309ED","beginDate":"2012-03-07","endDate":null,"createdBy":"WONGW","dateCreated":"2012-03-26","modifiedBy":"ONEDATA","dateModified":"2012-03-26","deletedIndicator":"No"},{"value":"11","valueDescription":"Germinoma (Stratum 2) patients who are unable to undergo second look surgery due to safety concerns or <PR without second look surgery.","ValueMeaning":{"publicId":"3421711","version":"1","preferredName":"Germinoma (Stratum 2) patients who are unable to undergo second look surgery due to safety concerns or <PR without second look surgery.","longName":"3421711","preferredDefinition":"Germinoma (Stratum 2) patients who are unable to undergo second look surgery due to safety concerns or <PR without second look surgery.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC2DFBD3-1F3D-8513-E040-BB89AD4309ED","latestVersionIndicator":"Yes","beginDate":"2012-03-26","endDate":null,"createdBy":"WONGW","dateCreated":"2012-03-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BC2DFBD3-2030-8513-E040-BB89AD4309ED","beginDate":"2012-03-26","endDate":null,"createdBy":"WONGW","dateCreated":"2012-03-26","modifiedBy":"ONEDATA","dateModified":"2012-03-26","deletedIndicator":"No"},{"value":"4","valueDescription":"Development of second malignancy","ValueMeaning":{"publicId":"3389975","version":"1","preferredName":"Development of second malignancy","longName":"3389975v1.00","preferredDefinition":"Processes that involve and promote formation of more mature organs, organ systems, or organisms; general development. (NCI)_Coming next after the first in position in space or time or degree or magnitude._A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Development","conceptCode":"C18732","definition":"Processes that involve and promote formation of more mature organs, organ systems, or organisms; general development. (NCI)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Second","conceptCode":"C25666","definition":"Coming next after the first in position in space or time or degree or magnitude.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Malignant Neoplasm","conceptCode":"C9305","definition":"A neoplasm composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA09DDE8-2BD7-B133-E040-BB89AD431578","latestVersionIndicator":"Yes","beginDate":"2012-02-28","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2012-02-28","modifiedBy":"KUMMEROA","dateModified":"2023-01-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BB513AE0-734E-68A2-E040-BB89AD437D24","beginDate":"2012-02-28","endDate":null,"createdBy":"WONGW","dateCreated":"2012-03-15","modifiedBy":"ONEDATA","dateModified":"2012-03-15","deletedIndicator":"No"},{"value":"1","valueDescription":"Lost to follow-up","ValueMeaning":{"publicId":"2569172","version":"1","preferredName":"Lost to follow-up","longName":"2569172","preferredDefinition":"The loss or lack of continuation of subject participation after a study has officially closed.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lost To Follow-Up","conceptCode":"C48227","definition":"The loss or lack of continuation of subject participation after a study has officially closed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-DB41-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-04-13","endDate":null,"createdBy":"MAESKEB","dateCreated":"2004-04-13","modifiedBy":"COOPERM","dateModified":"2015-01-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BB513AE0-738A-68A2-E040-BB89AD437D24","beginDate":"2012-02-28","endDate":null,"createdBy":"WONGW","dateCreated":"2012-03-15","modifiedBy":"ONEDATA","dateModified":"2012-03-15","deletedIndicator":"No"},{"value":"2","valueDescription":"Physician determines it is in patient's best interest","ValueMeaning":{"publicId":"3392383","version":"1","preferredName":"Physician determines it is in patient's best interest","longName":"3392383","preferredDefinition":"Physician determines it is in patient's best interest","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA10B423-BB7E-24EC-E040-BB89AD437279","latestVersionIndicator":"Yes","beginDate":"2012-02-28","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2012-02-28","modifiedBy":"PWEST","dateModified":"2013-09-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BB513AE0-73EE-68A2-E040-BB89AD437D24","beginDate":"2012-02-28","endDate":null,"createdBy":"WONGW","dateCreated":"2012-03-15","modifiedBy":"ONEDATA","dateModified":"2012-03-15","deletedIndicator":"No"},{"value":"5","valueDescription":"Progressive disease with increasing markers during Induction chemotherapy","ValueMeaning":{"publicId":"3389981","version":"1","preferredName":"Progressive disease with increasing markers during Induction chemotherapy","longName":"3389981","preferredDefinition":"Progressive disease with increasing markers during Induction chemotherapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA09DDE8-2CA9-B133-E040-BB89AD431578","latestVersionIndicator":"Yes","beginDate":"2012-02-28","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2012-02-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BB51A69C-8261-84FC-E040-BB89AD430B17","beginDate":"2012-02-28","endDate":null,"createdBy":"WONGW","dateCreated":"2012-03-15","modifiedBy":"ONEDATA","dateModified":"2012-03-15","deletedIndicator":"No"},{"value":"3","valueDescription":"Refusal of further protocol therapy by patient/parent/guardian","ValueMeaning":{"publicId":"3389978","version":"1","preferredName":"Refusal of further protocol therapy by patient/parent/guardian","longName":"3389978","preferredDefinition":"Refusal of further protocol therapy by patient/parent/guardian","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA09DDE8-2C40-B133-E040-BB89AD431578","latestVersionIndicator":"Yes","beginDate":"2012-02-28","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2012-02-28","modifiedBy":"PWEST","dateModified":"2013-09-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BB513AE0-742A-68A2-E040-BB89AD437D24","beginDate":"2012-02-28","endDate":null,"createdBy":"WONGW","dateCreated":"2012-03-15","modifiedBy":"ONEDATA","dateModified":"2012-03-15","deletedIndicator":"No"},{"value":"24","valueDescription":"Patients who do not meet criteria to start next treatment cycle within 21 days after planned subsequent cycle start date (>= 3 week delay in start of next cycle)","ValueMeaning":{"publicId":"3574983","version":"1","preferredName":"Patients who do not meet criteria to start next treatment cycle within 21 days after planned subsequent cycle start date (>= 3 week delay in start of next cycle)","longName":"3574983","preferredDefinition":"Patients who do not meet criteria to start next treatment cycle within 21 days after planned subsequent cycle start date (>= 3 week delay in start of next cycle)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C87E1DB1-5CB3-BAE0-E040-BB89AD434901","latestVersionIndicator":"Yes","beginDate":"2012-08-30","endDate":null,"createdBy":"SHIDED","dateCreated":"2012-08-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C87E1DB1-5CCC-BAE0-E040-BB89AD434901","beginDate":"2012-08-30","endDate":null,"createdBy":"SHIDED","dateCreated":"2012-08-30","modifiedBy":"ONEDATA","dateModified":"2012-08-30","deletedIndicator":"No"},{"value":"23","valueDescription":"Completion of maximum allowable number of cycles of therapy (section 4.1)","ValueMeaning":{"publicId":"3574984","version":"1","preferredName":"Completion of maximum allowable number of cycles of therapy (section 4.1)","longName":"3574984","preferredDefinition":"Completion of maximum allowable number of cycles of therapy (section 4.1)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C87E1DB1-5CD6-BAE0-E040-BB89AD434901","latestVersionIndicator":"Yes","beginDate":"2012-08-30","endDate":null,"createdBy":"SHIDED","dateCreated":"2012-08-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C87E1DB1-5CEF-BAE0-E040-BB89AD434901","beginDate":"2012-08-30","endDate":null,"createdBy":"SHIDED","dateCreated":"2012-08-30","modifiedBy":"ONEDATA","dateModified":"2012-08-30","deletedIndicator":"No"},{"value":"22","valueDescription":"Intolerance of study therapy as described in Section 5","ValueMeaning":{"publicId":"3574985","version":"1","preferredName":"Intolerance of study therapy as described in Section 5","longName":"3574985","preferredDefinition":"Intolerance of study therapy as described in Section 5","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C87E1DB1-5CF9-BAE0-E040-BB89AD434901","latestVersionIndicator":"Yes","beginDate":"2012-08-30","endDate":null,"createdBy":"SHIDED","dateCreated":"2012-08-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C87E1DB1-5D12-BAE0-E040-BB89AD434901","beginDate":"2012-08-30","endDate":null,"createdBy":"SHIDED","dateCreated":"2012-08-30","modifiedBy":"ONEDATA","dateModified":"2012-08-30","deletedIndicator":"No"},{"value":"21","valueDescription":"Repeat eligibility studies are outside the parameters required for eligibility (section  3.2)","ValueMeaning":{"publicId":"3574986","version":"1","preferredName":"Repeat eligibility studies are outside the parameters required for eligibility (section  3.2)","longName":"3574986","preferredDefinition":"Repeat eligibility studies are outside the parameters required for eligibility (section  3.2)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C87E1DB1-5D1C-BAE0-E040-BB89AD434901","latestVersionIndicator":"Yes","beginDate":"2012-08-30","endDate":null,"createdBy":"SHIDED","dateCreated":"2012-08-30","modifiedBy":"KUMMEROA","dateModified":"2022-10-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C87E1DB1-5D35-BAE0-E040-BB89AD434901","beginDate":"2012-08-30","endDate":null,"createdBy":"SHIDED","dateCreated":"2012-08-30","modifiedBy":"ONEDATA","dateModified":"2012-08-30","deletedIndicator":"No"},{"value":"27","valueDescription":"Initiation of other non-protocol anti-cancer therapy prior to completion of BuMel transplant and local radiation","ValueMeaning":{"publicId":"3649117","version":"1","preferredName":"Initiation of other non-protocol anti-cancer therapy prior to completion of BuMel transplant and local radiation","longName":"3649117","preferredDefinition":"Initiation of other non-protocol anti-cancer therapy prior to completion of BuMel transplant and local radiation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D27DFAA2-06F5-0A28-E040-BB89AD43425B","latestVersionIndicator":"Yes","beginDate":"2013-01-04","endDate":null,"createdBy":"CORRALC","dateCreated":"2013-01-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D27DFAA2-070E-0A28-E040-BB89AD43425B","beginDate":"2013-01-04","endDate":null,"createdBy":"CORRALC","dateCreated":"2013-01-04","modifiedBy":"ONEDATA","dateModified":"2013-01-04","deletedIndicator":"No"},{"value":"28","valueDescription":"Patient unable to meet criteria to begin consolidation therapy within 12 weeks from the start of cycle 5 induction therapy.","ValueMeaning":{"publicId":"3652351","version":"1","preferredName":"Patient unable to meet criteria to begin consolidation therapy within 12 weeks from the start of cycle 5 induction therapy.","longName":"3652351","preferredDefinition":"Patient unable to meet criteria to begin consolidation therapy within 12 weeks from the start of cycle 5 induction therapy.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D359C873-9FD9-2077-E040-BB89AD43074E","latestVersionIndicator":"Yes","beginDate":"2013-01-15","endDate":null,"createdBy":"CORRALC","dateCreated":"2013-01-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D359C873-9FF2-2077-E040-BB89AD43074E","beginDate":"2013-01-15","endDate":null,"createdBy":"CORRALC","dateCreated":"2013-01-15","modifiedBy":"ONEDATA","dateModified":"2013-01-15","deletedIndicator":"No"},{"value":"26","valueDescription":"Grade 4 organ toxicity during Induction not related to underlying infection or metabolic derangement that fails to resolve to < Grade 2 or cannot be controlled by treatment by 8 weeks from last cycle of Induction chemotherapy","ValueMeaning":{"publicId":"3682576","version":"1","preferredName":"Grade 4 organ toxicity during Induction not related to underlying infection or metabolic derangement that fails to resolve to < Grade 2 or cannot be controlled by treatment by 8 weeks from last cycle of Induction chemotherapy","longName":"3682576","preferredDefinition":"Grade 4 organ toxicity during Induction not related to underlying infection or metabolic derangement that fails to resolve to < Grade 2 or cannot be controlled by treatment by 8 weeks from last cycle of Induction chemotherapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D52A03D3-B4E2-67DD-E040-BB89AD434C67","latestVersionIndicator":"Yes","beginDate":"2013-02-07","endDate":null,"createdBy":"WONGW","dateCreated":"2013-02-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D52A03D3-B4FB-67DD-E040-BB89AD434C67","beginDate":"2013-01-04","endDate":null,"createdBy":"WONGW","dateCreated":"2013-02-07","modifiedBy":"ONEDATA","dateModified":"2013-02-07","deletedIndicator":"No"},{"value":"29","valueDescription":"Patients unable to receive radiotherapy and will have completed Consolidation phase of treatment at the time of initiation of any subsequent therapy.","ValueMeaning":{"publicId":"3653293","version":"1","preferredName":"Patients unable to receive radiotherapy and will have completed Consolidation phase of treatment at the time of initiation of any subsequent therapy.","longName":"3653293","preferredDefinition":"Patients unable to receive radiotherapy and will have completed Consolidation phase of treatment at the time of initiation of any subsequent therapy.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D384ED55-77DD-7E70-E040-BB89AD433C68","latestVersionIndicator":"Yes","beginDate":"2013-01-17","endDate":null,"createdBy":"CORRALC","dateCreated":"2013-01-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D384ED55-77F6-7E70-E040-BB89AD433C68","beginDate":"2013-01-17","endDate":null,"createdBy":"CORRALC","dateCreated":"2013-01-17","modifiedBy":"ONEDATA","dateModified":"2013-01-17","deletedIndicator":"No"},{"value":"25","valueDescription":"Progressive disease at the end of cycle 4 or 5 of Induction therapy or any time after BuMel Consolidation therapy","ValueMeaning":{"publicId":"3653818","version":"1","preferredName":"Progressive disease at the end of cycle 4 or 5 of Induction therapy or any time after BuMel Consolidation therapy","longName":"3653818","preferredDefinition":"Progressive disease at the end of cycle 4 or 5 of Induction therapy or any time after BuMel Consolidation therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D398B5E8-9FE4-F656-E040-BB89AD43233D","latestVersionIndicator":"Yes","beginDate":"2013-01-18","endDate":null,"createdBy":"WONGW","dateCreated":"2013-01-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D398B5E8-9FFD-F656-E040-BB89AD43233D","beginDate":"2013-01-04","endDate":null,"createdBy":"WONGW","dateCreated":"2013-01-18","modifiedBy":"ONEDATA","dateModified":"2013-01-18","deletedIndicator":"No"},{"value":"30","valueDescription":"Criteria to proceed to HCT not met within 1 year of enrollment","ValueMeaning":{"publicId":"3755511","version":"1","preferredName":"Criteria to proceed to HCT not met within 1 year of enrollment","longName":"3755511","preferredDefinition":"Criteria to proceed to HCT not met within 1 year of enrollment","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DC3B8691-FABB-06DC-E040-BB89AD433164","latestVersionIndicator":"Yes","beginDate":"2013-05-08","endDate":null,"createdBy":"WONGW","dateCreated":"2013-05-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DC3C4CC8-E3D3-574E-E040-BB89AD4354A2","beginDate":"2013-05-08","endDate":null,"createdBy":"WONGW","dateCreated":"2013-05-08","modifiedBy":"ONEDATA","dateModified":"2013-05-08","deletedIndicator":"No"},{"value":"32","valueDescription":"RELAPSE","ValueMeaning":{"publicId":"2562196","version":"1","preferredName":"RELAPSE","longName":"2562196","preferredDefinition":"RELAPSE","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Relapse","conceptCode":"C18265","definition":"The return of signs and symptoms of cancer after a period of improvement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C001-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-08-01","endDate":null,"createdBy":"CVALMONT","dateCreated":"2002-08-01","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E60CF88E-9849-F250-E040-BB89AD436160","beginDate":"2013-09-10","endDate":null,"createdBy":"CORRALC","dateCreated":"2013-09-10","modifiedBy":"ONEDATA","dateModified":"2013-09-10","deletedIndicator":"No"},{"value":"31","valueDescription":"Completion of planned therapy and post-therapy sample collections","ValueMeaning":{"publicId":"3762701","version":"1","preferredName":"Completion of planned therapy and post-therapy sample collections","longName":"3762701","preferredDefinition":"To possess every necessary or normal part or component or step; having come or been brought to a conclusion.: Planned; devised, contrived, or formed in design.: An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: Occurring after a procedure.\r\n: Any material sample taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes, including a sample obtained from a living organism or taken from the biological object after halting of all its life functions. Biospecimen can contain one or more components including but not limited to cellular molecules, cells, tissues, organs, body fluids, embryos, and body excretory products.: The act of gathering things together; having been brought together in one place.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Complete","conceptCode":"C25250","definition":"To possess every necessary or normal part or component or step; having come or been brought to a conclusion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Plan","conceptCode":"C25619","definition":"To devise, contrive, or form in design.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Post-Therapy","conceptCode":"C54735","definition":"Occurring after a therapeutic procedure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Biospecimen","conceptCode":"C70699","definition":"Any material sample taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes, including a sample obtained from a living organism or taken from the biological object after halting of all its life functions. Biospecimen can contain one or more components including but not limited to cellular molecules, cells, tissues, organs, body fluids, embryos, and body excretory products.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Collection","conceptCode":"C25453","definition":"The act of gathering things together; having been brought together in one place.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DCC5FB90-66E1-F7C2-E040-BB89AD432C37","latestVersionIndicator":"Yes","beginDate":"2013-05-15","endDate":null,"createdBy":"TSANE","dateCreated":"2013-05-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DCC5FB90-66FA-F7C2-E040-BB89AD432C37","beginDate":"2013-05-15","endDate":null,"createdBy":"TSANE","dateCreated":"2013-05-15","modifiedBy":"ONEDATA","dateModified":"2013-05-15","deletedIndicator":"No"},{"value":"33","valueDescription":"Study is terminated by Sponsor","ValueMeaning":{"publicId":"3397019","version":"1","preferredName":"Study is terminated by Sponsor","longName":"3397019","preferredDefinition":"Study is terminated by Sponsor","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA34F3E4-90FF-41C1-E040-BB89AD433B93","latestVersionIndicator":"Yes","beginDate":"2012-03-01","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-03-01","modifiedBy":"CAMPBELB","dateModified":"2013-09-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E6846DE3-8AC5-8BFB-E040-BB89AD433438","beginDate":"2013-09-16","endDate":null,"createdBy":"CORRALC","dateCreated":"2013-09-16","modifiedBy":"ONEDATA","dateModified":"2013-09-16","deletedIndicator":"No"},{"value":"43","valueDescription":"Pregnancy","ValueMeaning":{"publicId":"3187561","version":"1","preferredName":"Pregnancy","longName":"3187561","preferredDefinition":"The condition of having a developing embryo or fetus in the body, after union of an ovum and spermatozoon. (Dorland, 27th ed)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pregnancy","conceptCode":"C25742","definition":"The state or condition of having a developing embryo or fetus in the body (uterus), after union of an ovum and spermatozoon, during the period from conception to birth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9ADBFE58-7759-F1A8-E040-BB89AD436F84","latestVersionIndicator":"Yes","beginDate":"2011-01-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-01-27","modifiedBy":"KUMMEROA","dateModified":"2022-07-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E6C5D790-4466-1165-E040-BB89AD4310FE","beginDate":"2013-09-19","endDate":null,"createdBy":"WONGW","dateCreated":"2013-09-19","modifiedBy":"ONEDATA","dateModified":"2013-09-19","deletedIndicator":"No"},{"value":"42","valueDescription":"Adverse Events requiring removal from protocol therapy","ValueMeaning":{"publicId":"3397024","version":"1","preferredName":"Adverse Events requiring removal from protocol therapy","longName":"3397024","preferredDefinition":"Adverse Events requiring removal from protocol therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA34F3E4-91B8-41C1-E040-BB89AD433B93","latestVersionIndicator":"Yes","beginDate":"2012-03-01","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-03-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E6C5D790-447B-1165-E040-BB89AD4310FE","beginDate":"2013-09-19","endDate":null,"createdBy":"WONGW","dateCreated":"2013-09-19","modifiedBy":"ONEDATA","dateModified":"2013-09-19","deletedIndicator":"No"},{"value":"37","valueDescription":"Enrollment onto COG study ACCL0934","ValueMeaning":{"publicId":"3904087","version":"1","preferredName":"Enrollment onto COG study ACCL0934","longName":"3904087","preferredDefinition":"Enrollment onto another clinical protocol, Protocol # ACCL0934 sponsored by the Children's Oncology Group","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E6C13409-F7FC-574A-E040-BB89AD4367E6","latestVersionIndicator":"Yes","beginDate":"2013-09-19","endDate":null,"createdBy":"PWEST","dateCreated":"2013-09-19","modifiedBy":"PWEST","dateModified":"2013-09-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E6C13409-F815-574A-E040-BB89AD4367E6","beginDate":"2013-09-19","endDate":null,"createdBy":"PWEST","dateCreated":"2013-09-19","modifiedBy":"ONEDATA","dateModified":"2013-09-19","deletedIndicator":"No"},{"value":"36","valueDescription":"Emergent un-blinding","ValueMeaning":{"publicId":"3903212","version":"1","preferredName":"Emergent un-blinding","longName":"3903212","preferredDefinition":"A protocol specific reason for being off-treatment due to emergent unblinding","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E6C13409-F7B0-574A-E040-BB89AD4367E6","latestVersionIndicator":"Yes","beginDate":"2013-09-19","endDate":null,"createdBy":"PWEST","dateCreated":"2013-09-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E6C13409-F7C9-574A-E040-BB89AD4367E6","beginDate":"2013-09-19","endDate":null,"createdBy":"PWEST","dateCreated":"2013-09-19","modifiedBy":"ONEDATA","dateModified":"2013-09-19","deletedIndicator":"No"},{"value":"35","valueDescription":"Patient received Sorafenib after study enrollment","ValueMeaning":{"publicId":"3902411","version":"1","preferredName":"Patient received Sorafenib after study enrollment","longName":"3902411","preferredDefinition":"A protocol-specific reason for patient to be off protocol therapy or off study due to administration of contraindicated medication (sorafenib) after time of patient enrollment","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E6A994DA-86E7-CBC3-E040-BB89AD437344","latestVersionIndicator":"Yes","beginDate":"2013-09-18","endDate":null,"createdBy":"PWEST","dateCreated":"2013-09-18","modifiedBy":"PWEST","dateModified":"2013-09-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E6A994DA-8700-CBC3-E040-BB89AD437344","beginDate":"2013-09-18","endDate":null,"createdBy":"PWEST","dateCreated":"2013-09-18","modifiedBy":"ONEDATA","dateModified":"2013-09-18","deletedIndicator":"No"},{"value":"34","valueDescription":"A problem with skin integrity (generalized skin breakdown such as severe skin GVHD or other severe generalized skin disruption) judged by the attending physician to prevent administration of study treatment","ValueMeaning":{"publicId":"3902412","version":"1","preferredName":"A problem with skin integrity (generalized skin breakdown such as severe skin GVHD or other severe generalized skin disruption) judged by the attending physician to prevent administration of study treatment","longName":"3902412","preferredDefinition":"A protocol-specific reason for patient to be off protocol therapy or off study as determined by the physician that treatment cannot be administered due to severe skin disruption or breakdown","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E6A994DA-870A-CBC3-E040-BB89AD437344","latestVersionIndicator":"Yes","beginDate":"2013-09-18","endDate":null,"createdBy":"PWEST","dateCreated":"2013-09-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E6A994DA-8723-CBC3-E040-BB89AD437344","beginDate":"2013-09-18","endDate":null,"createdBy":"PWEST","dateCreated":"2013-09-18","modifiedBy":"ONEDATA","dateModified":"2013-09-18","deletedIndicator":"No"},{"value":"38","valueDescription":"Completion of planned study assessments","ValueMeaning":{"publicId":"3905685","version":"1","preferredName":"Completion of planned study assessments","longName":"3905685","preferredDefinition":"Research conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects; includes development of new technologies, mechanism of human diseases, therapy, clinical trials, epidemiology, behavior and health services research. : The final result of a determination of the value, significance, or extent of.: To possess every necessary or normal part or component or step; having come or been brought to a conclusion.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical Study","conceptCode":"C15206","definition":"Research conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects; includes development of new technologies, study of mechanisms of human diseases, therapy, clinical trials, epidemiologic, behavior, and health services research.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Assessment","conceptCode":"C0679207","definition":"The final result of a determination of the value, significance, or extent of.","evsSource":"UMLS_CUI","primaryIndicator":"No","displayOrder":"1"},{"longName":"Complete","conceptCode":"C25250","definition":"To possess every necessary or normal part or component or step; having come or been brought to a conclusion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E6C39D49-284A-B42C-E040-BB89AD432F1B","latestVersionIndicator":"Yes","beginDate":"2013-09-19","endDate":null,"createdBy":"PWEST","dateCreated":"2013-09-19","modifiedBy":"PWEST","dateModified":"2013-09-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E6C39D49-2863-B42C-E040-BB89AD432F1B","beginDate":"2013-09-19","endDate":null,"createdBy":"PWEST","dateCreated":"2013-09-19","modifiedBy":"ONEDATA","dateModified":"2013-09-19","deletedIndicator":"No"},{"value":"40","valueDescription":"Any skin reaction thought to be caused by allergy to the cleansing product","ValueMeaning":{"publicId":"3905728","version":"1","preferredName":"Any skin reaction thought to be caused by allergy to the cleansing product","longName":"3905728","preferredDefinition":"Any skin reaction thought to be caused by allergy to the cleansing product.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E6C39D49-29F5-B42C-E040-BB89AD432F1B","latestVersionIndicator":"Yes","beginDate":"2013-09-19","endDate":null,"createdBy":"PWEST","dateCreated":"2013-09-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E6C39D49-2A0E-B42C-E040-BB89AD432F1B","beginDate":"2013-09-19","endDate":null,"createdBy":"PWEST","dateCreated":"2013-09-19","modifiedBy":"ONEDATA","dateModified":"2013-09-19","deletedIndicator":"No"},{"value":"41","valueDescription":"Any non-allergic skin reaction >= Grade 3 possibly, probably, or definitely related to the cleansing product","ValueMeaning":{"publicId":"3905727","version":"1","preferredName":"Any non-allergic skin reaction >= Grade 3 possibly, probably, or definitely related to the cleansing product","longName":"3905727","preferredDefinition":"Any non-allergic skin reaction greater or equal to Grade 3 that is possibly, probably, or definitely related to the cleansing product.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E6C39D49-29D2-B42C-E040-BB89AD432F1B","latestVersionIndicator":"Yes","beginDate":"2013-09-19","endDate":null,"createdBy":"PWEST","dateCreated":"2013-09-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E6C39D49-29EB-B42C-E040-BB89AD432F1B","beginDate":"2013-09-19","endDate":null,"createdBy":"PWEST","dateCreated":"2013-09-19","modifiedBy":"ONEDATA","dateModified":"2013-09-19","deletedIndicator":"No"},{"value":"46","valueDescription":"Breastfeeding","ValueMeaning":{"publicId":"3983811","version":"1","preferredName":"Breastfeeding","longName":"3983811","preferredDefinition":"Breastfeeding","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ED34C2A6-2412-965F-E040-BB89AD432FF1","latestVersionIndicator":"Yes","beginDate":"2013-12-10","endDate":null,"createdBy":"WONGW","dateCreated":"2013-12-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ED34C2A6-242B-965F-E040-BB89AD432FF1","beginDate":"2013-12-10","endDate":null,"createdBy":"WONGW","dateCreated":"2013-12-10","modifiedBy":"ONEDATA","dateModified":"2013-12-10","deletedIndicator":"No"},{"value":"45","valueDescription":"Non-compliance that in the opinion of the investigator does not allow for ongoing participation.","ValueMeaning":{"publicId":"3983812","version":"1","preferredName":"Non-compliance that in the opinion of the investigator does not allow for ongoing participation.","longName":"3983812","preferredDefinition":"Non-compliance that in the opinion of the investigator does not allow for ongoing participation.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ED34C2A6-2435-965F-E040-BB89AD432FF1","latestVersionIndicator":"Yes","beginDate":"2013-12-10","endDate":null,"createdBy":"WONGW","dateCreated":"2013-12-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ED34C2A6-244E-965F-E040-BB89AD432FF1","beginDate":"2013-12-10","endDate":null,"createdBy":"WONGW","dateCreated":"2013-12-10","modifiedBy":"ONEDATA","dateModified":"2013-12-10","deletedIndicator":"No"},{"value":"44","valueDescription":"Patients received concurrent anticancer or investigational therapy","ValueMeaning":{"publicId":"3983813","version":"1","preferredName":"Patients received concurrent anticancer or investigational therapy","longName":"3983813","preferredDefinition":"Patients received concurrent anticancer or investigational therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ED34C2A6-2458-965F-E040-BB89AD432FF1","latestVersionIndicator":"Yes","beginDate":"2013-12-10","endDate":null,"createdBy":"WONGW","dateCreated":"2013-12-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ED34C2A6-2471-965F-E040-BB89AD432FF1","beginDate":"2013-12-10","endDate":null,"createdBy":"WONGW","dateCreated":"2013-12-10","modifiedBy":"ONEDATA","dateModified":"2013-12-10","deletedIndicator":"No"},{"value":"54","valueDescription":"Central artery occlusion after an injection which does not recanalize prior to the subsequent injection","ValueMeaning":{"publicId":"4142253","version":"1","preferredName":"Central artery occlusion after an injection which does not recanalize prior to the subsequent injection","longName":"4142253","preferredDefinition":"Central artery occlusion after an injection which does not recanalize prior to the subsequent injection","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F1C0823D-F0B2-921E-E040-BB89AD437EBF","latestVersionIndicator":"Yes","beginDate":"2014-02-06","endDate":null,"createdBy":"WONGW","dateCreated":"2014-02-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F1C0823D-F0CB-921E-E040-BB89AD437EBF","beginDate":"2014-02-06","endDate":null,"createdBy":"WONGW","dateCreated":"2014-02-06","modifiedBy":"ONEDATA","dateModified":"2014-02-06","deletedIndicator":"No"},{"value":"53","valueDescription":"Positive disease found in the contralateral eye after receiving protocol treatment","ValueMeaning":{"publicId":"4142254","version":"1","preferredName":"Positive disease found in the contralateral eye after receiving protocol treatment","longName":"4142254","preferredDefinition":"Positive disease found in the contralateral eye after receiving protocol treatment","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F1C0823D-F0D5-921E-E040-BB89AD437EBF","latestVersionIndicator":"Yes","beginDate":"2014-02-06","endDate":null,"createdBy":"WONGW","dateCreated":"2014-02-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F1C0823D-F0EE-921E-E040-BB89AD437EBF","beginDate":"2014-02-06","endDate":null,"createdBy":"WONGW","dateCreated":"2014-02-06","modifiedBy":"ONEDATA","dateModified":"2014-02-06","deletedIndicator":"No"},{"value":"51","valueDescription":"Enucleation occurred prior to any Melphalan injection.","ValueMeaning":{"publicId":"4120092","version":"1","preferredName":"Enucleation occurred prior to any Melphalan injection.","longName":"4120092","preferredDefinition":"Enucleation occurred prior to any Melphalan injection.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F123A688-A879-6E88-E040-BB89AD4364F3","latestVersionIndicator":"Yes","beginDate":"2014-01-29","endDate":null,"createdBy":"WONGW","dateCreated":"2014-01-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F123A688-A892-6E88-E040-BB89AD4364F3","beginDate":"2014-01-29","endDate":null,"createdBy":"WONGW","dateCreated":"2014-01-29","modifiedBy":"ONEDATA","dateModified":"2014-01-29","deletedIndicator":"No"},{"value":"50","valueDescription":"Massive/Profound intra-vitreal hemorrhage","ValueMeaning":{"publicId":"4120093","version":"1","preferredName":"Massive/Profound intra-vitreal hemorrhage","longName":"4120093","preferredDefinition":"Massive/Profound intra-vitreal hemorrhage","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F123A688-A89C-6E88-E040-BB89AD4364F3","latestVersionIndicator":"Yes","beginDate":"2014-01-29","endDate":null,"createdBy":"WONGW","dateCreated":"2014-01-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F123A688-A8B5-6E88-E040-BB89AD4364F3","beginDate":"2014-01-29","endDate":null,"createdBy":"WONGW","dateCreated":"2014-01-29","modifiedBy":"ONEDATA","dateModified":"2014-01-29","deletedIndicator":"No"},{"value":"49","valueDescription":"Occurrence of metastases","ValueMeaning":{"publicId":"4120094","version":"1","preferredName":"Occurrence of metastases","longName":"4120094","preferredDefinition":"Occurrence of metastases","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F123A688-A8BF-6E88-E040-BB89AD4364F3","latestVersionIndicator":"Yes","beginDate":"2014-01-29","endDate":null,"createdBy":"WONGW","dateCreated":"2014-01-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F123A688-A8D8-6E88-E040-BB89AD4364F3","beginDate":"2014-01-29","endDate":null,"createdBy":"WONGW","dateCreated":"2014-01-29","modifiedBy":"ONEDATA","dateModified":"2014-01-29","deletedIndicator":"No"},{"value":"48","valueDescription":"Intraocular progression of disease is documented by the institutional assessment.","ValueMeaning":{"publicId":"4120095","version":"1","preferredName":"Intraocular progression of disease is documented by the institutional assessment.","longName":"4120095","preferredDefinition":"Intraocular progression of disease is documented by the institutional assessment.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F123A688-A8E2-6E88-E040-BB89AD4364F3","latestVersionIndicator":"Yes","beginDate":"2014-01-29","endDate":null,"createdBy":"WONGW","dateCreated":"2014-01-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F123A688-A8FB-6E88-E040-BB89AD4364F3","beginDate":"2014-01-29","endDate":null,"createdBy":"WONGW","dateCreated":"2014-01-29","modifiedBy":"ONEDATA","dateModified":"2014-01-29","deletedIndicator":"No"},{"value":"47","valueDescription":"Any non-protocol chemotherapy or external beam radiation therapy is given.","ValueMeaning":{"publicId":"4120096","version":"1","preferredName":"Any non-protocol chemotherapy or external beam radiation therapy is given.","longName":"4120096","preferredDefinition":"Any non-protocol chemotherapy or external beam radiation therapy is given.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F123A688-A905-6E88-E040-BB89AD4364F3","latestVersionIndicator":"Yes","beginDate":"2014-01-29","endDate":null,"createdBy":"WONGW","dateCreated":"2014-01-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F123A688-A91E-6E88-E040-BB89AD4364F3","beginDate":"2014-01-29","endDate":null,"createdBy":"WONGW","dateCreated":"2014-01-29","modifiedBy":"ONEDATA","dateModified":"2014-01-29","deletedIndicator":"No"},{"value":"77","valueDescription":"VHR T-LLy with biopsy-proven persistent disease and/or morphologically positive bone marrow at end of 3 HR Intensification Blocks","ValueMeaning":{"publicId":"4436911","version":"1","preferredName":"VHR T-LLy with biopsy-proven persistent disease and/or morphologically positive bone marrow at end of 3 HR Intensification Blocks","longName":"4436911","preferredDefinition":"VHR T-LLy with biopsy-proven persistent disease and/or morphologically positive bone marrow at end of 3 HR Intensification Blocks","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FFFA3585-684D-B4CB-E040-BB89AD436673","latestVersionIndicator":"Yes","beginDate":"2014-08-06","endDate":null,"createdBy":"WONGW","dateCreated":"2014-08-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FFFA3585-6866-B4CB-E040-BB89AD436673","beginDate":"2014-07-28","endDate":null,"createdBy":"WONGW","dateCreated":"2014-08-06","modifiedBy":"ONEDATA","dateModified":"2014-08-06","deletedIndicator":"No"},{"value":"55","valueDescription":"Mandatory baseline specimens not submitted (patient declared ineligible)","ValueMeaning":{"publicId":"4199421","version":"1","preferredName":"Mandatory baseline specimens not submitted (patient declared ineligible)","longName":"4199421","preferredDefinition":"The scientific study of living organisms.: A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.: Data from an original source is not present, accessible or ready for use or service.: Something that is a necessary condition; something that is obligatory.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Biology","conceptCode":"C16345","definition":"The scientific study of living organisms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Study","conceptCode":"C63536","definition":"A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Source Data Not Available","conceptCode":"C67329","definition":"Data from an original source is not present, accessible or ready for use or service.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Requirement","conceptCode":"C25652","definition":"Something that is a necessary condition; something that is obligatory.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3F58A02-5A65-08F3-E040-BB89AD43037A","latestVersionIndicator":"Yes","beginDate":"2014-03-06","endDate":null,"createdBy":"CORRALC","dateCreated":"2014-03-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F3F58A02-5A7E-08F3-E040-BB89AD43037A","beginDate":"2014-03-06","endDate":null,"createdBy":"CORRALC","dateCreated":"2014-03-06","modifiedBy":"ONEDATA","dateModified":"2014-03-06","deletedIndicator":"No"},{"value":"59","valueDescription":"Unacceptable toxicity due to protocol therapy","ValueMeaning":{"publicId":"4264211","version":"1","preferredName":"Unacceptable toxicity due to protocol therapy","longName":"4264211","preferredDefinition":"Unacceptable toxicity due to protocol therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F64209E0-D65C-49EF-E040-BB89AD43331D","latestVersionIndicator":"Yes","beginDate":"2014-04-04","endDate":null,"createdBy":"TSANE","dateCreated":"2014-04-04","modifiedBy":"KUMMEROA","dateModified":"2022-11-30","changeDescription":null,"administrativeNotes":"2022.11.30 Alt VM added for ticket request CADSR0001748. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F64209E0-D675-49EF-E040-BB89AD43331D","beginDate":"2014-04-04","endDate":null,"createdBy":"TSANE","dateCreated":"2014-04-04","modifiedBy":"ONEDATA","dateModified":"2014-04-04","deletedIndicator":"No"},{"value":"39","valueDescription":"Entry onto another COG therapeutic protocol","ValueMeaning":{"publicId":"4204502","version":"1","preferredName":"Entry onto another COG therapeutic protocol","longName":"4204502","preferredDefinition":"Entry onto another COG therapeutic protocol","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F40D335D-B4C8-5499-E040-BB89AD436B5F","latestVersionIndicator":"Yes","beginDate":"2014-03-07","endDate":null,"createdBy":"WONGW","dateCreated":"2014-03-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D335D-B4E1-5499-E040-BB89AD436B5F","beginDate":"2014-03-07","endDate":null,"createdBy":"WONGW","dateCreated":"2014-03-07","modifiedBy":"ONEDATA","dateModified":"2014-03-07","deletedIndicator":"No"},{"value":"56","valueDescription":"Unacceptable toxicity due to protocol","ValueMeaning":{"publicId":"4236871","version":"1","preferredName":"Unacceptable toxicity due to protocol","longName":"4236871","preferredDefinition":"Unacceptable toxicity due to protocol","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F4FCC609-1264-7BA1-E040-BB89AD4343F8","latestVersionIndicator":"Yes","beginDate":"2014-03-19","endDate":null,"createdBy":"TSANE","dateCreated":"2014-03-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F4FCC609-127D-7BA1-E040-BB89AD4343F8","beginDate":"2014-03-19","endDate":null,"createdBy":"TSANE","dateCreated":"2014-03-19","modifiedBy":"ONEDATA","dateModified":"2014-03-19","deletedIndicator":"No"},{"value":"64","valueDescription":"Metastatic disease progression at any time during treatment","ValueMeaning":{"publicId":"4359387","version":"1","preferredName":"Metastatic disease progression at any time during treatment","longName":"4359387","preferredDefinition":"Metastatic disease progression at any time during treatment","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC252F57-3C73-AF3F-E040-BB89AD434186","latestVersionIndicator":"Yes","beginDate":"2014-06-18","endDate":null,"createdBy":"TSANE","dateCreated":"2014-06-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FC252F57-3C8C-AF3F-E040-BB89AD434186","beginDate":"2014-06-18","endDate":null,"createdBy":"TSANE","dateCreated":"2014-06-18","modifiedBy":"ONEDATA","dateModified":"2014-06-18","deletedIndicator":"No"},{"value":"65","valueDescription":"Patients who meet Group B clinical criteria but whose tumors are found to have unfavorable histology and/or unfavorable genomic features","ValueMeaning":{"publicId":"4359388","version":"1","preferredName":"Patients who meet Group B clinical criteria but whose tumors are found to have unfavorable histology and/or unfavorable genomic features","longName":"4359388","preferredDefinition":"Patients who meet Group B clinical criteria but whose tumors are found to have unfavorable histology and/or unfavorable genomic features","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC252F57-3C97-AF3F-E040-BB89AD434186","latestVersionIndicator":"Yes","beginDate":"2014-06-18","endDate":null,"createdBy":"TSANE","dateCreated":"2014-06-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FC252F57-3CB0-AF3F-E040-BB89AD434186","beginDate":"2014-06-18","endDate":null,"createdBy":"TSANE","dateCreated":"2014-06-18","modifiedBy":"ONEDATA","dateModified":"2014-06-18","deletedIndicator":"No"},{"value":"66","valueDescription":"Group B patients who fail to achieve a PR or better after 8 cycles of First-Line ANBL1232 chemotherapy +/- surgery","ValueMeaning":{"publicId":"4359525","version":"1","preferredName":"Group B patients who fail to achieve a PR or better after 8 cycles of First-Line ANBL1232 chemotherapy +/- surgery","longName":"4359525","preferredDefinition":"Group B patients who fail to achieve a PR or better after 8 cycles of First-Line ANBL1232 chemotherapy +/- surgery","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC25C97F-3229-71C5-E040-BB89AD437A1B","latestVersionIndicator":"Yes","beginDate":"2014-06-18","endDate":null,"createdBy":"TSANE","dateCreated":"2014-06-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FC25C97F-3242-71C5-E040-BB89AD437A1B","beginDate":"2014-06-18","endDate":null,"createdBy":"TSANE","dateCreated":"2014-06-18","modifiedBy":"ONEDATA","dateModified":"2014-06-18","deletedIndicator":"No"},{"value":"68","valueDescription":"Developed a new metastatic site at any time during treatment","ValueMeaning":{"publicId":"4359738","version":"1","preferredName":"Developed a new metastatic site at any time during treatment","longName":"4359738","preferredDefinition":"Developed a new metastatic site at any time during treatment","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC26BBA4-9B09-E297-E040-BB89AD4337AA","latestVersionIndicator":"Yes","beginDate":"2014-06-18","endDate":null,"createdBy":"TSANE","dateCreated":"2014-06-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FC26BBA4-9B22-E297-E040-BB89AD4337AA","beginDate":"2014-06-18","endDate":null,"createdBy":"TSANE","dateCreated":"2014-06-18","modifiedBy":"ONEDATA","dateModified":"2014-06-18","deletedIndicator":"No"},{"value":"69","valueDescription":"Group A patients with disease progression or persistently elevated urine or serum catecholamines who go on to have surgical resection.","ValueMeaning":{"publicId":"4363991","version":"1","preferredName":"Group A patients with disease progression or persistently elevated urine or serum catecholamines who go on to have surgical resection.","longName":"4363991","preferredDefinition":"Group A patients with disease progression or persistently elevated urine or serum catecholamines who go on to have surgical resection.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC9AC495-A4BD-1F2E-E040-BB89AD432B5A","latestVersionIndicator":"Yes","beginDate":"2014-06-24","endDate":null,"createdBy":"WONGW","dateCreated":"2014-06-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FC9AC495-A4D6-1F2E-E040-BB89AD432B5A","beginDate":"2014-06-24","endDate":null,"createdBy":"WONGW","dateCreated":"2014-06-24","modifiedBy":"ONEDATA","dateModified":"2014-06-24","deletedIndicator":"No"},{"value":"52","valueDescription":"Progressive disease - Unable to control disease","ValueMeaning":{"publicId":"4155114","version":"1","preferredName":"Progressive disease - Unable to control disease","longName":"4155114","preferredDefinition":"Progressive disease - Unable to control disease","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F23EFED1-36EF-F77B-E040-BB89AD431593","latestVersionIndicator":"Yes","beginDate":"2014-02-12","endDate":null,"createdBy":"WONGW","dateCreated":"2014-02-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F23EFED1-3708-F77B-E040-BB89AD431593","beginDate":"2014-02-06","endDate":null,"createdBy":"WONGW","dateCreated":"2014-02-12","modifiedBy":"ONEDATA","dateModified":"2014-02-12","deletedIndicator":"No"},{"value":"63","valueDescription":"Patients found to have high-risk neuroblastoma","ValueMeaning":{"publicId":"4351859","version":"1","preferredName":"Patients found to have high-risk neuroblastoma","longName":"4351859","preferredDefinition":"Patients found to have high-risk neuroblastoma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FB09EF45-F060-D4DA-E040-BB89AD4366BA","latestVersionIndicator":"Yes","beginDate":"2014-06-04","endDate":null,"createdBy":"TSANE","dateCreated":"2014-06-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FB09EF45-F079-D4DA-E040-BB89AD4366BA","beginDate":"2014-06-04","endDate":null,"createdBy":"TSANE","dateCreated":"2014-06-04","modifiedBy":"ONEDATA","dateModified":"2014-06-04","deletedIndicator":"No"},{"value":"62","valueDescription":"Group B patients with unfavorable histology and/or unfavorable genomic features","ValueMeaning":{"publicId":"4351860","version":"1","preferredName":"Group B patients with unfavorable histology and/or unfavorable genomic features","longName":"4351860","preferredDefinition":"Group B patients with unfavorable histology and/or unfavorable genomic features","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FB09EF45-F083-D4DA-E040-BB89AD4366BA","latestVersionIndicator":"Yes","beginDate":"2014-06-04","endDate":null,"createdBy":"TSANE","dateCreated":"2014-06-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FB09EF45-F09C-D4DA-E040-BB89AD4366BA","beginDate":"2014-06-04","endDate":null,"createdBy":"TSANE","dateCreated":"2014-06-04","modifiedBy":"ONEDATA","dateModified":"2014-06-04","deletedIndicator":"No"},{"value":"60","valueDescription":"Surgery or radiation performed on any site of measurable disease before the end of the 5th cycle","ValueMeaning":{"publicId":"4297021","version":"1","preferredName":"Surgery or radiation performed on any site of measurable disease before the end of the 5th cycle","longName":"4297021","preferredDefinition":"Surgery or radiation performed on any site of measurable disease before the end of the 5th cycle","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F936D6E6-D2E8-F577-E040-BB89AD433EE6","latestVersionIndicator":"Yes","beginDate":"2014-05-12","endDate":null,"createdBy":"WANGC","dateCreated":"2014-05-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F962A445-5C3D-DADB-E040-BB89AD436593","beginDate":"2014-05-12","endDate":null,"createdBy":"WANGC","dateCreated":"2014-05-14","modifiedBy":"ONEDATA","dateModified":"2014-05-14","deletedIndicator":"No"},{"value":"58","valueDescription":"Biopsy positive viable tumor after completion of Metastatic Site Radiation","ValueMeaning":{"publicId":"4251211","version":"1","preferredName":"Biopsy positive viable tumor after completion of Metastatic Site Radiation","longName":"4251211","preferredDefinition":"Biopsy positive viable tumor after completion of Metastatic Site Radiation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F576B5B9-3380-EE38-E040-BB89AD431BD7","latestVersionIndicator":"Yes","beginDate":"2014-03-25","endDate":null,"createdBy":"CORRALC","dateCreated":"2014-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F576B5B9-3399-EE38-E040-BB89AD431BD7","beginDate":"2014-03-25","endDate":null,"createdBy":"CORRALC","dateCreated":"2014-03-25","modifiedBy":"ONEDATA","dateModified":"2014-03-25","deletedIndicator":"No"},{"value":"57","valueDescription":"Biopsy positive residual bone marrow metastatic disease by routine morphology at the end-Consolidation","ValueMeaning":{"publicId":"4251212","version":"1","preferredName":"Biopsy positive residual bone marrow metastatic disease by routine morphology at the end-Consolidation","longName":"4251212","preferredDefinition":"Biopsy positive residual bone marrow metastatic disease by routine morphology at the end-Consolidation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F576B5B9-33A3-EE38-E040-BB89AD431BD7","latestVersionIndicator":"Yes","beginDate":"2014-03-25","endDate":null,"createdBy":"CORRALC","dateCreated":"2014-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F576B5B9-33BC-EE38-E040-BB89AD431BD7","beginDate":"2014-03-25","endDate":null,"createdBy":"CORRALC","dateCreated":"2014-03-25","modifiedBy":"ONEDATA","dateModified":"2014-03-25","deletedIndicator":"No"},{"value":"61","valueDescription":"Failure to recover from surgery within 6 weeks","ValueMeaning":{"publicId":"4313180","version":"1","preferredName":"Failure to recover from surgery within 6 weeks","longName":"4313180","preferredDefinition":"Failure to recover from surgery within 6 weeks","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F962A445-5C48-DADB-E040-BB89AD436593","latestVersionIndicator":"Yes","beginDate":"2014-05-14","endDate":null,"createdBy":"WANGC","dateCreated":"2014-05-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F962A445-5C61-DADB-E040-BB89AD436593","beginDate":"2014-05-14","endDate":null,"createdBy":"WANGC","dateCreated":"2014-05-14","modifiedBy":"ONEDATA","dateModified":"2014-05-14","deletedIndicator":"No"},{"value":"76","valueDescription":"VHR T-ALL who have an M2/M3 marrow and/or detectable MRD at the end of the 3 HR Intensification Blocks","ValueMeaning":{"publicId":"4409051","version":"1","preferredName":"VHR T-ALL who have an M2/M3 marrow and/or detectable MRD at the end of the 3 HR Intensification Blocks","longName":"4409051","preferredDefinition":"VHR T-ALL who have an M2/M3 marrow and/or detectable MRD at the end of the 3 HR Intensification Blocks","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF466D8B-7D6B-C107-E040-BB89AD4314A4","latestVersionIndicator":"Yes","beginDate":"2014-07-28","endDate":null,"createdBy":"WONGW","dateCreated":"2014-07-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF466D8B-7D84-C107-E040-BB89AD4314A4","beginDate":"2014-07-28","endDate":null,"createdBy":"WONGW","dateCreated":"2014-07-28","modifiedBy":"ONEDATA","dateModified":"2014-07-28","deletedIndicator":"No"},{"value":"71","valueDescription":"Group B patients who fail to achieve a PR or better after 8 cycles of first-line ANBL1232 chemotherapy +/- surgery or who experience metastatic disease progression at any time during treatment.","ValueMeaning":{"publicId":"4377784","version":"1","preferredName":"Group B patients who fail to achieve a PR or better after 8 cycles of first-line ANBL1232 chemotherapy +/- surgery or who experience metastatic disease progression at any time during treatment.","longName":"4377784","preferredDefinition":"Group B patients who fail to achieve a PR or better after 8 cycles of first-line ANBL1232 chemotherapy +/- surgery or who experience metastatic disease progression at any time during treatment.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD262518-0C27-8897-E040-BB89AD4324B8","latestVersionIndicator":"Yes","beginDate":"2014-07-01","endDate":null,"createdBy":"WONGW","dateCreated":"2014-07-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD262518-0C40-8897-E040-BB89AD4324B8","beginDate":"2014-07-01","endDate":null,"createdBy":"WONGW","dateCreated":"2014-07-01","modifiedBy":"ONEDATA","dateModified":"2014-07-01","deletedIndicator":"No"},{"value":"67","valueDescription":"Group C patients who fail to achieve a PR or better and resolution of symptoms after 8 cycles of First-Line ANBL1232 chemotherapy or who develop a new metastatic site at any time during treatment.","ValueMeaning":{"publicId":"4378100","version":"1","preferredName":"Group C patients who fail to achieve a PR or better and resolution of symptoms after 8 cycles of First-Line ANBL1232 chemotherapy or who develop a new metastatic site at any time during treatment.","longName":"4378100","preferredDefinition":"Group C patients who fail to achieve a PR or better and resolution of symptoms after 8 cycles of First-Line ANBL1232 chemotherapy or who develop a new metastatic site at any time during treatment.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD290ACA-DD97-B432-E040-BB89AD435BB9","latestVersionIndicator":"Yes","beginDate":"2014-07-01","endDate":null,"createdBy":"WONGW","dateCreated":"2014-07-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD290ACA-DDB0-B432-E040-BB89AD435BB9","beginDate":"2014-06-18","endDate":null,"createdBy":"WONGW","dateCreated":"2014-07-01","modifiedBy":"ONEDATA","dateModified":"2014-07-01","deletedIndicator":"No"},{"value":"75","valueDescription":"Relapse/Progression","ValueMeaning":{"publicId":"4404349","version":"1","preferredName":"Relapse/Progression","longName":"4404349","preferredDefinition":"Relapse/Progression","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF08FAE3-EA05-8876-E040-BB89AD43155C","latestVersionIndicator":"Yes","beginDate":"2014-07-25","endDate":null,"createdBy":"WONGW","dateCreated":"2014-07-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF08FAE3-EA1E-8876-E040-BB89AD43155C","beginDate":"2014-07-25","endDate":null,"createdBy":"WONGW","dateCreated":"2014-07-25","modifiedBy":"ONEDATA","dateModified":"2014-07-25","deletedIndicator":"No"},{"value":"74","valueDescription":"Inevaluable","ValueMeaning":{"publicId":"3859385","version":"1","preferredName":"Inevaluable","longName":"3859385","preferredDefinition":"No imaging/ measurement is done at all at a particular time point","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E462F981-5B8A-4D96-E040-BB89AD4326C1","latestVersionIndicator":"Yes","beginDate":"2013-08-20","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2013-08-20","modifiedBy":"ONEDATA","dateModified":"2013-08-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FEE09F75-4BCA-9CD2-E040-BB89AD432A38","beginDate":"2014-07-23","endDate":null,"createdBy":"WONGW","dateCreated":"2014-07-23","modifiedBy":"ONEDATA","dateModified":"2014-07-23","deletedIndicator":"No"},{"value":"73","valueDescription":"Identified to have Ph+ T-LLy","ValueMeaning":{"publicId":"4400358","version":"1","preferredName":"Identified to have Ph+ T-LLy","longName":"4400358","preferredDefinition":"Identified to have Ph+ T-LLy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FEE04FAF-6E03-61E5-E040-BB89AD430E9D","latestVersionIndicator":"Yes","beginDate":"2014-07-23","endDate":null,"createdBy":"WONGW","dateCreated":"2014-07-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FEE04FAF-6E1C-61E5-E040-BB89AD430E9D","beginDate":"2014-07-23","endDate":null,"createdBy":"WONGW","dateCreated":"2014-07-23","modifiedBy":"ONEDATA","dateModified":"2014-07-23","deletedIndicator":"No"},{"value":"72","valueDescription":"Identified to have Ph+ T-ALL","ValueMeaning":{"publicId":"4400359","version":"1","preferredName":"Identified to have Ph+ T-ALL","longName":"4400359","preferredDefinition":"Identified to have Ph+ T-ALL","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FEE04FAF-6E26-61E5-E040-BB89AD430E9D","latestVersionIndicator":"Yes","beginDate":"2014-07-23","endDate":null,"createdBy":"WONGW","dateCreated":"2014-07-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FEE04FAF-6E3F-61E5-E040-BB89AD430E9D","beginDate":"2014-07-23","endDate":null,"createdBy":"WONGW","dateCreated":"2014-07-23","modifiedBy":"ONEDATA","dateModified":"2014-07-23","deletedIndicator":"No"},{"value":"79","valueDescription":"Pre-Randomization (HR/IR or LR): Interval development of significant central nervous system pathology that would preclude treatment with blinatumomab (see Section 3.2.5.13 for definition)","ValueMeaning":{"publicId":"4515178","version":"1","preferredName":"Pre-Randomization (HR/IR or LR): Interval development of significant central nervous system pathology that would preclude treatment with blinatumomab (see Section 3.2.5.13 for definition)","longName":"4515178","preferredDefinition":"Pre-Randomization (HR/IR or LR): Interval development of significant central nervous system pathology that would preclude treatment with blinatumomab (see Section 3.2.5.13 for definition)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"04DC79D0-A29C-21B6-E050-BB89AD434721","latestVersionIndicator":"Yes","beginDate":"2014-10-07","endDate":null,"createdBy":"WANGC","dateCreated":"2014-10-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"04DC5BF8-4D25-9C12-E050-BB89AD434D75","beginDate":"2014-10-07","endDate":null,"createdBy":"WANGC","dateCreated":"2014-10-07","modifiedBy":"ONEDATA","dateModified":"2014-10-07","deletedIndicator":"No"},{"value":"78","valueDescription":"Treatment failure but not eligible to receive blinatumomab salvage","ValueMeaning":{"publicId":"4515179","version":"1","preferredName":"Treatment failure but not eligible to receive blinatumomab salvage","longName":"4515179","preferredDefinition":"Treatment failure but not eligible to receive blinatumomab salvage","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"04DC79D0-A2BF-21B6-E050-BB89AD434721","latestVersionIndicator":"Yes","beginDate":"2014-10-07","endDate":null,"createdBy":"WANGC","dateCreated":"2014-10-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"04DC5BF8-4D39-9C12-E050-BB89AD434D75","beginDate":"2014-10-07","endDate":null,"createdBy":"WANGC","dateCreated":"2014-10-07","modifiedBy":"ONEDATA","dateModified":"2014-10-07","deletedIndicator":"No"},{"value":"80","valueDescription":"Found to be ineligible for HSCT  (see section 4.9.1)","ValueMeaning":{"publicId":"4518048","version":"1","preferredName":"Found to be ineligible for HSCT  (see section 4.9.1)","longName":"4518048","preferredDefinition":"Found to be ineligible for HSCT  (see section 4.9.1)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"04DDB8F3-9A09-F5D3-E050-BB89AD430713","latestVersionIndicator":"Yes","beginDate":"2014-10-07","endDate":null,"createdBy":"WANGC","dateCreated":"2014-10-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"04DDB8F3-9A22-F5D3-E050-BB89AD430713","beginDate":"2014-10-07","endDate":null,"createdBy":"WANGC","dateCreated":"2014-10-07","modifiedBy":"ONEDATA","dateModified":"2014-10-07","deletedIndicator":"No"},{"value":"81","valueDescription":"Second relapse at any site","ValueMeaning":{"publicId":"4522737","version":"1","preferredName":"Second relapse at any site","longName":"4522737","preferredDefinition":"Second relapse at any site","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"04F02C9E-A613-07C7-E050-BB89AD43074A","latestVersionIndicator":"Yes","beginDate":"2014-10-08","endDate":null,"createdBy":"WANGC","dateCreated":"2014-10-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"04F02C9E-A62C-07C7-E050-BB89AD43074A","beginDate":"2014-10-08","endDate":null,"createdBy":"WANGC","dateCreated":"2014-10-08","modifiedBy":"ONEDATA","dateModified":"2014-10-08","deletedIndicator":"No"},{"value":"90","valueDescription":"Group C patients who develop a new metastatic lesion at any time during treatment.","ValueMeaning":{"publicId":"4671231","version":"1","preferredName":"Group C patients who develop a new metastatic lesion at any time during treatment.","longName":"4671231","preferredDefinition":"Group C patients who develop a new metastatic lesion at any time during treatment.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0D333F52-3DD1-F7B3-E050-BB89AD431029","latestVersionIndicator":"Yes","beginDate":"2015-01-21","endDate":null,"createdBy":"WONGW","dateCreated":"2015-01-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0D333F52-3DEA-F7B3-E050-BB89AD431029","beginDate":"2015-01-21","endDate":null,"createdBy":"WONGW","dateCreated":"2015-01-21","modifiedBy":"ONEDATA","dateModified":"2015-01-21","deletedIndicator":"No"},{"value":"89","valueDescription":"Group C patients who fail to achieve a PR or better and resolution of symptoms after 8 cycles of first-line ANBL1232 chemotherapy.","ValueMeaning":{"publicId":"4671232","version":"1","preferredName":"Group C patients who fail to achieve a PR or better and resolution of symptoms after 8 cycles of first-line ANBL1232 chemotherapy.","longName":"4671232","preferredDefinition":"Group C patients who fail to achieve a PR or better and resolution of symptoms after 8 cycles of first-line ANBL1232 chemotherapy.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0D333F52-3DF4-F7B3-E050-BB89AD431029","latestVersionIndicator":"Yes","beginDate":"2015-01-21","endDate":null,"createdBy":"WONGW","dateCreated":"2015-01-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0D333F52-3E0D-F7B3-E050-BB89AD431029","beginDate":"2015-01-21","endDate":null,"createdBy":"WONGW","dateCreated":"2015-01-21","modifiedBy":"ONEDATA","dateModified":"2015-01-21","deletedIndicator":"No"},{"value":"87","valueDescription":"Group B patients who experience metastatic disease progression at any time during treatment.","ValueMeaning":{"publicId":"4671234","version":"1","preferredName":"Group B patients who experience metastatic disease progression at any time during treatment.","longName":"4671234","preferredDefinition":"Group B patients who experience metastatic disease progression at any time during treatment.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0D333F52-3E3A-F7B3-E050-BB89AD431029","latestVersionIndicator":"Yes","beginDate":"2015-01-21","endDate":null,"createdBy":"WONGW","dateCreated":"2015-01-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0D333F52-3E53-F7B3-E050-BB89AD431029","beginDate":"2015-01-21","endDate":null,"createdBy":"WONGW","dateCreated":"2015-01-21","modifiedBy":"ONEDATA","dateModified":"2015-01-21","deletedIndicator":"No"},{"value":"86","valueDescription":"Group A patients who go on to have surgical resection and have completed a 60 day evaluation period following resection.","ValueMeaning":{"publicId":"4671235","version":"1","preferredName":"Group A patients who go on to have surgical resection and have completed a 60 day evaluation period following resection.","longName":"4671235","preferredDefinition":"Group A patients who go on to have surgical resection and have completed a 60 day evaluation period following resection.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0D333F52-3E5D-F7B3-E050-BB89AD431029","latestVersionIndicator":"Yes","beginDate":"2015-01-21","endDate":null,"createdBy":"WONGW","dateCreated":"2015-01-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0D333F52-3E76-F7B3-E050-BB89AD431029","beginDate":"2015-01-21","endDate":null,"createdBy":"WONGW","dateCreated":"2015-01-21","modifiedBy":"ONEDATA","dateModified":"2015-01-21","deletedIndicator":"No"},{"value":"85","valueDescription":"Group A patients who experience disease progression and do not go on to have surgical resection.","ValueMeaning":{"publicId":"4671236","version":"1","preferredName":"Group A patients who experience disease progression and do not go on to have surgical resection.","longName":"4671236","preferredDefinition":"Group A patients who experience disease progression and do not go on to have surgical resection.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0D333F52-3E80-F7B3-E050-BB89AD431029","latestVersionIndicator":"Yes","beginDate":"2015-01-21","endDate":null,"createdBy":"WONGW","dateCreated":"2015-01-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0D333F52-3E99-F7B3-E050-BB89AD431029","beginDate":"2015-01-21","endDate":null,"createdBy":"WONGW","dateCreated":"2015-01-21","modifiedBy":"ONEDATA","dateModified":"2015-01-21","deletedIndicator":"No"},{"value":"82","valueDescription":"Treatment failure that receives Blinatumomab salvage but does not achieve CR","ValueMeaning":{"publicId":"4570754","version":"1","preferredName":"Treatment failure that receives Blinatumomab salvage but does not achieve CR","longName":"4570754","preferredDefinition":"Treatment failure that receives Blinatumomab salvage but does not achieve CR","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"06FA10EA-E39E-C1ED-E050-BB89AD434729","latestVersionIndicator":"Yes","beginDate":"2014-11-03","endDate":null,"createdBy":"WANGC","dateCreated":"2014-11-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"06FA10EA-E3B7-C1ED-E050-BB89AD434729","beginDate":"2014-11-03","endDate":null,"createdBy":"WANGC","dateCreated":"2014-11-03","modifiedBy":"ONEDATA","dateModified":"2014-11-03","deletedIndicator":"No"},{"value":"83","valueDescription":"RQ-PCR determines patient to be PML-RAR&#945; negative at diagnosis or RQ-PCR inevaluable","ValueMeaning":{"publicId":"4645860","version":"1","preferredName":"RQ-PCR determines patient to be PML-RAR negative at diagnosis or RQ-PCR inevaluable","longName":"4645860","preferredDefinition":"RQ-PCR determines patient to be PML-RAR negative at diagnosis or RQ-PCR inevaluable","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0B625D14-1E95-246B-E050-BB89AD4327B1","latestVersionIndicator":"Yes","beginDate":"2014-12-29","endDate":null,"createdBy":"TSANE","dateCreated":"2014-12-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0B625D14-1EAE-246B-E050-BB89AD4327B1","beginDate":"2014-12-29","endDate":null,"createdBy":"TSANE","dateCreated":"2014-12-29","modifiedBy":"ONEDATA","dateModified":"2014-12-29","deletedIndicator":"No"},{"value":"84","valueDescription":"RQ-PCR sample not collected prior to initiation of protocol therapy","ValueMeaning":{"publicId":"4645859","version":"1","preferredName":"RQ-PCR sample not collected prior to initiation of protocol therapy","longName":"4645859","preferredDefinition":"RQ-PCR sample not collected prior to initiation of protocol therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0B625D14-1E72-246B-E050-BB89AD4327B1","latestVersionIndicator":"Yes","beginDate":"2014-12-29","endDate":null,"createdBy":"TSANE","dateCreated":"2014-12-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0B625D14-1E8B-246B-E050-BB89AD4327B1","beginDate":"2014-12-29","endDate":null,"createdBy":"TSANE","dateCreated":"2014-12-29","modifiedBy":"ONEDATA","dateModified":"2014-12-29","deletedIndicator":"No"},{"value":"96","valueDescription":"Progressive disease with positive or increasing markers at the end of Induction chemotherapy, following second-look surgery or during radiation therapy.","ValueMeaning":{"publicId":"4720754","version":"1","preferredName":"Progressive disease with positive or increasing markers at the end of Induction chemotherapy, following second-look surgery or during radiation therapy.","longName":"4720754","preferredDefinition":"Progressive disease with positive or increasing markers at the end of Induction chemotherapy, following second-look surgery or during radiation therapy.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F644B56-6B63-7171-E050-BB89AD434FD5","latestVersionIndicator":"Yes","beginDate":"2015-02-18","endDate":null,"createdBy":"WONGW","dateCreated":"2015-02-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F644B56-6B7C-7171-E050-BB89AD434FD5","beginDate":"2015-02-18","endDate":null,"createdBy":"WONGW","dateCreated":"2015-02-18","modifiedBy":"ONEDATA","dateModified":"2015-02-18","deletedIndicator":"No"},{"value":"103","valueDescription":"Patient did not receive protocol treatment after study enrollment","ValueMeaning":{"publicId":"4865696","version":"1","preferredName":"Patient did not receive protocol treatment after study enrollment","longName":"4865696","preferredDefinition":"Patient did not receive protocol treatment after study enrollment","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1858F115-DFF5-9AD1-E050-BB89AD437DB7","latestVersionIndicator":"Yes","beginDate":"2015-06-12","endDate":null,"createdBy":"CORRALC","dateCreated":"2015-06-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1858F115-E00E-9AD1-E050-BB89AD437DB7","beginDate":"2015-06-12","endDate":null,"createdBy":"CORRALC","dateCreated":"2015-06-12","modifiedBy":"ONEDATA","dateModified":"2015-06-12","deletedIndicator":"No"},{"value":"102","valueDescription":"Fracture excluding pathological fracture at the site of osteosarcoma bone metastasis or fracture at the site of prior orthopedic surgery","ValueMeaning":{"publicId":"4835731","version":"1","preferredName":"Fracture excluding pathological fracture at the site of osteosarcoma bone metastasis or fracture at the site of prior orthopedic surgery","longName":"4835731","preferredDefinition":"Fracture excluding pathological fracture at the site of osteosarcoma bone metastasis or fracture at the site of prior orthopedic surgery","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"169AF304-9884-03F0-E050-BB89AD4342AF","latestVersionIndicator":"Yes","beginDate":"2015-05-21","endDate":null,"createdBy":"WANGC","dateCreated":"2015-05-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"169AF304-989D-03F0-E050-BB89AD4342AF","beginDate":"2015-05-21","endDate":null,"createdBy":"WANGC","dateCreated":"2015-05-21","modifiedBy":"ONEDATA","dateModified":"2015-05-21","deletedIndicator":"No"},{"value":"101","valueDescription":"Osteonecrosis of the jaw","ValueMeaning":{"publicId":"4835732","version":"1","preferredName":"Osteonecrosis of the jaw","longName":"4835732","preferredDefinition":"Osteonecrosis of the jaw","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"169AF304-98A7-03F0-E050-BB89AD4342AF","latestVersionIndicator":"Yes","beginDate":"2015-05-21","endDate":null,"createdBy":"WANGC","dateCreated":"2015-05-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"169AF304-98C0-03F0-E050-BB89AD4342AF","beginDate":"2015-05-21","endDate":null,"createdBy":"WANGC","dateCreated":"2015-05-21","modifiedBy":"ONEDATA","dateModified":"2015-05-21","deletedIndicator":"No"},{"value":"113","valueDescription":"Failure to obtain a result for the MRD test at the end of Induction I","ValueMeaning":{"publicId":"4844514","version":"1","preferredName":"Failure to obtain a result for the MRD test at the end of Induction I","longName":"4844514","preferredDefinition":"Failure to obtain a result for the MRD test at the end of Induction I","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"178DABC8-E5CE-B429-E050-BB89AD43792B","latestVersionIndicator":"Yes","beginDate":"2015-06-02","endDate":null,"createdBy":"LEEW","dateCreated":"2015-06-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1C083CDC-7618-0D12-E050-BB89AD435C1F","beginDate":"2015-06-02","endDate":null,"createdBy":"WONGW","dateCreated":"2015-07-29","modifiedBy":"ONEDATA","dateModified":"2015-07-29","deletedIndicator":"No"},{"value":"111","valueDescription":"Patient enrollment onto another COG study with tumor therapeutic intent (eg, at recurrence)","ValueMeaning":{"publicId":"4854741","version":"1","preferredName":"Patient enrollment onto another COG study with tumor therapeutic intent (eg, at recurrence)","longName":"4854741","preferredDefinition":"Patient enrollment onto another COG study with tumor therapeutic intent (eg, at recurrence)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"17E2BBDF-23FB-BAF3-E050-BB89AD43633F","latestVersionIndicator":"Yes","beginDate":"2015-06-06","endDate":null,"createdBy":"LEEW","dateCreated":"2015-06-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1C083CDC-7645-0D12-E050-BB89AD435C1F","beginDate":"2015-06-06","endDate":null,"createdBy":"WONGW","dateCreated":"2015-07-29","modifiedBy":"ONEDATA","dateModified":"2015-07-29","deletedIndicator":"No"},{"value":"110","valueDescription":"Grade 3 or  greater neurotoxicity, myelitis and nervous system disorder, and other, including cerebellar toxicity from HD Ara-C","ValueMeaning":{"publicId":"4844513","version":"1","preferredName":"Grade 3 or  greater neurotoxicity, myelitis and nervous system disorder, and other, including cerebellar toxicity from HD Ara-C","longName":"4844513","preferredDefinition":"Grade 3 or  greater neurotoxicity, myelitis and nervous system disorder, and other, including cerebellar toxicity from HD Ara-C","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"178DABC8-E5AB-B429-E050-BB89AD43792B","latestVersionIndicator":"Yes","beginDate":"2015-06-02","endDate":null,"createdBy":"LEEW","dateCreated":"2015-06-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1C081F81-7CE3-6259-E050-BB89AD436B37","beginDate":"2015-06-02","endDate":null,"createdBy":"WONGW","dateCreated":"2015-07-29","modifiedBy":"ONEDATA","dateModified":"2015-07-29","deletedIndicator":"No"},{"value":"112","valueDescription":"Patient received concurrent anticancer or investigational therapy","ValueMeaning":{"publicId":"4861212","version":"1","preferredName":"Patient received concurrent anticancer or investigational therapy","longName":"4861212","preferredDefinition":"Patient received concurrent anticancer or investigational therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"182E6E70-FF34-AC92-E050-BB89AD4321C1","latestVersionIndicator":"Yes","beginDate":"2015-06-10","endDate":null,"createdBy":"CORRALC","dateCreated":"2015-06-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1C081F81-7CFA-6259-E050-BB89AD436B37","beginDate":"2015-06-10","endDate":null,"createdBy":"WONGW","dateCreated":"2015-07-29","modifiedBy":"ONEDATA","dateModified":"2015-07-29","deletedIndicator":"No"},{"value":"104","valueDescription":"Persistent CNS leukemia after 6 doses of IT Arac-C after Induction I","ValueMeaning":{"publicId":"4844512","version":"1","preferredName":"Persistent CNS leukemia after 6 doses of IT Arac-C after Induction I","longName":"4844512","preferredDefinition":"Persistent CNS leukemia after 6 doses of IT Arac-C after Induction I","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"178DABC8-E588-B429-E050-BB89AD43792B","latestVersionIndicator":"Yes","beginDate":"2015-06-02","endDate":null,"createdBy":"LEEW","dateCreated":"2015-06-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"18A88AE1-0E22-1A1A-E050-BB89AD435CA0","beginDate":"2015-06-02","endDate":null,"createdBy":"LEEW","dateCreated":"2015-06-16","modifiedBy":"ONEDATA","dateModified":"2015-06-16","deletedIndicator":"No"},{"value":"105","valueDescription":"PR, RD, or relapse following Induction II","ValueMeaning":{"publicId":"4844511","version":"1","preferredName":"PR, RD, or relapse following Induction II","longName":"4844511","preferredDefinition":"PR, RD, or relapse following Induction II","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"178DABC8-E565-B429-E050-BB89AD43792B","latestVersionIndicator":"Yes","beginDate":"2015-06-02","endDate":null,"createdBy":"LEEW","dateCreated":"2015-06-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"18A88AE1-0E36-1A1A-E050-BB89AD435CA0","beginDate":"2015-06-02","endDate":null,"createdBy":"LEEW","dateCreated":"2015-06-16","modifiedBy":"ONEDATA","dateModified":"2015-06-16","deletedIndicator":"No"},{"value":"106","valueDescription":"Repeat eligibility studies (if required) prior to the initiation of protocol therapy are outside the parameters required for eligibility (see Section 3.2).","ValueMeaning":{"publicId":"4844451","version":"1","preferredName":"Repeat eligibility studies (if required) prior to the initiation of protocol therapy are outside the parameters required for eligibility (see Section 3.2).","longName":"4844451","preferredDefinition":"Repeat eligibility studies (if required) prior to the initiation of protocol therapy are outside the parameters required for eligibility (see Section 3.2).","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"178C9BEE-92C0-C0D5-E050-BB89AD433B48","latestVersionIndicator":"Yes","beginDate":"2015-06-02","endDate":null,"createdBy":"LEEW","dateCreated":"2015-06-02","modifiedBy":"KUMMEROA","dateModified":"2022-10-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"18A88AE1-0E4A-1A1A-E050-BB89AD435CA0","beginDate":"2015-06-02","endDate":null,"createdBy":"LEEW","dateCreated":"2015-06-16","modifiedBy":"ONEDATA","dateModified":"2015-06-16","deletedIndicator":"No"},{"value":"108","valueDescription":"Surgery or radiation performed in a patient who has not achieved a confirmed complete or partial response","ValueMeaning":{"publicId":"4883091","version":"1","preferredName":"Surgery or radiation performed in a patient who has not achieved a confirmed complete or partial response","longName":"4883091","preferredDefinition":"Surgery or radiation performed in a patient who has not achieved a confirmed complete or partial response","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"18E761DF-0C14-58A0-E050-BB89AD431194","latestVersionIndicator":"Yes","beginDate":"2015-06-19","endDate":null,"createdBy":"MIRANDAA","dateCreated":"2015-06-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"18E761DF-0C2D-58A0-E050-BB89AD431194","beginDate":"2015-06-19","endDate":null,"createdBy":"MIRANDAA","dateCreated":"2015-06-19","modifiedBy":"ONEDATA","dateModified":"2015-06-19","deletedIndicator":"No"},{"value":"109","valueDescription":"Completion of planned therapy","ValueMeaning":{"publicId":"3397022","version":"1","preferredName":"Completion of planned therapy","longName":"3397022","preferredDefinition":"Completion of planned therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA34F3E4-9168-41C1-E040-BB89AD433B93","latestVersionIndicator":"Yes","beginDate":"2012-03-01","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-03-01","modifiedBy":"KUMMEROA","dateModified":"2022-10-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"18E7A5C9-582D-B3BC-E050-BB89AD434C13","beginDate":"2015-06-19","endDate":null,"createdBy":"MIRANDAA","dateCreated":"2015-06-19","modifiedBy":"ONEDATA","dateModified":"2015-06-19","deletedIndicator":"No"},{"value":"98","valueDescription":"Germinoma (Stratum 2) patients who are unable to undergo second-look surgery due to safety concerns and they do not meet the criteria for at least PR with <= 1.5 cm residual disease without second-look surgery.","ValueMeaning":{"publicId":"4740555","version":"1","preferredName":"Germinoma (Stratum 2) patients who are unable to undergo second-look surgery due to safety concerns and they do not meet the criteria for at least PR with <= 1.5 cm residual disease without second-look surgery.","longName":"4740555","preferredDefinition":"Germinoma (Stratum 2) patients who are unable to undergo second-look surgery due to safety concerns and they do not meet the criteria for at least PR with <= 1.5 cm residual disease without second-look surgery.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"10A79807-542B-DC78-E050-BB89AD435043","latestVersionIndicator":"Yes","beginDate":"2015-03-06","endDate":null,"createdBy":"WONGW","dateCreated":"2015-03-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10A79807-5444-DC78-E050-BB89AD435043","beginDate":"2015-02-18","endDate":null,"createdBy":"WONGW","dateCreated":"2015-03-06","modifiedBy":"ONEDATA","dateModified":"2015-03-06","deletedIndicator":"No"},{"value":"100","valueDescription":"Relapse during Consolidation therapy","ValueMeaning":{"publicId":"4770781","version":"1","preferredName":"Relapse during Consolidation therapy","longName":"4770781","preferredDefinition":"Relapse during Consolidation therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"12C3982B-D597-1D7C-E050-BB89AD432D16","latestVersionIndicator":"Yes","beginDate":"2015-04-02","endDate":null,"createdBy":"WONGW","dateCreated":"2015-04-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"12C3982B-D5B0-1D7C-E050-BB89AD432D16","beginDate":"2015-04-02","endDate":null,"createdBy":"WONGW","dateCreated":"2015-04-02","modifiedBy":"ONEDATA","dateModified":"2015-04-02","deletedIndicator":"No"},{"value":"99","valueDescription":"Failure to achieve molecular remission following the MRD Positive Consolidation cycle","ValueMeaning":{"publicId":"4770782","version":"1","preferredName":"Failure to achieve molecular remission following the MRD Positive Consolidation cycle","longName":"4770782","preferredDefinition":"Failure to achieve molecular remission following the MRD Positive Consolidation cycle","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"12C3982B-D5BA-1D7C-E050-BB89AD432D16","latestVersionIndicator":"Yes","beginDate":"2015-04-02","endDate":null,"createdBy":"WONGW","dateCreated":"2015-04-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"12C3982B-D5D3-1D7C-E050-BB89AD432D16","beginDate":"2015-04-02","endDate":null,"createdBy":"WONGW","dateCreated":"2015-04-02","modifiedBy":"ONEDATA","dateModified":"2015-04-02","deletedIndicator":"No"},{"value":"91","valueDescription":"Failure to achieve hCR/hCRi by Day 70 of induction","ValueMeaning":{"publicId":"4770783","version":"1","preferredName":"Failure to achieve hCR/hCRi by Day 70 of induction","longName":"4770783","preferredDefinition":"Failure to achieve hCR/hCRi by Day 70 of induction","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"12C3982B-D5DD-1D7C-E050-BB89AD432D16","latestVersionIndicator":"Yes","beginDate":"2015-04-02","endDate":null,"createdBy":"WONGW","dateCreated":"2015-04-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"12C3982B-D5F6-1D7C-E050-BB89AD432D16","beginDate":"2015-02-03","endDate":null,"createdBy":"WONGW","dateCreated":"2015-04-02","modifiedBy":"ONEDATA","dateModified":"2015-04-02","deletedIndicator":"No"},{"value":"92","valueDescription":"Refractory CNS leukemia following 6 doses of intrathecal therapy","ValueMeaning":{"publicId":"4770784","version":"1","preferredName":"Refractory CNS leukemia following 6 doses of intrathecal therapy","longName":"4770784","preferredDefinition":"Refractory CNS leukemia following 6 doses of intrathecal therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"12C3982B-D600-1D7C-E050-BB89AD432D16","latestVersionIndicator":"Yes","beginDate":"2015-04-02","endDate":null,"createdBy":"WONGW","dateCreated":"2015-04-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"12C3982B-D619-1D7C-E050-BB89AD432D16","beginDate":"2015-02-03","endDate":null,"createdBy":"WONGW","dateCreated":"2015-04-02","modifiedBy":"ONEDATA","dateModified":"2015-04-02","deletedIndicator":"No"},{"value":"95","valueDescription":"Radiotherapy cannot be initiated within 6 weeks after Day 1 of the last cycle of Induction chemotherapy or within 31 days after second-look surgery (Sections 15.2.3 and 15.2.4).","ValueMeaning":{"publicId":"4719970","version":"1","preferredName":"Radiotherapy cannot be initiated within 6 weeks after Day 1 of the last cycle of Induction chemotherapy or within 31 days after second-look surgery (Sections 15.2.3 and 15.2.4).","longName":"4719970","preferredDefinition":"Radiotherapy cannot be initiated within 6 weeks after Day 1 of the last cycle of Induction chemotherapy or within 31 days after second-look surgery (Sections 15.2.3 and 15.2.4).","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F6277EB-606A-3FA6-E050-BB89AD43414C","latestVersionIndicator":"Yes","beginDate":"2015-02-18","endDate":null,"createdBy":"WONGW","dateCreated":"2015-02-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F6277EB-6083-3FA6-E050-BB89AD43414C","beginDate":"2015-02-18","endDate":null,"createdBy":"WONGW","dateCreated":"2015-02-18","modifiedBy":"ONEDATA","dateModified":"2015-02-18","deletedIndicator":"No"},{"value":"94","valueDescription":"Germinoma (Stratum 2) patients with any viable tumor (except mature teratoma, fibrosis, scar or non-viable tumor) after second-look surgery.","ValueMeaning":{"publicId":"4719971","version":"1","preferredName":"Germinoma (Stratum 2) patients with any viable tumor (except mature teratoma, fibrosis, scar or non-viable tumor) after second-look surgery.","longName":"4719971","preferredDefinition":"Germinoma (Stratum 2) patients with any viable tumor (except mature teratoma, fibrosis, scar or non-viable tumor) after second-look surgery.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F6277EB-608D-3FA6-E050-BB89AD43414C","latestVersionIndicator":"Yes","beginDate":"2015-02-18","endDate":null,"createdBy":"WONGW","dateCreated":"2015-02-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F6277EB-60A6-3FA6-E050-BB89AD43414C","beginDate":"2015-02-18","endDate":null,"createdBy":"WONGW","dateCreated":"2015-02-18","modifiedBy":"ONEDATA","dateModified":"2015-02-18","deletedIndicator":"No"},{"value":"93","valueDescription":"NGGCT (Stratum 1) patients with < PR after second look surgery or any viable tumor (except mature teratoma) after second-look surgery.","ValueMeaning":{"publicId":"4719972","version":"1","preferredName":"NGGCT (Stratum 1) patients with < PR after second look surgery or any viable tumor (except mature teratoma) after second-look surgery.","longName":"4719972","preferredDefinition":"NGGCT (Stratum 1) patients with < PR after second look surgery or any viable tumor (except mature teratoma) after second-look surgery.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F6277EB-60B0-3FA6-E050-BB89AD43414C","latestVersionIndicator":"Yes","beginDate":"2015-02-18","endDate":null,"createdBy":"WONGW","dateCreated":"2015-02-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F6277EB-60C9-3FA6-E050-BB89AD43414C","beginDate":"2015-02-18","endDate":null,"createdBy":"WONGW","dateCreated":"2015-02-18","modifiedBy":"ONEDATA","dateModified":"2015-02-18","deletedIndicator":"No"},{"value":"97","valueDescription":"NGGCT (Stratum 1) patients who are unable to undergo second-look surgery due to safety or other reasons and do not meet criteria for CR/PR (imaging and tumor markers).","ValueMeaning":{"publicId":"4720751","version":"1","preferredName":"NGGCT (Stratum 1) patients who are unable to undergo second-look surgery due to safety or other reasons and do not meet criteria for CR/PR (imaging and tumor markers).","longName":"4720751","preferredDefinition":"NGGCT (Stratum 1) patients who are unable to undergo second-look surgery due to safety or other reasons and do not meet criteria for CR/PR (imaging and tumor markers).","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F6277EB-6199-3FA6-E050-BB89AD43414C","latestVersionIndicator":"Yes","beginDate":"2015-02-18","endDate":null,"createdBy":"WONGW","dateCreated":"2015-02-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F6277EB-61B2-3FA6-E050-BB89AD43414C","beginDate":"2015-02-18","endDate":null,"createdBy":"WONGW","dateCreated":"2015-02-18","modifiedBy":"ONEDATA","dateModified":"2015-02-18","deletedIndicator":"No"},{"value":"117","valueDescription":"Treatment failure","ValueMeaning":{"publicId":"5067151","version":"1","preferredName":"Treatment failure","longName":"5067151","preferredDefinition":"Treatment failure","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"25F4E6D2-E884-841F-E050-BB89AD430F79","latestVersionIndicator":"Yes","beginDate":"2015-12-02","endDate":null,"createdBy":"MIRANDAA","dateCreated":"2015-12-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"29176E81-BDC5-C53C-E050-BB89AD4306CF","beginDate":"2016-01-11","endDate":null,"createdBy":"MIRANDAA","dateCreated":"2016-01-11","modifiedBy":"ONEDATA","dateModified":"2016-01-11","deletedIndicator":"No"},{"value":"115","valueDescription":"The fifth anniversary of the date the patient was enrolled on this study.","ValueMeaning":{"publicId":"5098831","version":"1","preferredName":"The fifth anniversary of the date the patient was enrolled on this study.","longName":"5098831","preferredDefinition":"The fifth anniversary of the date the patient was enrolled on this study.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"29168FFF-838A-90CF-E050-BB89AD434961","latestVersionIndicator":"Yes","beginDate":"2016-01-11","endDate":null,"createdBy":"MIRANDAA","dateCreated":"2016-01-11","modifiedBy":"KUMMEROA","dateModified":"2022-07-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"29168FFF-83A3-90CF-E050-BB89AD434961","beginDate":"2016-01-11","endDate":null,"createdBy":"MIRANDAA","dateCreated":"2016-01-11","modifiedBy":"ONEDATA","dateModified":"2016-01-11","deletedIndicator":"No"},{"value":"116","valueDescription":"Relapsed disease","ValueMeaning":{"publicId":"5067152","version":"1","preferredName":"Relapsed disease","longName":"5067152","preferredDefinition":"Relapsed disease","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"25F4E6D2-E8A7-841F-E050-BB89AD430F79","latestVersionIndicator":"Yes","beginDate":"2015-12-02","endDate":null,"createdBy":"MIRANDAA","dateCreated":"2015-12-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"291759E6-086D-C12F-E050-BB89AD432F27","beginDate":"2016-01-11","endDate":null,"createdBy":"MIRANDAA","dateCreated":"2016-01-11","modifiedBy":"ONEDATA","dateModified":"2016-01-11","deletedIndicator":"No"},{"value":"114","valueDescription":"Surgery or radiation performed on any site of measurable disease before the end of the 6th cycle","ValueMeaning":{"publicId":"5070801","version":"1","preferredName":"Surgery or radiation performed on any site of measurable disease before the end of the 6th cycle","longName":"5070801","preferredDefinition":"Surgery or radiation performed on any site of measurable disease before the end of the 6th cycle","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2603D867-5A52-D3D5-E050-BB89AD432D5B","latestVersionIndicator":"Yes","beginDate":"2015-12-03","endDate":null,"createdBy":"DAVISJ","dateCreated":"2015-12-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"26A3F73B-764D-A576-E050-BB89AD431B74","beginDate":"2015-12-03","endDate":null,"createdBy":"DAVISJ","dateCreated":"2015-12-11","modifiedBy":"ONEDATA","dateModified":"2015-12-11","deletedIndicator":"No"},{"value":"121","valueDescription":"Progressive disease or relapse","ValueMeaning":{"publicId":"5166202","version":"1","preferredName":"Progressive disease or relapse","longName":"5166202","preferredDefinition":"Progressive disease or relapse","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2E4236CD-7834-968E-E050-BB89AD4346E8","latestVersionIndicator":"Yes","beginDate":"2016-03-17","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-03-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2EBA1F38-2098-9B92-E050-BB89AD4336E7","beginDate":"2016-03-17","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-03-23","modifiedBy":"ONEDATA","dateModified":"2016-03-23","deletedIndicator":"No"},{"value":"122","valueDescription":"FOXO1 fusion positive with Group IV/Stage 4 disease","ValueMeaning":{"publicId":"5166201","version":"1","preferredName":"FOXO1 fusion positive with Group IV/Stage 4 disease","longName":"5166201","preferredDefinition":"FOXO1 fusion positive with Group IV/Stage 4 disease","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2E4236CD-7811-968E-E050-BB89AD4346E8","latestVersionIndicator":"Yes","beginDate":"2016-03-17","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-03-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2EBA1F38-20AE-9B92-E050-BB89AD4336E7","beginDate":"2016-03-17","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-03-23","modifiedBy":"ONEDATA","dateModified":"2016-03-23","deletedIndicator":"No"},{"value":"123","valueDescription":"Refusal to transfer to Regimen C for patients meeting eligibility requirements for Regimen C","ValueMeaning":{"publicId":"5166200","version":"1","preferredName":"Refusal to transfer to Regimen C for patients meeting eligibility requirements for Regimen C","longName":"5166200","preferredDefinition":"Refusal to transfer to Regimen C for patients meeting eligibility requirements for Regimen C","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2E4236CD-77EE-968E-E050-BB89AD4346E8","latestVersionIndicator":"Yes","beginDate":"2016-03-17","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-03-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2EBA1F38-20C2-9B92-E050-BB89AD4336E7","beginDate":"2016-03-17","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-03-23","modifiedBy":"ONEDATA","dateModified":"2016-03-23","deletedIndicator":"No"},{"value":"119","valueDescription":"FOXO1 fusion status not determined by the institution by Day 21","ValueMeaning":{"publicId":"5188866","version":"1","preferredName":"FOXO1 fusion status not determined by the institution by Day 21","longName":"5188866","preferredDefinition":"FOXO1 fusion status not determined by the institution by Day 21","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2E95F66A-8E0F-CDCD-E050-BB89AD4368E6","latestVersionIndicator":"Yes","beginDate":"2016-03-21","endDate":null,"createdBy":"MIRANDAA","dateCreated":"2016-03-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2E95F66A-8E28-CDCD-E050-BB89AD4368E6","beginDate":"2016-03-21","endDate":null,"createdBy":"MIRANDAA","dateCreated":"2016-03-21","modifiedBy":"ONEDATA","dateModified":"2016-03-21","deletedIndicator":"No"},{"value":"124","valueDescription":"Relapse/Progressive disease","ValueMeaning":{"publicId":"5234435","version":"1","preferredName":"Relapse/Progressive disease","longName":"5234435","preferredDefinition":"Relapse/Progressive disease","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31575AAE-B8E9-0F77-E050-BB89AD4319E0","latestVersionIndicator":"Yes","beginDate":"2016-04-25","endDate":null,"createdBy":"HAMMA","dateCreated":"2016-04-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"31575AAE-B902-0F77-E050-BB89AD4319E0","beginDate":"2016-04-25","endDate":null,"createdBy":"HAMMA","dateCreated":"2016-04-25","modifiedBy":"ONEDATA","dateModified":"2016-04-25","deletedIndicator":"No"},{"value":"127","valueDescription":"Patient became pregnant","ValueMeaning":{"publicId":"5234436","version":"1","preferredName":"Patient became pregnant","longName":"5234436","preferredDefinition":"Patient became pregnant","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31575AAE-B90D-0F77-E050-BB89AD4319E0","latestVersionIndicator":"Yes","beginDate":"2016-04-25","endDate":null,"createdBy":"HAMMA","dateCreated":"2016-04-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"31575AAE-B926-0F77-E050-BB89AD4319E0","beginDate":"2016-04-25","endDate":null,"createdBy":"HAMMA","dateCreated":"2016-04-25","modifiedBy":"ONEDATA","dateModified":"2016-04-25","deletedIndicator":"No"},{"value":"126","valueDescription":"Patient could not begin treatment within 36 days after definitive surgery","ValueMeaning":{"publicId":"5234437","version":"1","preferredName":"Patient could not begin treatment within 36 days after definitive surgery","longName":"5234437","preferredDefinition":"Patient could not begin treatment within 36 days after definitive surgery","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31575AAE-B930-0F77-E050-BB89AD4319E0","latestVersionIndicator":"Yes","beginDate":"2016-04-25","endDate":null,"createdBy":"HAMMA","dateCreated":"2016-04-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"31575AAE-B949-0F77-E050-BB89AD4319E0","beginDate":"2016-04-25","endDate":null,"createdBy":"HAMMA","dateCreated":"2016-04-25","modifiedBy":"ONEDATA","dateModified":"2016-04-25","deletedIndicator":"No"},{"value":"125","valueDescription":"Repeat eligibility studies are outside the parameters required for eligibility (Section 3.3)","ValueMeaning":{"publicId":"5234438","version":"1","preferredName":"Repeat eligibility studies are outside the parameters required for eligibility (Section 3.3)","longName":"5234438","preferredDefinition":"Repeat eligibility studies are outside the parameters required for eligibility (Section 3.3)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31575AAE-B953-0F77-E050-BB89AD4319E0","latestVersionIndicator":"Yes","beginDate":"2016-04-25","endDate":null,"createdBy":"HAMMA","dateCreated":"2016-04-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"31575AAE-B96C-0F77-E050-BB89AD4319E0","beginDate":"2016-04-25","endDate":null,"createdBy":"HAMMA","dateCreated":"2016-04-25","modifiedBy":"ONEDATA","dateModified":"2016-04-25","deletedIndicator":"No"},{"value":"128","valueDescription":"Maintenance cannot be initiated within 6 weeks after completion of radiation therapy","ValueMeaning":{"publicId":"5252615","version":"1","preferredName":"Maintenance cannot be initiated within 6 weeks after completion of radiation therapy","longName":"5252615","preferredDefinition":"Maintenance cannot be initiated within 6 weeks after completion of radiation therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"321C7197-7909-2153-E050-BB89AD437FC6","latestVersionIndicator":"Yes","beginDate":"2016-05-05","endDate":null,"createdBy":"HAMMA","dateCreated":"2016-05-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"321C7197-7922-2153-E050-BB89AD437FC6","beginDate":"2016-05-05","endDate":null,"createdBy":"HAMMA","dateCreated":"2016-05-05","modifiedBy":"ONEDATA","dateModified":"2016-05-05","deletedIndicator":"No"},{"value":"135","valueDescription":"Assigned to Arm LMP-TC without an available matched LMP-specific T cell product","ValueMeaning":{"publicId":"5509530","version":"1","preferredName":"Assigned to Arm LMP-TC without an available matched LMP-specific T cell product","longName":"5509530","preferredDefinition":"Assigned to Arm LMP-TC without an available matched LMP-specific T cell product","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3E9F7E9E-F080-5ED4-E053-F662850AE86E","latestVersionIndicator":"Yes","beginDate":"2016-10-11","endDate":null,"createdBy":"CHANGP","dateCreated":"2016-10-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3F531ADA-96B9-4B75-E053-F662850ADFC0","beginDate":"2016-10-11","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-10-20","modifiedBy":"ONEDATA","dateModified":"2016-10-20","deletedIndicator":"No"},{"value":"136","valueDescription":"Assigned to Arm LMP-TC without HLA typing available by the Callback","ValueMeaning":{"publicId":"5509529","version":"1","preferredName":"Assigned to Arm LMP-TC without HLA typing available by the Callback","longName":"5509529","preferredDefinition":"Assigned to Arm LMP-TC without HLA typing available by the Callback","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3E9F7E9E-F05D-5ED4-E053-F662850AE86E","latestVersionIndicator":"Yes","beginDate":"2016-10-11","endDate":null,"createdBy":"CHANGP","dateCreated":"2016-10-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3F531ADA-96CD-4B75-E053-F662850ADFC0","beginDate":"2016-10-11","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-10-20","modifiedBy":"ONEDATA","dateModified":"2016-10-20","deletedIndicator":"No"},{"value":"137","valueDescription":"Progressive disease after or during Course RTX2, Course LMP-TC1, Course LMP-TC2","ValueMeaning":{"publicId":"5509531","version":"1","preferredName":"Progressive disease after or during Course RTX2, Course LMP-TC1, Course LMP-TC2","longName":"5509531","preferredDefinition":"Progressive disease after or during Course RTX2, Course LMP-TC1, Course LMP-TC2","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3E9F7E9E-F0A3-5ED4-E053-F662850AE86E","latestVersionIndicator":"Yes","beginDate":"2016-10-11","endDate":null,"createdBy":"CHANGP","dateCreated":"2016-10-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3F531ADA-96E1-4B75-E053-F662850ADFC0","beginDate":"2016-10-11","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-10-20","modifiedBy":"ONEDATA","dateModified":"2016-10-20","deletedIndicator":"No"},{"value":"138","valueDescription":"Evidence of Hepatitis B or C infection during any course of treatment with rituximab","ValueMeaning":{"publicId":"5508822","version":"1","preferredName":"Evidence of Hepatitis B or C infection during any course of treatment with rituximab","longName":"5508822","preferredDefinition":"Evidence of Hepatitis B or C infection during any course of treatment with rituximab","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3E62CF59-B78E-5D5B-E053-F662850A137A","latestVersionIndicator":"Yes","beginDate":"2016-10-08","endDate":null,"createdBy":"CHANGP","dateCreated":"2016-10-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3F531ADA-970D-4B75-E053-F662850ADFC0","beginDate":"2016-10-08","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-10-20","modifiedBy":"ONEDATA","dateModified":"2016-10-20","deletedIndicator":"No"},{"value":"134","valueDescription":"Adverse events/side effects/complications","ValueMeaning":{"publicId":"3090987","version":"1","preferredName":"Adverse events/side effects/complications","longName":"3090987","preferredDefinition":"Adverse events/side effects/complications","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"871570E4-29E6-7B29-E040-BB89AD43510F","latestVersionIndicator":"Yes","beginDate":"2010-05-21","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-05-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3E27EC89-D12C-7701-E053-F662850ABF7C","beginDate":"2016-10-05","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-10-05","modifiedBy":"ONEDATA","dateModified":"2016-10-05","deletedIndicator":"No"},{"value":"133","valueDescription":"Relapse at any site after achieving remission","ValueMeaning":{"publicId":"5505893","version":"1","preferredName":"Relapse at any site after achieving remission","longName":"5505893","preferredDefinition":"Relapse at any site after achieving remission","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3E27EC89-D136-7701-E053-F662850ABF7C","latestVersionIndicator":"Yes","beginDate":"2016-10-05","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-10-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3E27EC89-D14F-7701-E053-F662850ABF7C","beginDate":"2016-10-05","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-10-05","modifiedBy":"ONEDATA","dateModified":"2016-10-05","deletedIndicator":"No"},{"value":"132","valueDescription":"Failure to achieve M1 marrow status following completion of Consolidation therapy","ValueMeaning":{"publicId":"5505894","version":"1","preferredName":"Failure to achieve M1 marrow status following completion of Consolidation therapy","longName":"5505894","preferredDefinition":"Failure to achieve M1 marrow status following completion of Consolidation therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3E27EC89-D159-7701-E053-F662850ABF7C","latestVersionIndicator":"Yes","beginDate":"2016-10-05","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-10-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3E27EC89-D172-7701-E053-F662850ABF7C","beginDate":"2016-10-05","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-10-05","modifiedBy":"ONEDATA","dateModified":"2016-10-05","deletedIndicator":"No"},{"value":"131","valueDescription":"Two or more dose limiting toxicities (DLTs) in an individual patient","ValueMeaning":{"publicId":"5505895","version":"1","preferredName":"Two or more dose limiting toxicities (DLTs) in an individual patient","longName":"5505895","preferredDefinition":"Two or more dose limiting toxicities (DLTs) in an individual patient","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3E27EC89-D17C-7701-E053-F662850ABF7C","latestVersionIndicator":"Yes","beginDate":"2016-10-05","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-10-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3E27EC89-D195-7701-E053-F662850ABF7C","beginDate":"2016-10-05","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-10-05","modifiedBy":"ONEDATA","dateModified":"2016-10-05","deletedIndicator":"No"},{"value":"130","valueDescription":"Patients with KMT2A (MLL) rearranged leukemia who do not meet the criteria to start EPI Block #1 by Day 50","ValueMeaning":{"publicId":"5505896","version":"1","preferredName":"Patients with KMT2A (MLL) rearranged leukemia who do not meet the criteria to start EPI Block #1 by Day 50","longName":"5505896","preferredDefinition":"Patients with KMT2A (MLL) rearranged leukemia who do not meet the criteria to start EPI Block #1 by Day 50","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3E27EC89-D19F-7701-E053-F662850ABF7C","latestVersionIndicator":"Yes","beginDate":"2016-10-05","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-10-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3E27EC89-D1B8-7701-E053-F662850ABF7C","beginDate":"2016-10-05","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-10-05","modifiedBy":"ONEDATA","dateModified":"2016-10-05","deletedIndicator":"No"},{"value":"129","valueDescription":"Patients without KMT2A (MLL) rearranged leukemia following Induction and prior to EPI Block #1","ValueMeaning":{"publicId":"5505897","version":"1","preferredName":"Patients without KMT2A (MLL) rearranged leukemia following Induction and prior to EPI Block #1","longName":"5505897","preferredDefinition":"Patients without KMT2A (MLL) rearranged leukemia following Induction and prior to EPI Block #1","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3E27EC89-D1C2-7701-E053-F662850ABF7C","latestVersionIndicator":"Yes","beginDate":"2016-10-05","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-10-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3E27EC89-D1DB-7701-E053-F662850ABF7C","beginDate":"2016-10-05","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-10-05","modifiedBy":"ONEDATA","dateModified":"2016-10-05","deletedIndicator":"No"},{"value":"140","valueDescription":"Patient enrollment onto another COG anti-cancer therapeutic study (e.g., at recurrence) (section 8.2)","ValueMeaning":{"publicId":"5577149","version":"1","preferredName":"Patient enrollment onto another COG anti-cancer therapeutic study (e.g., at recurrence) (section 8.2)","longName":"5577149","preferredDefinition":"Patient enrollment onto another COG anti-cancer therapeutic study (e.g., at recurrence) (section 8.2)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"415CA243-5B05-211A-E053-F662850A906A","latestVersionIndicator":"Yes","beginDate":"2016-11-15","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-11-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"415CA243-5B1E-211A-E053-F662850A906A","beginDate":"2016-11-15","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-11-15","modifiedBy":"ONEDATA","dateModified":"2016-11-15","deletedIndicator":"No"},{"value":"139","valueDescription":"Patient experiences Grade 2 or greater SOS/VOD","ValueMeaning":{"publicId":"5577150","version":"1","preferredName":"Patient experiences Grade 2 or greater SOS/VOD","longName":"5577150","preferredDefinition":"Patient experiences Grade 2 or greater SOS/VOD","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"415CA243-5B28-211A-E053-F662850A906A","latestVersionIndicator":"Yes","beginDate":"2016-11-15","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-11-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"415CA243-5B41-211A-E053-F662850A906A","beginDate":"2016-11-15","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-11-15","modifiedBy":"ONEDATA","dateModified":"2016-11-15","deletedIndicator":"No"},{"value":"148","valueDescription":"Patients with KMT2A-R leukemia who meet criteria to start EPI Block #1, following the treatment of 6 patients with azacitidine, but prior to completion of interim toxicity analysis","ValueMeaning":{"publicId":"5615617","version":"1","preferredName":"Patients with KMT2A-R leukemia who meet criteria to start EPI Block #1, following the treatment of 6 patients with azacitidine, but prior to completion of interim toxicity analysis","longName":"5615617","preferredDefinition":"Patients with KMT2A-R leukemia who meet criteria to start EPI Block #1, following the treatment of 6 patients with azacitidine, but prior to completion of interim toxicity analysis","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45630DC1-AC14-4A29-E053-F662850A899C","latestVersionIndicator":"Yes","beginDate":"2017-01-05","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-01-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"45630DC1-AC2D-4A29-E053-F662850A899C","beginDate":"2017-01-05","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-01-05","modifiedBy":"ONEDATA","dateModified":"2017-01-05","deletedIndicator":"No"},{"value":"147","valueDescription":"Treatment failure as defined in Section 3.5.10","ValueMeaning":{"publicId":"5603984","version":"1","preferredName":"Treatment failure as defined in Section 3.5.10","longName":"5603984","preferredDefinition":"Treatment failure as defined in Section 3.5.10","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"43933164-5B20-1DB1-E053-F662850AE812","latestVersionIndicator":"Yes","beginDate":"2016-12-13","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-12-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"43933164-5B39-1DB1-E053-F662850AE812","beginDate":"2016-12-13","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-12-13","modifiedBy":"ONEDATA","dateModified":"2016-12-13","deletedIndicator":"No"},{"value":"146","valueDescription":"Unacceptable toxicity (DLT related) due to protocol therapy","ValueMeaning":{"publicId":"5578367","version":"1","preferredName":"Unacceptable toxicity (DLT related) due to protocol therapy","longName":"5578367","preferredDefinition":"Unacceptable toxicity (DLT related) due to protocol therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4183E0E7-43FE-7C0F-E053-F662850AC6C3","latestVersionIndicator":"Yes","beginDate":"2016-11-17","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-11-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4183E0E7-4417-7C0F-E053-F662850AC6C3","beginDate":"2016-11-17","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-11-17","modifiedBy":"ONEDATA","dateModified":"2016-11-17","deletedIndicator":"No"},{"value":"145","valueDescription":"Unacceptable toxicity (non-DLT related) due to protocol therapy","ValueMeaning":{"publicId":"5578368","version":"1","preferredName":"Unacceptable toxicity (non-DLT related) due to protocol therapy","longName":"5578368","preferredDefinition":"Unacceptable toxicity (non-DLT related) due to protocol therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4183E0E7-4421-7C0F-E053-F662850AC6C3","latestVersionIndicator":"Yes","beginDate":"2016-11-17","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-11-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4183E0E7-443A-7C0F-E053-F662850AC6C3","beginDate":"2016-11-17","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-11-17","modifiedBy":"ONEDATA","dateModified":"2016-11-17","deletedIndicator":"No"},{"value":"144","valueDescription":"Progressive disease during Cycle 1 or 2","ValueMeaning":{"publicId":"5578369","version":"1","preferredName":"Progressive disease during Cycle 1 or 2","longName":"5578369","preferredDefinition":"Progressive disease during Cycle 1 or 2","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4183E0E7-4444-7C0F-E053-F662850AC6C3","latestVersionIndicator":"Yes","beginDate":"2016-11-17","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-11-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4183E0E7-445D-7C0F-E053-F662850AC6C3","beginDate":"2016-11-17","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-11-17","modifiedBy":"ONEDATA","dateModified":"2016-11-17","deletedIndicator":"No"},{"value":"143","valueDescription":"Patient fails to achieve CR or CRi at the end of Cycle 2","ValueMeaning":{"publicId":"5578370","version":"1","preferredName":"Patient fails to achieve CR or CRi at the end of Cycle 2","longName":"5578370","preferredDefinition":"Patient fails to achieve CR or CRi at the end of Cycle 2","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4183E0E7-4467-7C0F-E053-F662850AC6C3","latestVersionIndicator":"Yes","beginDate":"2016-11-17","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-11-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4183E0E7-4480-7C0F-E053-F662850AC6C3","beginDate":"2016-11-17","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-11-17","modifiedBy":"ONEDATA","dateModified":"2016-11-17","deletedIndicator":"No"},{"value":"142","valueDescription":"CNS3 patient has persistent CNS3 disease after Cycle 1","ValueMeaning":{"publicId":"5578371","version":"1","preferredName":"CNS3 patient has persistent CNS3 disease after Cycle 1","longName":"5578371","preferredDefinition":"CNS3 patient has persistent CNS3 disease after Cycle 1","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4183E0E7-448A-7C0F-E053-F662850AC6C3","latestVersionIndicator":"Yes","beginDate":"2016-11-17","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-11-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4183E0E7-44A3-7C0F-E053-F662850AC6C3","beginDate":"2016-11-17","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-11-17","modifiedBy":"ONEDATA","dateModified":"2016-11-17","deletedIndicator":"No"},{"value":"141","valueDescription":"Patient is CNS2 or CNS3 or has persistent testicular or other extramedullary disease at the end of Cycle 2","ValueMeaning":{"publicId":"5578372","version":"1","preferredName":"Patient is CNS2 or CNS3 or has persistent testicular or other extramedullary disease at the end of Cycle 2","longName":"5578372","preferredDefinition":"Patient is CNS2 or CNS3 or has persistent testicular or other extramedullary disease at the end of Cycle 2","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4183E0E7-44AD-7C0F-E053-F662850AC6C3","latestVersionIndicator":"Yes","beginDate":"2016-11-17","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-11-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4183E0E7-44C6-7C0F-E053-F662850AC6C3","beginDate":"2016-11-17","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-11-17","modifiedBy":"ONEDATA","dateModified":"2016-11-17","deletedIndicator":"No"},{"value":"155","valueDescription":"Complete End Point Follow-up","ValueMeaning":{"publicId":"5702589","version":"1","preferredName":"Complete End Point Follow-up","longName":"5702589","preferredDefinition":"To possess every necessary or normal part or component or step; having come or been brought to a conclusion.: A place of termination or completion. This may be a primary or secondary outcome variable used to judge the effectiveness of a treatment.: The process by which information about the health status of an individual is obtained after a study has officially closed; an activity that continues something that has already begun or that repeats something that has already been done.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Complete","conceptCode":"C25250","definition":"To possess every necessary or normal part or component or step; having come or been brought to a conclusion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"End Point","conceptCode":"C25212","definition":"A place of termination or completion. This may be a primary or secondary outcome variable used to judge the effectiveness of a treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Follow-Up","conceptCode":"C16033","definition":"The process by which information about the health status of an individual is obtained after a study has officially closed; an activity that continues something that has already begun or that repeats something that has already been done.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A6327A8-6593-12D3-E053-F662850AA11C","latestVersionIndicator":"Yes","beginDate":"2017-03-10","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-03-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4A6327A8-65AE-12D3-E053-F662850AA11C","beginDate":"2017-03-10","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-03-10","modifiedBy":"ONEDATA","dateModified":"2017-03-10","deletedIndicator":"No"},{"value":"151","valueDescription":"Resistant disease","ValueMeaning":{"publicId":"5659944","version":"1","preferredName":"Resistant disease","longName":"5659944","preferredDefinition":"Resistant disease","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"48374D35-B67B-6039-E053-F662850A7584","latestVersionIndicator":"Yes","beginDate":"2017-02-10","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-02-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"48374D35-B694-6039-E053-F662850A7584","beginDate":"2017-02-10","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-02-10","modifiedBy":"ONEDATA","dateModified":"2017-02-10","deletedIndicator":"No"},{"value":"150","valueDescription":"HR patients who receive any other chemotherapy pre-HSCT other than treatment specified in the protocol","ValueMeaning":{"publicId":"5659945","version":"1","preferredName":"HR patients who receive any other chemotherapy pre-HSCT other than treatment specified in the protocol","longName":"5659945","preferredDefinition":"HR patients who receive any other chemotherapy pre-HSCT other than treatment specified in the protocol","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"48374D35-B69E-6039-E053-F662850A7584","latestVersionIndicator":"Yes","beginDate":"2017-02-10","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-02-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"48374D35-B6B7-6039-E053-F662850A7584","beginDate":"2017-02-10","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-02-10","modifiedBy":"ONEDATA","dateModified":"2017-02-10","deletedIndicator":"No"},{"value":"152","valueDescription":"Development of LBP-associated bacteremia","ValueMeaning":{"publicId":"5684627","version":"1","preferredName":"Development of LBP-associated bacteremia","longName":"5684627","preferredDefinition":"Development of LBP-associated bacteremia","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"499E7ADA-1828-7F30-E053-F662850ACF9F","latestVersionIndicator":"Yes","beginDate":"2017-02-28","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-02-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"499E7ADA-186D-7F30-E053-F662850ACF9F","beginDate":"2017-02-28","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-02-28","modifiedBy":"ONEDATA","dateModified":"2017-02-28","deletedIndicator":"No"},{"value":"153","valueDescription":"Subject Unblinding Event Record Emergency","ValueMeaning":{"publicId":"5699587","version":"1","preferredName":"Subject Unblinding Event Record Emergency","longName":"5699587","preferredDefinition":"A record detailing the act of breaking the blind for an individual subject, urgently if needed, or when interim or final unblinding occurs. Treatment unblinding may be controlled by interactive response technology (IRT) or manually. [Adapted from TMF-RM]: A sudden unforeseen crisis that requires immediate action.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Subject Unblinding Event Record","conceptCode":"C115572","definition":"Documentation pertaining to the revelation of a previously masked component of the study.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Emergency","conceptCode":"C62648","definition":"A sudden unforeseen crisis that requires immediate action.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A3C6A6F-F53F-7E9C-E053-F662850A57CC","latestVersionIndicator":"Yes","beginDate":"2017-03-08","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-03-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4A3CC418-16EF-22E0-E053-F662850A68F1","beginDate":"2017-03-08","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-03-08","modifiedBy":"ONEDATA","dateModified":"2017-03-08","deletedIndicator":"No"},{"value":"149","valueDescription":"Tenth anniversary of the date the patient was enrolled on this study","ValueMeaning":{"publicId":"5632753","version":"1","preferredName":"Tenth anniversary of the date the patient was enrolled on this study","longName":"5632753","preferredDefinition":"Tenth anniversary of the date the patient was enrolled on this study","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"46C983A7-2FAA-23D5-E053-F662850A766F","latestVersionIndicator":"Yes","beginDate":"2017-01-23","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-01-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"46C983A7-2FC3-23D5-E053-F662850A766F","beginDate":"2017-01-23","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-01-23","modifiedBy":"ONEDATA","dateModified":"2017-01-23","deletedIndicator":"No"},{"value":"154","valueDescription":"Therapeutic Procedure Subject Unblinding Event Record","ValueMeaning":{"publicId":"5702588","version":"1","preferredName":"Therapeutic Procedure Subject Unblinding Event Record","longName":"5702588","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.: A record detailing the act of breaking the blind for an individual subject, urgently if needed, or when interim or final unblinding occurs. Treatment unblinding may be controlled by interactive response technology (IRT) or manually. [Adapted from TMF-RM]","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Subject Unblinding Event Record","conceptCode":"C115572","definition":"Documentation pertaining to the revelation of a previously masked component of the study.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A65C251-50BA-73B6-E053-F662850A43FF","latestVersionIndicator":"Yes","beginDate":"2017-03-10","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-03-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4A65C251-50D5-73B6-E053-F662850A43FF","beginDate":"2017-03-10","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-03-10","modifiedBy":"ONEDATA","dateModified":"2017-03-10","deletedIndicator":"No"},{"value":"156","valueDescription":"Progressive disease for patients receiving chemotherapy according to SR1 and SR2 treatment plan","ValueMeaning":{"publicId":"5630549","version":"1","preferredName":"Progressive disease for patients receiving chemotherapy according to SR1 and SR2 treatment plan","longName":"5630549","preferredDefinition":"Progressive disease for patients receiving chemotherapy according to SR1 and SR2 treatment plan","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"467D0F3B-C3DE-612D-E053-F662850A5050","latestVersionIndicator":"Yes","beginDate":"2017-01-19","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-01-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4BF7CD57-1B39-15A4-E053-F662850AE823","beginDate":"2017-01-19","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-03-30","modifiedBy":"ONEDATA","dateModified":"2017-03-30","deletedIndicator":"No"},{"value":"157","valueDescription":"SR patients who decline randomization","ValueMeaning":{"publicId":"5658009","version":"1","preferredName":"SR patients who decline randomization","longName":"5658009","preferredDefinition":"SR patients who decline randomization","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4824667F-9DCD-6C6A-E053-F662850A93A5","latestVersionIndicator":"Yes","beginDate":"2017-02-10","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-02-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4BF7CD57-1B4F-15A4-E053-F662850AE823","beginDate":"2017-02-10","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-03-30","modifiedBy":"ONEDATA","dateModified":"2017-03-30","deletedIndicator":"No"},{"value":"158","valueDescription":"Toxicity requiring removal as defined in Section 5","ValueMeaning":{"publicId":"5630550","version":"1","preferredName":"Toxicity requiring removal as defined in Section 5","longName":"5630550","preferredDefinition":"Toxicity requiring removal as defined in Section 5","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"467D1293-67F8-5A7D-E053-F662850A4559","latestVersionIndicator":"Yes","beginDate":"2017-01-19","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-01-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4BF7CD57-1B65-15A4-E053-F662850AE823","beginDate":"2017-01-19","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-03-30","modifiedBy":"ONEDATA","dateModified":"2017-03-30","deletedIndicator":"No"},{"value":"159","valueDescription":"Neoplasm ALK Gene Defect History Thromboembolism","ValueMeaning":{"publicId":"5782320","version":"1","preferredName":"Neoplasm ALK Gene Defect History Thromboembolism","longName":"5782320","preferredDefinition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.: This gene is involved in brain development and neuronal specificity.: A failing or deficiency.: The aggregate of past events; the continuum of events occurring in succession leading from the past to the present; a record or narrative description of past events.: Occlusion of the lumen of a vessel by a thrombus that has migrated from a distal site via the blood stream.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neoplasm","conceptCode":"C3262","definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"ALK Gene","conceptCode":"C38184","definition":"This gene is involved in brain development and neuronal specificity.","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Defect","conceptCode":"C43429","definition":"A failing or deficiency.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"History","conceptCode":"C54625","definition":"The aggregate of past events; the continuum of events occurring in succession leading from the past to the present; a record or narrative description of past events.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Thromboembolism","conceptCode":"C28195","definition":"Occlusion of the lumen of a vessel by a thrombus that has migrated from a distal site via the blood stream.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4E1A048C-263A-579B-E053-F662850A5757","latestVersionIndicator":"Yes","beginDate":"2017-04-26","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-04-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4E1A048C-2655-579B-E053-F662850A5757","beginDate":"2017-04-26","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-04-26","modifiedBy":"ONEDATA","dateModified":"2017-04-26","deletedIndicator":"No"},{"value":"160","valueDescription":"Delay Therapeutic Procedure","ValueMeaning":{"publicId":"5782319","version":"1","preferredName":"Delay Therapeutic Procedure","longName":"5782319","preferredDefinition":"Time during which some action is awaited; inactivity resulting in something being put off until a later time; the state of being slower or later.: An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Delay","conceptCode":"C25476","definition":"Time during which some action is awaited; inactivity resulting in something being put off until a later time; the state of being slower or later.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4E1A048C-260F-579B-E053-F662850A5757","latestVersionIndicator":"Yes","beginDate":"2017-04-26","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-04-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4E1A048C-262A-579B-E053-F662850A5757","beginDate":"2017-04-26","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-04-26","modifiedBy":"ONEDATA","dateModified":"2017-04-26","deletedIndicator":"No"},{"value":"166","valueDescription":"Completion of 12 cycles of therapy","ValueMeaning":{"publicId":"5776341","version":"1","preferredName":"Completion of 12 cycles of therapy","longName":"5776341","preferredDefinition":"Completion of 12 cycles of therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D5E71F3-FE9A-0AA7-E053-F662850AC305","latestVersionIndicator":"Yes","beginDate":"2017-04-17","endDate":null,"createdBy":"LEEW","dateCreated":"2017-04-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5036A76D-8772-7433-E053-F662850AB76F","beginDate":"2017-04-17","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-05-23","modifiedBy":"ONEDATA","dateModified":"2017-05-23","deletedIndicator":"No"},{"value":"163","valueDescription":"Any Time Begin Cycle Three Until End Therapeutic Procedure Progressive Disease","ValueMeaning":{"publicId":"5782838","version":"1","preferredName":"Any Time Begin Cycle Three Until End Therapeutic Procedure Progressive Disease","longName":"5782838","preferredDefinition":"One, some, every, or all without specification.: The continuum of experience in which events pass from the future through the present to the past.: Have a beginning, in a temporal, spatial, or evaluative sense; the point in space or time where something begins.: An event or sequence of events that constitute a round or succession of observable phenomena, recurring usually at regular or approximately regular time intervals and in the same sequence.: A natural number greater than 2 and less than 4 and the quantity that it denotes: the sum of two and one.: Up to the point of some specific time or event.: The point or place at which something terminates in time, space, or extent.: An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.: A disease process that is increasing in scope or severity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Any","conceptCode":"C81168","definition":"One, some, every, or all without specification.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"8"},{"longName":"Time","conceptCode":"C25207","definition":"The continuum of experience in which events pass from the future through the present to the past.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"7"},{"longName":"Begin","conceptCode":"C25431","definition":"Have a beginning, in a temporal, spatial, or evaluative sense; the point in space or time where something begins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Cycle","conceptCode":"C25472","definition":"An event or sequence of events that constitute a round or succession of observable phenomena, recurring usually at regular or approximately regular time intervals and in the same sequence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Three","conceptCode":"C66834","definition":"A natural number greater than 2 and less than 4 and the quantity that it denotes: the sum of two and one.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Until","conceptCode":"C65136","definition":"Up to the point of some specific time or event.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"End","conceptCode":"C25496","definition":"The point or place at which something terminates in time, space, or extent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Progressive Disease","conceptCode":"C35571","definition":"A clinical, pathologic, and/or molecular finding indicating that the course of a disease is worsening in terms of extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4E280779-FE3A-1098-E053-F662850A5F55","latestVersionIndicator":"Yes","beginDate":"2017-04-27","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-04-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4E280779-FE55-1098-E053-F662850A5F55","beginDate":"2017-04-27","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-04-27","modifiedBy":"ONEDATA","dateModified":"2017-04-27","deletedIndicator":"No"},{"value":"162","valueDescription":"Inadequate To Support Arm Assignment Or Negation Ability Harvest Procedure Stem Cell","ValueMeaning":{"publicId":"5782839","version":"1","preferredName":"Inadequate To Support Arm Assignment Or Negation Ability Harvest Procedure Stem Cell","longName":"5782839","preferredDefinition":"Not meeting a quantitative or qualitative measure necessary for a requirement.: Used as a function word to indicate direction, purpose, or movement.: Moral, psychological, physical, or financial aid or assistance; approval.: The portion of the upper extremity between the shoulder and the elbow. For clinical purposes this term is also used to refer to the whole superior limb.: An allotting or an appointment to a particular person or use, or for a particular time or object.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: An operation in which a term denies or inverts the meaning of another term or construction.: The quality of being able to perform; a quality that permits or facilitates achievement or accomplishment.: Remove from a culture or a living or dead body, as for the purposes of transplantation.: An unspecialized cell that has the capacity for reproduction through cell division and can be induced to differentiate into a tissue or organ specific cell.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Inadequate","conceptCode":"C69177","definition":"Not meeting a quantitative or qualitative measure necessary for a requirement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"9"},{"longName":"To","conceptCode":"C65107","definition":"Used as a function word to indicate direction, purpose, or movement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"8"},{"longName":"Support","conceptCode":"C37902","definition":"Moral, psychological, physical, or financial aid or assistance; approval.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"7"},{"longName":"Arm","conceptCode":"C32141","definition":"The portion of the upper extremity between the shoulder and the elbow. For clinical purposes this term is also used to refer to the whole superior limb.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Assignment","conceptCode":"C25426","definition":"An allotting or an appointment to a particular person or use, or for a particular time or object.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Ability","conceptCode":"C78209","definition":"The quality of being able to perform; a quality that permits or facilitates achievement or accomplishment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Harvest Procedure","conceptCode":"C37963","definition":"Remove from a culture or a living or dead body, as for the purposes of transplantation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Stem Cell","conceptCode":"C12662","definition":"An unspecialized cell that has the capacity for reproduction through cell division and can be induced to differentiate into a tissue or organ specific cell.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4E280779-FE6A-1098-E053-F662850A5F55","latestVersionIndicator":"Yes","beginDate":"2017-04-27","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-04-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4E280779-FE85-1098-E053-F662850A5F55","beginDate":"2017-04-27","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-04-27","modifiedBy":"ONEDATA","dateModified":"2017-04-27","deletedIndicator":"No"},{"value":"161","valueDescription":"Therapeutic Procedure Consent Assignment Arm Or Parent Patient Guardian Refuse","ValueMeaning":{"publicId":"5782840","version":"1","preferredName":"Therapeutic Procedure Consent Assignment Arm Or Parent Patient Guardian Refuse","longName":"5782840","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.: Permission to do something.: An allotting or an appointment to a particular person or use, or for a particular time or object.: The portion of the upper extremity between the shoulder and the elbow. For clinical purposes this term is also used to refer to the whole superior limb.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: A mother or a father; an immediate progenitor.: A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.: An individual who is authorized under applicable State or local law to consent on behalf of a child or incapable person to general medical care including participation in clinical research.: To decline to do, accept, give, or allow something.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"8"},{"longName":"Consent","conceptCode":"C25460","definition":"Permission to do something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"7"},{"longName":"Assignment","conceptCode":"C25426","definition":"An allotting or an appointment to a particular person or use, or for a particular time or object.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Arm","conceptCode":"C32141","definition":"The portion of the upper extremity between the shoulder and the elbow. For clinical purposes this term is also used to refer to the whole superior limb.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Parent","conceptCode":"C42709","definition":"A mother or a father; an immediate progenitor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Guardian","conceptCode":"C51828","definition":"An individual who is authorized under applicable State or local law to consent on behalf of a child or incapable person to general medical care including participation in clinical research.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Refuse","conceptCode":"C49161","definition":"To decline to do, accept, give, or allow something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4E280779-FE99-1098-E053-F662850A5F55","latestVersionIndicator":"Yes","beginDate":"2017-04-27","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-04-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4E280779-FEB4-1098-E053-F662850A5F55","beginDate":"2017-04-27","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-04-27","modifiedBy":"ONEDATA","dateModified":"2017-04-27","deletedIndicator":"No"},{"value":"167","valueDescription":"Patients initially enrolled and randomized with a diagnosis of Ewing sarcoma or PNET for whom the initial enrolling diagnosis is changed to a diagnosis other than Ewing sarcoma or PNET","ValueMeaning":{"publicId":"5907539","version":"1","preferredName":"Patients initially enrolled and randomized with a diagnosis of Ewing sarcoma or PNET for whom the initial enrolling diagnosis is changed to a diagnosis other than Ewing sarcoma or PNET","longName":"5907539","preferredDefinition":"Patients initially enrolled and randomized with a diagnosis of Ewing sarcoma or PNET for whom the initial enrolling diagnosis is changed to a diagnosis other than Ewing sarcoma or PNET","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5423101B-D0B8-47BC-E053-F662850AAB96","latestVersionIndicator":"Yes","beginDate":"2017-07-12","endDate":null,"createdBy":"LEEW","dateCreated":"2017-07-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5423101B-D0D1-47BC-E053-F662850AAB96","beginDate":"2017-07-12","endDate":null,"createdBy":"LEEW","dateCreated":"2017-07-12","modifiedBy":"ONEDATA","dateModified":"2017-07-12","deletedIndicator":"No"},{"value":"164","valueDescription":"No Receive Allogeneic Conditioning","ValueMeaning":{"publicId":"5801514","version":"1","preferredName":"No Receive Allogeneic Conditioning","longName":"5801514","preferredDefinition":"The non-affirmative response to a question.: To take, accept, or get something offered.: A preparative treatment regimen given prior to a cell transplantation from a genetically non-identical donor. The regimen consists of chemotherapy with or without radiation and is intended to kill cancerous cells before the transplantation and to provide immunosuppression to prevent the rejection of the donor's stem cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Receive","conceptCode":"C25639","definition":"To take, accept, or get something offered.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Allogeneic Conditioning","conceptCode":"C107095","definition":"A preparative treatment regimen given prior to a cell transplantation from a genetically non-identical donor. The regimen consists of chemotherapy with or without radiation and is intended to kill cancerous cells before the transplantation and to provide immunosuppression to prevent the rejection of the donor's stem cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4E7EA816-7679-0B9B-E053-F662850AD5D2","latestVersionIndicator":"Yes","beginDate":"2017-05-01","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-05-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4E7EA816-7694-0B9B-E053-F662850AD5D2","beginDate":"2017-05-01","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-05-01","modifiedBy":"ONEDATA","dateModified":"2017-05-01","deletedIndicator":"No"},{"value":"165","valueDescription":"Never Receive Transplant","ValueMeaning":{"publicId":"5826018","version":"1","preferredName":"Never Receive Transplant","longName":"5826018","preferredDefinition":"Not ever; at no time in the past (or future).: To take, accept, or get something offered.: Used with organs, tissues, or cells for transplantation from one site to another within the same subject, or from one subject to another of the same species or different species.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Never","conceptCode":"C70543","definition":"Not ever; at no time in the past (or future).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Receive","conceptCode":"C25639","definition":"To take, accept, or get something offered.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Transplant","conceptCode":"C0040733","definition":"Used with organs, tissues, or cells for transplantation from one site to another within the same subject, or from one subject to another of the same species or different species.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4F92F6B9-1E43-75F7-E053-F662850AA281","latestVersionIndicator":"Yes","beginDate":"2017-05-15","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-05-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4F92F6B9-1E5E-75F7-E053-F662850AA281","beginDate":"2017-05-15","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-05-15","modifiedBy":"ONEDATA","dateModified":"2017-05-15","deletedIndicator":"No"},{"value":"168","valueDescription":"Patient Begin Date Therapeutic Procedure Greater Than Forty Two Day From Date Collection Material Established Diagnosis Rhabdomyosarcoma","ValueMeaning":{"publicId":"6001119","version":"1","preferredName":"Patient Begin Date Therapeutic Procedure Greater Than Forty Two Day From Date Collection Material Established Diagnosis Rhabdomyosarcoma","longName":"6001119","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.: Begin Date; the calendar date on which an event began.: An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.: A statement about the relative size or order of two objects specifying that an object of interest exceeds another object in quantity or measure or value or status.: A natural number greater than thirty-nine and less than forty-one and the quantity that it denotes.: A natural number greater than 1 and less than 3 and the quantity that it denotes: the sum of one and one.: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.: Used to indicate a specified place or time as a starting point; used to indicate a source, cause, agent, or instrument.: The particular day, month and year an event has happened or will happen.: The act of gathering things together; having been brought together in one place.: The tangible substance that goes into the makeup of a physical object.: Shown to be valid beyond a reasonable doubt.: The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.: A rare aggressive malignant mesenchymal neoplasm arising from skeletal muscle. It usually occurs in children and young adults. Only a small percentage of tumors arise in the skeletal muscle of the extremities. The majority arise in other anatomical sites.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"13"},{"longName":"Begin Date","conceptCode":"C25383","definition":"Begin Date; the calendar date on which an event began.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"12"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"11"},{"longName":"Greater Than","conceptCode":"C61584","definition":"A statement about the relative size or order of two objects specifying that an object of interest exceeds another object in quantity or measure or value or status.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"10"},{"longName":"Forty","conceptCode":"C105795","definition":"A natural number greater than thirty-nine and less than forty-one and the quantity that it denotes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"9"},{"longName":"Two","conceptCode":"C66833","definition":"A natural number greater than 1 and less than 3 and the quantity that it denotes: the sum of one and one.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"8"},{"longName":"Day","conceptCode":"C25301","definition":"The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"7"},{"longName":"From","conceptCode":"C25516","definition":"Used to indicate a specified place or time as a starting point; used to indicate a source, cause, agent, or instrument.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Date","conceptCode":"C25164","definition":"The particular day, month and year an event has happened or will happen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Collection","conceptCode":"C25453","definition":"The act of gathering things together; having been brought together in one place.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Material","conceptCode":"C48187","definition":"The tangible substance that goes into the makeup of a physical object.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Established","conceptCode":"C71155","definition":"Shown to be valid beyond a reasonable doubt.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Diagnosis","conceptCode":"C15220","definition":"The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Rhabdomyosarcoma","conceptCode":"C3359","definition":"A rare aggressive malignant mesenchymal neoplasm arising from skeletal muscle. It usually occurs in children and young adults. Only a small percentage of tumors arise in the skeletal muscle of the extremities. The majority arise in other anatomic sites.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B391084-B948-3B75-E053-F662850A2F51","latestVersionIndicator":"Yes","beginDate":"2017-10-10","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-10-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B391084-B963-3B75-E053-F662850A2F51","beginDate":"2017-10-10","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-10-10","modifiedBy":"ONEDATA","dateModified":"2017-10-10","deletedIndicator":"No"},{"value":"169","valueDescription":"Patients with KMT2A (MLL) rearranged leukemia who do not meet the criteria to start EPI Block #1 by Day 64","ValueMeaning":{"publicId":"6059535","version":"1","preferredName":"Patients with KMT2A (MLL) rearranged leukemia who do not meet the criteria to start EPI Block #1 by Day 64","longName":"6059535","preferredDefinition":"Patients with KMT2A (MLL) rearranged leukemia who do not meet the criteria to start EPI Block #1 by Day 64","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6416F0D7-9FB0-6270-E053-F662850A5FAF","latestVersionIndicator":"Yes","beginDate":"2018-01-31","endDate":null,"createdBy":"LEEW","dateCreated":"2018-01-31","modifiedBy":"ONEDATA","dateModified":"2018-01-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6416F0D7-9FC9-6270-E053-F662850A5FAF","beginDate":"2018-01-31","endDate":null,"createdBy":"LEEW","dateCreated":"2018-01-31","modifiedBy":"ONEDATA","dateModified":"2018-01-31","deletedIndicator":"No"},{"value":"175","valueDescription":"For Group B and D patients, failure to complete treatment assignment Callback following completion of Cycle 2 (Group B) or induction Block 3 (Group D) but before initiation of the next cycle of protocol-specified chemotherapy","ValueMeaning":{"publicId":"6080701","version":"1","preferredName":"For Group B and D patients, failure to complete treatment assignment Callback following completion of Cycle 2 (Group B) or induction Block 3 (Group D) but before initiation of the next cycle of protocol-specified chemotherapy","longName":"6080701","preferredDefinition":"For Group B and D patients, failure to complete treatment assignment Callback following completion of Cycle 2 (Group B) or induction Block 3 (Group D) but before initiation of the next cycle of protocol-specified chemotherapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"65EA8960-A72F-16FC-E053-F662850ACD5D","latestVersionIndicator":"Yes","beginDate":"2018-02-23","endDate":null,"createdBy":"HLAINGY","dateCreated":"2018-02-23","modifiedBy":"ONEDATA","dateModified":"2018-02-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"65EA8960-A748-16FC-E053-F662850ACD5D","beginDate":"2018-02-23","endDate":null,"createdBy":"HLAINGY","dateCreated":"2018-02-23","modifiedBy":"ONEDATA","dateModified":"2018-02-23","deletedIndicator":"No"},{"value":"173","valueDescription":"Rapid central pathologic review (if applicable) is not completed within 14 days of enrollment","ValueMeaning":{"publicId":"6080703","version":"1","preferredName":"Rapid central pathologic review (if applicable) is not completed within 14 days of enrollment","longName":"6080703","preferredDefinition":"Rapid central pathologic review (if applicable) is not completed within 14 days of enrollment","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"65EA8960-A775-16FC-E053-F662850ACD5D","latestVersionIndicator":"Yes","beginDate":"2018-02-23","endDate":null,"createdBy":"HLAINGY","dateCreated":"2018-02-23","modifiedBy":"ONEDATA","dateModified":"2018-02-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"65EA8960-A78E-16FC-E053-F662850ACD5D","beginDate":"2018-02-23","endDate":null,"createdBy":"HLAINGY","dateCreated":"2018-02-23","modifiedBy":"ONEDATA","dateModified":"2018-02-23","deletedIndicator":"No"},{"value":"172","valueDescription":"Unacceptable toxicity as defined in Section 5.0.","ValueMeaning":{"publicId":"6080704","version":"1","preferredName":"Unacceptable toxicity as defined in Section 5.0.","longName":"6080704","preferredDefinition":"Unacceptable toxicity as defined in Section 5.0.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"65EA8960-A798-16FC-E053-F662850ACD5D","latestVersionIndicator":"Yes","beginDate":"2018-02-23","endDate":null,"createdBy":"HLAINGY","dateCreated":"2018-02-23","modifiedBy":"ONEDATA","dateModified":"2018-02-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"65EA8960-A7B1-16FC-E053-F662850ACD5D","beginDate":"2018-02-23","endDate":null,"createdBy":"HLAINGY","dateCreated":"2018-02-23","modifiedBy":"ONEDATA","dateModified":"2018-02-23","deletedIndicator":"No"},{"value":"171","valueDescription":"Failure to resume post-resection chemotherapy within 42 days of primary tumor resection","ValueMeaning":{"publicId":"6080705","version":"1","preferredName":"Failure to resume post-resection chemotherapy within 42 days of primary tumor resection","longName":"6080705","preferredDefinition":"Failure to resume post-resection chemotherapy within 42 days of primary tumor resection","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"65EA8960-A7BB-16FC-E053-F662850ACD5D","latestVersionIndicator":"Yes","beginDate":"2018-02-23","endDate":null,"createdBy":"HLAINGY","dateCreated":"2018-02-23","modifiedBy":"ONEDATA","dateModified":"2018-02-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"65EA8960-A7D4-16FC-E053-F662850ACD5D","beginDate":"2018-02-23","endDate":null,"createdBy":"HLAINGY","dateCreated":"2018-02-23","modifiedBy":"ONEDATA","dateModified":"2018-02-23","deletedIndicator":"No"},{"value":"170","valueDescription":"Failure to begin protocol therapy within 14 days of biopsy or within 42 days of upfront surgery","ValueMeaning":{"publicId":"6080706","version":"1","preferredName":"Failure to begin protocol therapy within 14 days of biopsy or within 42 days of upfront surgery","longName":"6080706","preferredDefinition":"Failure to begin protocol therapy within 14 days of biopsy or within 42 days of upfront surgery","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"65EA8960-A7DE-16FC-E053-F662850ACD5D","latestVersionIndicator":"Yes","beginDate":"2018-02-23","endDate":null,"createdBy":"HLAINGY","dateCreated":"2018-02-23","modifiedBy":"ONEDATA","dateModified":"2018-02-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"65EA8960-A7F7-16FC-E053-F662850ACD5D","beginDate":"2018-02-23","endDate":null,"createdBy":"HLAINGY","dateCreated":"2018-02-23","modifiedBy":"ONEDATA","dateModified":"2018-02-23","deletedIndicator":"No"},{"value":"174","valueDescription":"Rapid central pathologic review (if applicable) does not agree with institutional diagnosis (e.g., suspected HB patients who are either  8 years of age or have an AFP < 100 at diagnosis who are found to have HCC by central review)","ValueMeaning":{"publicId":"6080702","version":"1","preferredName":"Rapid central pathologic review (if applicable) does not agree with institutional diagnosis (e.g., suspected HB patients who are either  8 years of age or have an AFP < 100 at diagnosis who are found to have HCC by central review)","longName":"6080702","preferredDefinition":"Rapid central pathologic review (if applicable) does not agree with institutional diagnosis (e.g., suspected HB patients who are either  8 years of age or have an AFP < 100 at diagnosis who are found to have HCC by central review)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"65EA8960-A752-16FC-E053-F662850ACD5D","latestVersionIndicator":"Yes","beginDate":"2018-02-23","endDate":null,"createdBy":"HLAINGY","dateCreated":"2018-02-23","modifiedBy":"ONEDATA","dateModified":"2018-02-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"65EAB061-BC00-1722-E053-F662850ABE4A","beginDate":"2018-02-23","endDate":null,"createdBy":"HLAINGY","dateCreated":"2018-02-23","modifiedBy":"ONEDATA","dateModified":"2018-02-23","deletedIndicator":"No"},{"value":"186","valueDescription":"Patient failed to discontinue TKI within 5 working days of enrollment","ValueMeaning":{"publicId":"6381261","version":"1","preferredName":"Patient failed to discontinue TKI within 5 working days of enrollment","longName":"6381261","preferredDefinition":"Patient failed to discontinue TKI within 5 working days of enrollment","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"72660DB4-A3D7-1A5C-E053-F662850AAB9C","latestVersionIndicator":"Yes","beginDate":"2018-08-01","endDate":null,"createdBy":"LEEW","dateCreated":"2018-08-01","modifiedBy":"ONEDATA","dateModified":"2018-08-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"72661755-F7F8-4EED-E053-F662850A8B99","beginDate":"2018-08-01","endDate":null,"createdBy":"LEEW","dateCreated":"2018-08-01","modifiedBy":"ONEDATA","dateModified":"2018-08-01","deletedIndicator":"No"},{"value":"187","valueDescription":"For patients who lose their molecular remission, patient fails to restart TKI within 7 calendar days from the date the RQ-PCR result becomes available","ValueMeaning":{"publicId":"6381260","version":"1","preferredName":"For patients who lose their molecular remission, patient fails to restart TKI within 7 calendar days from the date the RQ-PCR result becomes available","longName":"6381260","preferredDefinition":"For patients who lose their molecular remission, patient fails to restart TKI within 7 calendar days from the date the RQ-PCR result becomes available","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"72660DB4-A3B4-1A5C-E053-F662850AAB9C","latestVersionIndicator":"Yes","beginDate":"2018-08-01","endDate":null,"createdBy":"LEEW","dateCreated":"2018-08-01","modifiedBy":"ONEDATA","dateModified":"2018-08-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"72661755-F80C-4EED-E053-F662850A8B99","beginDate":"2018-08-01","endDate":null,"createdBy":"LEEW","dateCreated":"2018-08-01","modifiedBy":"ONEDATA","dateModified":"2018-08-01","deletedIndicator":"No"},{"value":"177","valueDescription":"Patient Negation Ability Begin Radiation Therapy Within Thirty One Day Definitive Surgery","ValueMeaning":{"publicId":"6369278","version":"1","preferredName":"Patient Negation Ability Begin Radiation Therapy Within Thirty One Day Definitive Surgery","longName":"6369278","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.: An operation in which a term denies or inverts the meaning of another term or construction.: The quality of being able to perform; a quality that permits or facilitates achievement or accomplishment.: Have a beginning, in a temporal, spatial, or evaluative sense; the point in space or time where something begins.: Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.: On the inside; contained in.: A natural number greater than thirty and less than thirty-two and the quantity that it denotes.: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.: Supplying or being a final or conclusive settlement or result.: The branch of medical science that treats disease or injury by operative procedures.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"9"},{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"8"},{"longName":"Ability","conceptCode":"C78209","definition":"The quality of being able to perform; a quality that permits or facilitates achievement or accomplishment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"7"},{"longName":"Begin","conceptCode":"C25431","definition":"Have a beginning, in a temporal, spatial, or evaluative sense; the point in space or time where something begins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Radiation Therapy","conceptCode":"C15313","definition":"Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Within","conceptCode":"C25282","definition":"On the inside; contained in.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Thirty One","conceptCode":"C126863","definition":"A natural number greater than thirty and less than thirty-two and the quantity that it denotes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Day","conceptCode":"C25301","definition":"The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Definitive","conceptCode":"C62607","definition":"Supplying or being a final or conclusive settlement or result.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Surgery","conceptCode":"C17173","definition":"The branch of medical science that treats disease or injury by operative procedures.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"71B0A08C-3511-1738-E053-F662850AD738","latestVersionIndicator":"Yes","beginDate":"2018-07-23","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2018-07-23","modifiedBy":"ONEDATA","dateModified":"2018-07-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"71B0A08C-352C-1738-E053-F662850AD738","beginDate":"2018-07-20","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2018-07-23","modifiedBy":"ONEDATA","dateModified":"2018-07-23","deletedIndicator":"No"},{"value":"178","valueDescription":"Patient Negation Ability Begin Protocol Agent Within Thirty Four Day Definitive Surgery","ValueMeaning":{"publicId":"6369279","version":"1","preferredName":"Patient Negation Ability Begin Protocol Agent Within Thirty Four Day Definitive Surgery","longName":"6369279","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.: An operation in which a term denies or inverts the meaning of another term or construction.: The quality of being able to perform; a quality that permits or facilitates achievement or accomplishment.: Have a beginning, in a temporal, spatial, or evaluative sense; the point in space or time where something begins.: A medical product, practice, or application that is tested in a clinical trial.: On the inside; contained in.: A natural number greater than twenty-nine and less than thirty-one and the quantity that it denotes.: A natural number greater than 3 and less than 5 and the quantity that it denotes: the sum of three and one.: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.: Supplying or being a final or conclusive settlement or result.: The branch of medical science that treats disease or injury by operative procedures.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"10"},{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"9"},{"longName":"Ability","conceptCode":"C78209","definition":"The quality of being able to perform; a quality that permits or facilitates achievement or accomplishment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"8"},{"longName":"Begin","conceptCode":"C25431","definition":"Have a beginning, in a temporal, spatial, or evaluative sense; the point in space or time where something begins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"7"},{"longName":"Protocol Agent","conceptCode":"C41161","definition":"A medical product, practice, or application that is tested in a clinical trial.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Within","conceptCode":"C25282","definition":"On the inside; contained in.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Thirty","conceptCode":"C105797","definition":"A natural number greater than twenty-nine and less than thirty-one and the quantity that it denotes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Four","conceptCode":"C66835","definition":"A natural number greater than 3 and less than 5 and the quantity that it denotes: the sum of three and one.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Day","conceptCode":"C25301","definition":"The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Definitive","conceptCode":"C62607","definition":"Supplying or being a final or conclusive settlement or result.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Surgery","conceptCode":"C17173","definition":"The branch of medical science that treats disease or injury by operative procedures.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"71B0A08C-3542-1738-E053-F662850AD738","latestVersionIndicator":"Yes","beginDate":"2018-07-23","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2018-07-23","modifiedBy":"ONEDATA","dateModified":"2018-07-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"71B0A08C-355D-1738-E053-F662850AD738","beginDate":"2018-07-06","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2018-07-23","modifiedBy":"ONEDATA","dateModified":"2018-07-23","deletedIndicator":"No"},{"value":"185","valueDescription":"Repeat eligibility studies (if required) are outside the parameters required for eligibility","ValueMeaning":{"publicId":"6365332","version":"1","preferredName":"Repeat eligibility studies (if required) are outside the parameters required for eligibility","longName":"6365332","preferredDefinition":"Repeat eligibility studies (if required) are outside the parameters required for eligibility","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"71628C48-2A92-1C50-E053-F662850A2543","latestVersionIndicator":"Yes","beginDate":"2018-07-19","endDate":null,"createdBy":"TANGL","dateCreated":"2018-07-19","modifiedBy":"ONEDATA","dateModified":"2018-07-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"71628C48-2AAB-1C50-E053-F662850A2543","beginDate":"2018-07-19","endDate":null,"createdBy":"TANGL","dateCreated":"2018-07-19","modifiedBy":"ONEDATA","dateModified":"2018-07-19","deletedIndicator":"No"},{"value":"184","valueDescription":"Surgical resection of tumor lesions that are increasing in size while on therapy","ValueMeaning":{"publicId":"6365333","version":"1","preferredName":"Surgical resection of tumor lesions that are increasing in size while on therapy","longName":"6365333","preferredDefinition":"Surgical resection of tumor lesions that are increasing in size while on therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"71628C48-2AB5-1C50-E053-F662850A2543","latestVersionIndicator":"Yes","beginDate":"2018-07-19","endDate":null,"createdBy":"TANGL","dateCreated":"2018-07-19","modifiedBy":"ONEDATA","dateModified":"2018-07-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"71628C48-2ACE-1C50-E053-F662850A2543","beginDate":"2018-07-19","endDate":null,"createdBy":"TANGL","dateCreated":"2018-07-19","modifiedBy":"ONEDATA","dateModified":"2018-07-19","deletedIndicator":"No"},{"value":"183","valueDescription":"Tumor is surgically resected within the first 12 weeks of protocol therapy","ValueMeaning":{"publicId":"6365334","version":"1","preferredName":"Tumor is surgically resected within the first 12 weeks of protocol therapy","longName":"6365334","preferredDefinition":"Tumor is surgically resected within the first 12 weeks of protocol therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"71628C48-2AD8-1C50-E053-F662850A2543","latestVersionIndicator":"Yes","beginDate":"2018-07-19","endDate":null,"createdBy":"TANGL","dateCreated":"2018-07-19","modifiedBy":"ONEDATA","dateModified":"2018-07-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"71628C48-2AF1-1C50-E053-F662850A2543","beginDate":"2018-07-19","endDate":null,"createdBy":"TANGL","dateCreated":"2018-07-19","modifiedBy":"ONEDATA","dateModified":"2018-07-19","deletedIndicator":"No"},{"value":"182","valueDescription":"Response followed by progression","ValueMeaning":{"publicId":"6365335","version":"1","preferredName":"Response followed by progression","longName":"6365335","preferredDefinition":"Response followed by progression","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"71628C48-2AFB-1C50-E053-F662850A2543","latestVersionIndicator":"Yes","beginDate":"2018-07-19","endDate":null,"createdBy":"TANGL","dateCreated":"2018-07-19","modifiedBy":"ONEDATA","dateModified":"2018-07-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"71628C48-2B14-1C50-E053-F662850A2543","beginDate":"2018-07-19","endDate":null,"createdBy":"TANGL","dateCreated":"2018-07-19","modifiedBy":"ONEDATA","dateModified":"2018-07-19","deletedIndicator":"No"},{"value":"181","valueDescription":"Progressive disease of >= 20% increase from baseline in tumor size that occurs > 12 weeks after start of protocol therapy except pseudoprogression","ValueMeaning":{"publicId":"6365336","version":"1","preferredName":"Progressive disease of >= 20% increase from baseline in tumor size that occurs > 12 weeks after start of protocol therapy except pseudoprogression","longName":"6365336","preferredDefinition":"Progressive disease of >= 20% increase from baseline in tumor size that occurs > 12 weeks after start of protocol therapy, except if a patient met the criteria for pseudoprogression in the first 12 weeks and the tumor subsequently stabilizes or decreases in size","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"71628C48-2B1E-1C50-E053-F662850A2543","latestVersionIndicator":"Yes","beginDate":"2018-07-19","endDate":null,"createdBy":"TANGL","dateCreated":"2018-07-19","modifiedBy":"ONEDATA","dateModified":"2018-07-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"71628C48-2B37-1C50-E053-F662850A2543","beginDate":"2018-07-19","endDate":null,"createdBy":"TANGL","dateCreated":"2018-07-19","modifiedBy":"ONEDATA","dateModified":"2018-07-19","deletedIndicator":"No"},{"value":"180","valueDescription":"Progressive disease of >= 40% increase from baseline in tumor size at any time during protocol therapy","ValueMeaning":{"publicId":"6365337","version":"1","preferredName":"Progressive disease of >= 40% increase from baseline in tumor size at any time during protocol therapy","longName":"6365337","preferredDefinition":"Progressive disease of >= 40% increase from baseline in tumor size at any time during protocol therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"71628C48-2B41-1C50-E053-F662850A2543","latestVersionIndicator":"Yes","beginDate":"2018-07-19","endDate":null,"createdBy":"TANGL","dateCreated":"2018-07-19","modifiedBy":"ONEDATA","dateModified":"2018-07-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"71628C48-2B5A-1C50-E053-F662850A2543","beginDate":"2018-07-19","endDate":null,"createdBy":"TANGL","dateCreated":"2018-07-19","modifiedBy":"ONEDATA","dateModified":"2018-07-19","deletedIndicator":"No"},{"value":"179","valueDescription":"Patient enrollment onto another research study with tumor therapeutic intent","ValueMeaning":{"publicId":"6365367","version":"1","preferredName":"Patient enrollment onto another research study with tumor therapeutic intent","longName":"6365367","preferredDefinition":"Patient enrollment onto another research study with tumor therapeutic intent (eg, at recurrence)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"716279C6-4A75-438A-E053-F662850A10AB","latestVersionIndicator":"Yes","beginDate":"2018-07-19","endDate":null,"createdBy":"TANGL","dateCreated":"2018-07-19","modifiedBy":"ONEDATA","dateModified":"2018-07-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"716279C6-4A8E-438A-E053-F662850A10AB","beginDate":"2018-07-19","endDate":null,"createdBy":"TANGL","dateCreated":"2018-07-19","modifiedBy":"ONEDATA","dateModified":"2018-07-19","deletedIndicator":"No"},{"value":"198","valueDescription":"Development Severe Persistent Anemia Need Blood Transfusion To Maintenance Greater Than Or Same As Ten Gram Per Deciliter Hemoglobin","ValueMeaning":{"publicId":"6411305","version":"1","preferredName":"Development Severe Persistent Anemia Need Blood Transfusion To Maintenance Greater Than Or Same As Ten Gram Per Deciliter Hemoglobin","longName":"6411305","preferredDefinition":"Processes that involve and promote formation of more mature organs, organ systems, or organisms; general development. (NCI): Intensely bad or unpleasant in degree, quality or extent.: Retained; never-ceasing.: A reduction in the number of red blood cells, the amount of hemoglobin, and/or the volume of packed red blood cells. Clinically, anemia represents a reduction in the oxygen-transporting capacity of a designated volume of blood, resulting from an imbalance between blood loss (through hemorrhage or hemolysis) and blood production. Signs and symptoms of anemia may include pallor of the skin and mucous membranes, shortness of breath, palpitations of the heart, soft systolic murmurs, lethargy, and fatigability.: Anything that is necessary but lacking; the psychological feature that arouses an organism to action toward a desired goal; the reason for the action; that which gives purpose and direction to behavior.: The infusion of components of blood or whole blood into the bloodstream. The blood may be donated from another person, or it may have been taken from the person earlier and stored until needed.: Used as a function word to indicate direction, purpose, or movement.: The act of sustaining something in its current form or proper condition; upkeep.: A statement about the relative size or order of two objects specifying that an object of interest exceeds another object in quantity or measure or value or status.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: Equal, or closely similar or comparable, in kind or quality or quantity or degree.: In the same amount or manner; to the same degree; in the role, function, or capacity of.: A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: The metric unit of mass equal to one thousandth of a kil","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Development","conceptCode":"C18732","definition":"Processes that involve and promote formation of more mature organs, organ systems, or organisms; general development. (NCI)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"16"},{"longName":"Severe","conceptCode":"C70667","definition":"Intensely bad or unpleasant in degree, quality or extent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"15"},{"longName":"Persistent","conceptCode":"C43623","definition":"Retained; never-ceasing.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"14"},{"longName":"Anemia","conceptCode":"C2869","definition":"A reduction in the number of red blood cells, the amount of hemoglobin, and/or the volume of packed red blood cells. Clinically, anemia represents a reduction in the oxygen-transporting capacity of a designated volume of blood, resulting from an imbalance between blood loss (through hemorrhage or hemolysis) and blood production. Signs and symptoms of anemia may include pallor of the skin and mucous membranes, shortness of breath, palpitations of the heart, soft systolic murmurs, lethargy, and fatigability.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"13"},{"longName":"Need","conceptCode":"C41204","definition":"Anything that is necessary but lacking; the psychological feature that arouses an organism to action toward a desired goal; the reason for the action; that which gives purpose and direction to behavior.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"12"},{"longName":"Blood Transfusion","conceptCode":"C15192","definition":"The injection of whole blood or a blood component directly into the bloodstream.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"11"},{"longName":"To","conceptCode":"C65107","definition":"Used as a function word to indicate direction, purpose, or movement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"10"},{"longName":"Maintenance","conceptCode":"C53297","definition":"The act of sustaining something in its current form or proper condition; upkeep.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"9"},{"longName":"Greater Than","conceptCode":"C61584","definition":"A statement about the relative size or order of two objects specifying that an object of interest exceeds another object in quantity or measure or value or status.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"8"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"7"},{"longName":"Same","conceptCode":"C64637","definition":"Equal, or closely similar or comparable, in kind or quality or quantity or degree.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"As","conceptCode":"C64938","definition":"In the same amount or manner; to the same degree; in the role, function, or capacity of.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Ten","conceptCode":"C69122","definition":"A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Gram","conceptCode":"C48155","definition":"The metric unit of mass equal to one thousandth of a kilogram. One gram equals approximately 15.432 grains or 0.035 273 966 ounce.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Per","conceptCode":"C65039","definition":"For each, generally denoting a ratio.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Deciliter","conceptCode":"C64697","definition":"The unit of volume equal to one tenth of a liter. Accepted for use with the SI.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Hemoglobin","conceptCode":"C16676","definition":"The red respiratory protein of erythrocytes, consisting of approximately 3.8% heme and 96.2% globin (64.5 KD), which as oxyhemoglobin (HbO2) transports oxygen from the lungs to the tissues where the oxygen is readily released and HbO2 becomes Hb.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"74216BC5-F5EE-3CC2-E053-F662850A1284","latestVersionIndicator":"Yes","beginDate":"2018-08-23","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2018-08-23","modifiedBy":"ONEDATA","dateModified":"2018-08-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"74216BC5-F609-3CC2-E053-F662850A1284","beginDate":"2018-08-23","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2018-08-23","modifiedBy":"ONEDATA","dateModified":"2018-08-23","deletedIndicator":"No"},{"value":"188","valueDescription":"Patient stops taking TKI medication after restarting","ValueMeaning":{"publicId":"6429526","version":"1","preferredName":"Patient stops taking TKI medication after restarting","longName":"6429526","preferredDefinition":"Patient stops taking TKI medication after restarting","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"759FDE89-A8D7-6B28-E053-F662850A74A0","latestVersionIndicator":"Yes","beginDate":"2018-09-11","endDate":null,"createdBy":"LEEW","dateCreated":"2018-09-11","modifiedBy":"ONEDATA","dateModified":"2018-09-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"759FDE89-A8F0-6B28-E053-F662850A74A0","beginDate":"2018-09-11","endDate":null,"createdBy":"LEEW","dateCreated":"2018-09-11","modifiedBy":"ONEDATA","dateModified":"2018-09-11","deletedIndicator":"No"},{"value":"195","valueDescription":"Patient failed to discontinue TKI within 10 calendar days after enrollment","ValueMeaning":{"publicId":"6489428","version":"1","preferredName":"Patient failed to discontinue TKI within 10 calendar days after enrollment","longName":"6489428","preferredDefinition":"Patient failed to discontinue TKI within 10 calendar days after enrollment","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7873D4F1-C964-59DF-E053-F662850A1ED7","latestVersionIndicator":"Yes","beginDate":"2018-10-17","endDate":null,"createdBy":"LEEW","dateCreated":"2018-10-17","modifiedBy":"ONEDATA","dateModified":"2018-10-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7C5FB48D-7AA8-6170-E053-F662850AA8B6","beginDate":"2018-12-06","endDate":null,"createdBy":"LEEW","dateCreated":"2018-12-06","modifiedBy":"ONEDATA","dateModified":"2018-12-06","deletedIndicator":"No"},{"value":"194","valueDescription":"Patient becomes pregnant while taking TKI or with the need to restart TKI","ValueMeaning":{"publicId":"6571043","version":"1","preferredName":"Patient becomes pregnant while taking TKI or with the need to restart TKI","longName":"6571043","preferredDefinition":"Patient becomes pregnant while taking TKI or with the need to restart TKI","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7BBEE380-8B1A-1075-E053-F662850A6457","latestVersionIndicator":"Yes","beginDate":"2018-11-28","endDate":null,"createdBy":"LEEW","dateCreated":"2018-11-28","modifiedBy":"ONEDATA","dateModified":"2018-11-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7C5FB48D-7ABC-6170-E053-F662850AA8B6","beginDate":"2018-12-06","endDate":null,"createdBy":"LEEW","dateCreated":"2018-12-06","modifiedBy":"ONEDATA","dateModified":"2018-12-06","deletedIndicator":"No"},{"value":"199","valueDescription":"Stable Disease","ValueMeaning":{"publicId":"2982985","version":"1","preferredName":"Stable Disease","longName":"2982985","preferredDefinition":"Cancer that is neither decreasing nor increasing in extent or severity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stable Disease","conceptCode":"C18213","definition":"A disease that is neither decreasing nor increasing in extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C991ADD-0176-711A-E040-BB89AD432C85","latestVersionIndicator":"Yes","beginDate":"2010-01-07","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-01-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"80B7140C-F0AF-060D-E053-F662850A3D2E","beginDate":"2019-01-14","endDate":null,"createdBy":"PROSVIROVAB","dateCreated":"2019-01-30","modifiedBy":"ONEDATA","dateModified":"2019-01-30","deletedIndicator":"No"},{"value":"Assigned to Arm LMP-TC without HLA typing available by the Day 22 post induction Callback","valueDescription":"Assigned to Arm LMP-TC without HLA typing available by the Day 22 post induction Callback","ValueMeaning":{"publicId":"6617418","version":"1","preferredName":"Assigned to Arm LMP-TC without HLA typing available by the Day 22 post induction Callback","longName":"6617418","preferredDefinition":"Assigned to Arm LMP-TC without HLA typing available by the Day 22 post induction Callback","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7FAC14A2-F5A2-4088-E053-F662850A4340","latestVersionIndicator":"Yes","beginDate":"2019-01-17","endDate":null,"createdBy":"GALITG","dateCreated":"2019-01-17","modifiedBy":"ONEDATA","dateModified":"2019-01-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7FAC14A2-F5BB-4088-E053-F662850A4340","beginDate":"2019-01-17","endDate":null,"createdBy":"GALITG","dateCreated":"2019-01-17","modifiedBy":"ONEDATA","dateModified":"2019-01-17","deletedIndicator":"No"},{"value":"192","valueDescription":"Delays in therapy that meet the criteria in Sections 4.6.6 and 4.9.1","ValueMeaning":{"publicId":"6569789","version":"1","preferredName":"Delays in therapy that meet the criteria in Sections 4.6.6 and 4.9.1","longName":"6569789","preferredDefinition":"Delays in therapy that meet the criteria in Sections 4.6.6 and 4.9.1","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7BAE3B24-D3DB-34F0-E053-F662850A060D","latestVersionIndicator":"Yes","beginDate":"2018-11-27","endDate":null,"createdBy":"COBARRUBIAK","dateCreated":"2018-11-27","modifiedBy":"ONEDATA","dateModified":"2018-11-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7BAE3B24-D3F4-34F0-E053-F662850A060D","beginDate":"2018-11-27","endDate":null,"createdBy":"COBARRUBIAK","dateCreated":"2018-11-27","modifiedBy":"ONEDATA","dateModified":"2018-11-27","deletedIndicator":"No"},{"value":"191","valueDescription":"Progressive disease at any time from the end of Induction Cycle 4 until the end of protocol therapy. Patients with stable disease or better may remain on protocol therapy","ValueMeaning":{"publicId":"6569790","version":"1","preferredName":"Progressive disease at any time from the end of Induction Cycle 4 until the end of protocol therapy. Patients with stable disease or better may remain on protocol therapy","longName":"6569790","preferredDefinition":"Progressive disease at any time from the end of Induction Cycle 4 until the end of protocol therapy. Patients with stable disease or better may remain on protocol therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7BAE3B24-D3FE-34F0-E053-F662850A060D","latestVersionIndicator":"Yes","beginDate":"2018-11-27","endDate":null,"createdBy":"COBARRUBIAK","dateCreated":"2018-11-27","modifiedBy":"ONEDATA","dateModified":"2018-11-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7BAE3B24-D417-34F0-E053-F662850A060D","beginDate":"2018-11-27","endDate":null,"createdBy":"COBARRUBIAK","dateCreated":"2018-11-27","modifiedBy":"ONEDATA","dateModified":"2018-11-27","deletedIndicator":"No"},{"value":"190","valueDescription":"Did not receive dinutuximab during Induction therapy","ValueMeaning":{"publicId":"6569791","version":"1","preferredName":"Did not receive dinutuximab during Induction therapy","longName":"6569791","preferredDefinition":"Did not receive dinutuximab during Induction therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7BAE3B24-D421-34F0-E053-F662850A060D","latestVersionIndicator":"Yes","beginDate":"2018-11-27","endDate":null,"createdBy":"COBARRUBIAK","dateCreated":"2018-11-27","modifiedBy":"ONEDATA","dateModified":"2018-11-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7BAE3B24-D43A-34F0-E053-F662850A060D","beginDate":"2018-11-27","endDate":null,"createdBy":"COBARRUBIAK","dateCreated":"2018-11-27","modifiedBy":"ONEDATA","dateModified":"2018-11-27","deletedIndicator":"No"},{"value":"189","valueDescription":"Lack of sufficient stem cells to support tandem transplant or inability to harvest stem cells prior to Consolidation","ValueMeaning":{"publicId":"6569792","version":"1","preferredName":"Lack of sufficient stem cells to support tandem transplant or inability to harvest stem cells prior to Consolidation","longName":"6569792","preferredDefinition":"Lack of sufficient stem cells to support tandem transplant or inability to harvest stem cells prior to Consolidation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7BAE3B24-D444-34F0-E053-F662850A060D","latestVersionIndicator":"Yes","beginDate":"2018-11-27","endDate":null,"createdBy":"COBARRUBIAK","dateCreated":"2018-11-27","modifiedBy":"ONEDATA","dateModified":"2018-11-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7BAE3B24-D45D-34F0-E053-F662850A060D","beginDate":"2018-11-27","endDate":null,"createdBy":"COBARRUBIAK","dateCreated":"2018-11-27","modifiedBy":"ONEDATA","dateModified":"2018-11-27","deletedIndicator":"No"},{"value":"193","valueDescription":"For patients enrolled after the implementation of Amendment #4A: Patient is Standard Risk (MRD < 0.05% in the bone marrow) after Induction I.","ValueMeaning":{"publicId":"6580683","version":"1","preferredName":"For patients enrolled after the implementation of Amendment #4A: Patient is Standard Risk (MRD < 0.05% in the bone marrow) after Induction I.","longName":"6580683","preferredDefinition":"For patients enrolled after the implementation of Amendment #4A: Patient is Standard Risk (MRD < 0.05% in the bone marrow) after Induction I.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C5D5493-EB52-47E1-E053-F662850A8956","latestVersionIndicator":"Yes","beginDate":"2018-12-06","endDate":null,"createdBy":"LEEW","dateCreated":"2018-12-06","modifiedBy":"ONEDATA","dateModified":"2018-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7C5D5493-EB6A-47E1-E053-F662850A8956","beginDate":"2018-12-06","endDate":null,"createdBy":"LEEW","dateCreated":"2018-12-06","modifiedBy":"ONEDATA","dateModified":"2018-12-06","deletedIndicator":"No"},{"value":"301","valueDescription":"Assigned to Arm LMP-TC without HLA typing available by the Day 22 post induction Callback","ValueMeaning":{"publicId":"6617418","version":"1","preferredName":"Assigned to Arm LMP-TC without HLA typing available by the Day 22 post induction Callback","longName":"6617418","preferredDefinition":"Assigned to Arm LMP-TC without HLA typing available by the Day 22 post induction Callback","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7FAC14A2-F5A2-4088-E053-F662850A4340","latestVersionIndicator":"Yes","beginDate":"2019-01-17","endDate":null,"createdBy":"GALITG","dateCreated":"2019-01-17","modifiedBy":"ONEDATA","dateModified":"2019-01-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"84115A9B-1E0E-7B7B-E053-F662850AE5A7","beginDate":"2019-03-14","endDate":null,"createdBy":"GALITG","dateCreated":"2019-03-14","modifiedBy":"ONEDATA","dateModified":"2019-03-14","deletedIndicator":"No"},{"value":"200","valueDescription":"Persistent CNS leukemia","ValueMeaning":{"publicId":"6660760","version":"1","preferredName":"Persistent CNS leukemia","longName":"6660760","preferredDefinition":"Persistent CNS leukemia","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"82E33985-4641-45E3-E053-F662850A8EC3","latestVersionIndicator":"Yes","beginDate":"2019-02-27","endDate":null,"createdBy":"SHOARYAS","dateCreated":"2019-02-27","modifiedBy":"ONEDATA","dateModified":"2019-02-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"82E33985-465A-45E3-E053-F662850A8EC3","beginDate":"2019-02-27","endDate":null,"createdBy":"SHOARYAS","dateCreated":"2019-02-27","modifiedBy":"ONEDATA","dateModified":"2019-02-27","deletedIndicator":"No"},{"value":"196","valueDescription":"Patient found at any point after enrollment to be inevaluable","ValueMeaning":{"publicId":"6688469","version":"1","preferredName":"Patient found at any point after enrollment to be inevaluable","longName":"6688469","preferredDefinition":"Patient found at any point after enrollment to be inevaluable","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"860D49AB-6B53-2F3A-E053-F662850A2B74","latestVersionIndicator":"Yes","beginDate":"2019-04-08","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-08","modifiedBy":"ONEDATA","dateModified":"2019-04-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"86344A32-C233-32C0-E053-F662850AB4C1","beginDate":"2019-04-10","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-10","modifiedBy":"ONEDATA","dateModified":"2019-04-10","deletedIndicator":"No"},{"value":"197","valueDescription":"Patient found to be ineligible after enrollment","ValueMeaning":{"publicId":"6688028","version":"1","preferredName":"Patient found to be ineligible after enrollment","longName":"6688028","preferredDefinition":"Patient found to be ineligible after enrollment","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86092DA5-48F3-5CB3-E053-F662850AA978","latestVersionIndicator":"Yes","beginDate":"2019-04-08","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-08","modifiedBy":"ONEDATA","dateModified":"2019-04-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"86092DA5-490C-5CB3-E053-F662850AA978","beginDate":"2019-04-08","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-08","modifiedBy":"ONEDATA","dateModified":"2019-04-08","deletedIndicator":"No"},{"value":"Patient found at any point after enrollment to be inevaluable","valueDescription":"Patient found at any point after enrollment to be inevaluable","ValueMeaning":{"publicId":"6688469","version":"1","preferredName":"Patient found at any point after enrollment to be inevaluable","longName":"6688469","preferredDefinition":"Patient found at any point after enrollment to be inevaluable","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"860D49AB-6B53-2F3A-E053-F662850A2B74","latestVersionIndicator":"Yes","beginDate":"2019-04-08","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-08","modifiedBy":"ONEDATA","dateModified":"2019-04-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"860D49AB-6B6C-2F3A-E053-F662850A2B74","beginDate":"2019-04-08","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-08","modifiedBy":"ONEDATA","dateModified":"2019-04-08","deletedIndicator":"No"},{"value":"201","valueDescription":"Delay in selumetinib treatment of > 42 days for any reason (for example, decrease in BSA below 0.5 m2)","ValueMeaning":{"publicId":"6674819","version":"1","preferredName":"Delay in selumetinib treatment of > 42 days for any reason (for example, decrease in BSA below 0.5 m2)","longName":"6674819","preferredDefinition":"Delay in selumetinib treatment of > 42 days for any reason (for example, decrease in BSA below 0.5 m2)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"83FAF6BB-0A29-3A78-E053-F662850A93E5","latestVersionIndicator":"Yes","beginDate":"2019-03-13","endDate":null,"createdBy":"COBARRUBIAK","dateCreated":"2019-03-13","modifiedBy":"ONEDATA","dateModified":"2019-03-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"83FAF6BB-0A42-3A78-E053-F662850A93E5","beginDate":"2019-03-13","endDate":null,"createdBy":"COBARRUBIAK","dateCreated":"2019-03-13","modifiedBy":"ONEDATA","dateModified":"2019-03-13","deletedIndicator":"No"},{"value":"213","valueDescription":"Incomplete Induction data for risk stratification","ValueMeaning":{"publicId":"6720481","version":"1","preferredName":"Incomplete Induction data for risk stratification","longName":"6720481","preferredDefinition":"Incomplete Induction data for risk stratification","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"874B6901-55C7-7436-E053-F662850A2C0F","latestVersionIndicator":"Yes","beginDate":"2019-04-24","endDate":null,"createdBy":"GALITG","dateCreated":"2019-04-24","modifiedBy":"ONEDATA","dateModified":"2019-04-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8748D47B-763F-0BB0-E053-F662850A89FF","beginDate":"2019-04-24","endDate":null,"createdBy":"GALITG","dateCreated":"2019-04-24","modifiedBy":"ONEDATA","dateModified":"2019-04-24","deletedIndicator":"No"},{"value":"212","valueDescription":"Incomplete Induction data for risk stratification","ValueMeaning":{"publicId":"6720481","version":"1","preferredName":"Incomplete Induction data for risk stratification","longName":"6720481","preferredDefinition":"Incomplete Induction data for risk stratification","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"874B6901-55C7-7436-E053-F662850A2C0F","latestVersionIndicator":"Yes","beginDate":"2019-04-24","endDate":null,"createdBy":"GALITG","dateCreated":"2019-04-24","modifiedBy":"ONEDATA","dateModified":"2019-04-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8748D47B-7653-0BB0-E053-F662850A89FF","beginDate":"2019-04-24","endDate":null,"createdBy":"GALITG","dateCreated":"2019-04-24","modifiedBy":"ONEDATA","dateModified":"2019-04-24","deletedIndicator":"No"},{"value":"211","valueDescription":"Identified as Philadelphia Chromosome-positive (BCR-ABL1)","ValueMeaning":{"publicId":"6720482","version":"1","preferredName":"Identified as Philadelphia Chromosome-positive (BCR-ABL1)","longName":"6720482","preferredDefinition":"Identified as Philadelphia Chromosome-positive (BCR-ABL1)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"874B6901-55EA-7436-E053-F662850A2C0F","latestVersionIndicator":"Yes","beginDate":"2019-04-24","endDate":null,"createdBy":"GALITG","dateCreated":"2019-04-24","modifiedBy":"ONEDATA","dateModified":"2019-04-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8748D47B-7667-0BB0-E053-F662850A89FF","beginDate":"2019-04-24","endDate":null,"createdBy":"GALITG","dateCreated":"2019-04-24","modifiedBy":"ONEDATA","dateModified":"2019-04-24","deletedIndicator":"No"},{"value":"210","valueDescription":"Adverse Event requiring removal from protocol therapy","ValueMeaning":{"publicId":"6705348","version":"1","preferredName":"Adverse Event requiring removal from protocol therapy","longName":"6705348","preferredDefinition":"Adverse Event requiring removal from protocol therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86E54249-B652-2471-E053-F662850A813C","latestVersionIndicator":"Yes","beginDate":"2019-04-19","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-19","modifiedBy":"ONEDATA","dateModified":"2019-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"86E54249-B66B-2471-E053-F662850A813C","beginDate":"2019-04-19","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-19","modifiedBy":"ONEDATA","dateModified":"2019-04-19","deletedIndicator":"No"},{"value":"209","valueDescription":"Patient found at any point after enrollment to be inevaluable (e.g., major deviations from protocol therapy)","ValueMeaning":{"publicId":"6705349","version":"1","preferredName":"Patient found at any point after enrollment to be inevaluable (e.g., major deviations from protocol therapy)","longName":"6705349","preferredDefinition":"Patient found at any point after enrollment to be inevaluable (e.g., major deviations from protocol therapy)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86E54249-B675-2471-E053-F662850A813C","latestVersionIndicator":"Yes","beginDate":"2019-04-19","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-19","modifiedBy":"KUMMEROA","dateModified":"2022-11-21","changeDescription":null,"administrativeNotes":"2022.11.21 Alt VM added for ticket request CADSR0001670. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"86E54249-B68E-2471-E053-F662850A813C","beginDate":"2019-04-19","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-19","modifiedBy":"ONEDATA","dateModified":"2019-04-19","deletedIndicator":"No"},{"value":"208","valueDescription":"Definitive relapse","ValueMeaning":{"publicId":"6705350","version":"1","preferredName":"Definitive relapse","longName":"6705350","preferredDefinition":"Definitive relapse","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86E54249-B698-2471-E053-F662850A813C","latestVersionIndicator":"Yes","beginDate":"2019-04-19","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-19","modifiedBy":"ONEDATA","dateModified":"2019-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"86E54249-B6B1-2471-E053-F662850A813C","beginDate":"2019-04-19","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-19","modifiedBy":"ONEDATA","dateModified":"2019-04-19","deletedIndicator":"No"},{"value":"207","valueDescription":"Failure to achieve CR at the end of Consolidation","ValueMeaning":{"publicId":"6705351","version":"1","preferredName":"Failure to achieve CR at the end of Consolidation","longName":"6705351","preferredDefinition":"Failure to achieve CR at the end of Consolidation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86E54249-B6BB-2471-E053-F662850A813C","latestVersionIndicator":"Yes","beginDate":"2019-04-19","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-19","modifiedBy":"ONEDATA","dateModified":"2019-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"86E54249-B6D4-2471-E053-F662850A813C","beginDate":"2019-04-19","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-19","modifiedBy":"ONEDATA","dateModified":"2019-04-19","deletedIndicator":"No"},{"value":"206","valueDescription":"Consolidation failure","ValueMeaning":{"publicId":"6705352","version":"1","preferredName":"Consolidation failure","longName":"6705352v1.00","preferredDefinition":"Treatment that is given after initial therapy to kill any remaining cancer cells._A lack of occurrence or performance.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Consolidation Therapy","conceptCode":"C15679","definition":"Treatment that is given after initial therapy to kill any remaining cancer cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Failure","conceptCode":"C25745","definition":"A lack of occurrence or performance.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86E54249-B6DE-2471-E053-F662850A813C","latestVersionIndicator":"Yes","beginDate":"2019-04-19","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-19","modifiedBy":"KUMMEROA","dateModified":"2023-01-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"86E54249-B6F7-2471-E053-F662850A813C","beginDate":"2019-04-19","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-19","modifiedBy":"ONEDATA","dateModified":"2019-04-19","deletedIndicator":"No"},{"value":"205","valueDescription":"Progressive disease at the end of Induction","ValueMeaning":{"publicId":"6705353","version":"1","preferredName":"Progressive disease at the end of Induction","longName":"6705353","preferredDefinition":"Progressive disease at the end of Induction","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86E54249-B701-2471-E053-F662850A813C","latestVersionIndicator":"Yes","beginDate":"2019-04-19","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-19","modifiedBy":"ONEDATA","dateModified":"2019-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"86E54249-B71A-2471-E053-F662850A813C","beginDate":"2019-04-19","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-19","modifiedBy":"ONEDATA","dateModified":"2019-04-19","deletedIndicator":"No"},{"value":"250","valueDescription":"Induction Failure, with the exception of isolated biopsy-proven testicular disease at EOI (EOI MRD greater than or equal to 5 percent by central flow cytometry, IF-M3, IF- EM, or IF-MPAL as defined in Section 3.3)","ValueMeaning":{"publicId":"6823637","version":"1","preferredName":"Induction Failure, with the exception of isolated biopsy-proven testicular disease at EOI (EOI MRD greater than or equal to 5 percent by central flow cytometry, IF-M3, IF- EM, or IF-MPAL as defined in Section 3.3)","longName":"6823637","preferredDefinition":"Induction Failure, with the exception of isolated biopsy-proven testicular disease at EOI (EOI MRD greater than or equal to 5 percent by central flow cytometry, IF-M3, IF- EM, or IF-MPAL as defined in Section 3.3)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E4E2F6B-8509-4A83-E053-F662850AA326","latestVersionIndicator":"Yes","beginDate":"2019-07-23","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-23","modifiedBy":"ONEDATA","dateModified":"2019-07-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E4E2F6B-8522-4A83-E053-F662850AA326","beginDate":"2019-07-23","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-23","modifiedBy":"ONEDATA","dateModified":"2019-07-23","deletedIndicator":"No"},{"value":"251","valueDescription":"Incomplete cytogenetic testing for Ph+, done as part of APEC14B1","ValueMeaning":{"publicId":"6823609","version":"1","preferredName":"Incomplete cytogenetic testing for Ph+, done as part of APEC14B1","longName":"6823609","preferredDefinition":"Incomplete cytogenetic testing for Ph+, done as part of APEC14B1","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E5EA612-5CFB-102F-E053-F662850A0DBE","latestVersionIndicator":"Yes","beginDate":"2019-07-23","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-23","modifiedBy":"ONEDATA","dateModified":"2019-07-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E4E2F6B-8536-4A83-E053-F662850AA326","beginDate":"2019-07-23","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-23","modifiedBy":"ONEDATA","dateModified":"2019-07-23","deletedIndicator":"No"},{"value":"264","valueDescription":"Induction Failure, with the exception of isolated biopsy-proven testicular disease at EOI (EOI MRD greater than or equal to 5% by central flow cytometry, IF-M3, IF- EM, or IF-MPAL as defined in Section 3.3)","ValueMeaning":{"publicId":"6824218","version":"1","preferredName":"Induction Failure, with the exception of isolated biopsy-proven testicular disease at EOI (EOI MRD greater than or equal to 5% by central flow cytometry, IF-M3, IF- EM, or IF-MPAL as defined in Section 3.3)","longName":"6824218","preferredDefinition":"Induction Failure, with the exception of isolated biopsy-proven testicular disease at EOI (EOI MRD greater than or equal to 5% by central flow cytometry, IF-M3, IF- EM, or IF-MPAL as defined in Section 3.3)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E5EE933-28E3-3985-E053-F662850AC492","latestVersionIndicator":"Yes","beginDate":"2019-07-23","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-23","modifiedBy":"ONEDATA","dateModified":"2019-07-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E5EE933-28FC-3985-E053-F662850AC492","beginDate":"2019-07-23","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-23","modifiedBy":"ONEDATA","dateModified":"2019-07-23","deletedIndicator":"No"},{"value":"263","valueDescription":"End of Consolidation marrow with MRD greater than or equal to 0.01% to less than 1% by central flow cytometry for MPAL patients","ValueMeaning":{"publicId":"6824219","version":"1","preferredName":"End of Consolidation marrow with MRD greater than or equal to 0.01% to less than 1% by central flow cytometry for MPAL patients","longName":"6824219","preferredDefinition":"End of Consolidation marrow with MRD greater than or equal to 0.01% to less than 1% by central flow cytometry for MPAL patients","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E5EE933-2906-3985-E053-F662850AC492","latestVersionIndicator":"Yes","beginDate":"2019-07-23","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-23","modifiedBy":"ONEDATA","dateModified":"2019-07-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E5EE933-291F-3985-E053-F662850AC492","beginDate":"2019-07-23","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-23","modifiedBy":"ONEDATA","dateModified":"2019-07-23","deletedIndicator":"No"},{"value":"252","valueDescription":"Repeat eligibility studies (if required) prior to the initiation of protocol therapy are outside the parameters required for eligibility","ValueMeaning":{"publicId":"6823642","version":"1","preferredName":"Repeat eligibility studies (if required) prior to the initiation of protocol therapy are outside the parameters required for eligibility","longName":"6823642","preferredDefinition":"Repeat eligibility studies (if required) prior to the initiation of protocol therapy are outside the parameters required for eligibility","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E5E3EAB-263B-1144-E053-F662850A9A06","latestVersionIndicator":"Yes","beginDate":"2019-07-23","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-23","modifiedBy":"KUMMEROA","dateModified":"2022-11-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E5E3EAB-2654-1144-E053-F662850A9A06","beginDate":"2019-07-23","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-23","modifiedBy":"ONEDATA","dateModified":"2019-07-23","deletedIndicator":"No"},{"value":"262","valueDescription":"Consolidation Failure (EOC MRD greater than or equal to 1% by central flow cytometry or extramedullary disease) for MPAL patients","ValueMeaning":{"publicId":"6824220","version":"1","preferredName":"Consolidation Failure (EOC MRD greater than or equal to 1% by central flow cytometry or extramedullary disease) for MPAL patients","longName":"6824220","preferredDefinition":"Consolidation Failure (EOC MRD greater than or equal to 1% by central flow cytometry or extramedullary disease) for MPAL patients","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E5EE933-2929-3985-E053-F662850AC492","latestVersionIndicator":"Yes","beginDate":"2019-07-23","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-23","modifiedBy":"ONEDATA","dateModified":"2019-07-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E5EE933-2942-3985-E053-F662850AC492","beginDate":"2019-07-23","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-23","modifiedBy":"ONEDATA","dateModified":"2019-07-23","deletedIndicator":"No"},{"value":"261","valueDescription":"End of Consolidation marrow with MRD greater than or equal to 0.01% to less than 1% by central flow cytometry for NCI HR patients","ValueMeaning":{"publicId":"6824221","version":"1","preferredName":"End of Consolidation marrow with MRD greater than or equal to 0.01% to less than 1% by central flow cytometry for NCI HR patients","longName":"6824221","preferredDefinition":"End of Consolidation marrow with MRD greater than or equal to 0.01% to less than 1% by central flow cytometry for NCI HR patients","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E5EE933-294C-3985-E053-F662850AC492","latestVersionIndicator":"Yes","beginDate":"2019-07-23","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-23","modifiedBy":"ONEDATA","dateModified":"2019-07-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E5EE933-2965-3985-E053-F662850AC492","beginDate":"2019-07-23","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-23","modifiedBy":"ONEDATA","dateModified":"2019-07-23","deletedIndicator":"No"},{"value":"260","valueDescription":"Consolidation Failure (EOC MRD greater than or equal to 1% by central flow cytometry or extramedullary disease) for both NCI HR B-ALL and NCI SR B-ALL patients","ValueMeaning":{"publicId":"6824222","version":"1","preferredName":"Consolidation Failure (EOC MRD greater than or equal to 1% by central flow cytometry or extramedullary disease) for both NCI HR B-ALL and NCI SR B-ALL patients","longName":"6824222","preferredDefinition":"Consolidation Failure (EOC MRD greater than or equal to 1% by central flow cytometry or extramedullary disease) for both NCI HR B-ALL and NCI SR B-ALL patients","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E5EE933-296F-3985-E053-F662850AC492","latestVersionIndicator":"Yes","beginDate":"2019-07-23","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-23","modifiedBy":"ONEDATA","dateModified":"2019-07-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E5EE933-2988-3985-E053-F662850AC492","beginDate":"2019-07-23","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-23","modifiedBy":"ONEDATA","dateModified":"2019-07-23","deletedIndicator":"No"},{"value":"265","valueDescription":"Patient did not start radiation therapy within 31 days of radiographic diagnosis (for non-biopsied DIPG patients only) or definitive surgery.","ValueMeaning":{"publicId":"6930724","version":"1","preferredName":"Patient did not start radiation therapy within 31 days of radiographic diagnosis (for non-biopsied DIPG patients only) or definitive surgery.","longName":"6930724","preferredDefinition":"Patient did not start radiation therapy within 31 days of radiographic diagnosis (for non-biopsied DIPG patients only) or definitive surgery.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"924EA966-8BA8-3668-E053-F662850AE549","latestVersionIndicator":"Yes","beginDate":"2019-09-12","endDate":null,"createdBy":"SHIEHI","dateCreated":"2019-09-12","modifiedBy":"ONEDATA","dateModified":"2019-09-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"924EA966-8BC1-3668-E053-F662850AE549","beginDate":"2019-09-12","endDate":null,"createdBy":"SHIEHI","dateCreated":"2019-09-12","modifiedBy":"ONEDATA","dateModified":"2019-09-12","deletedIndicator":"No"},{"value":"220","valueDescription":"Randomization Inotuzumab Ozogamicin Closed","ValueMeaning":{"publicId":"6819952","version":"1","preferredName":"Randomization Inotuzumab Ozogamicin Closed","longName":"6819952","preferredDefinition":"The allocation of individuals to groups by chance, especially in order to control the variables in an experiment.: A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.: Not affording passage or access; blocked against entry.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Randomization","conceptCode":"C25196","definition":"The allocation of individuals to groups by chance, especially in order to control the variables in an experiment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Inotuzumab Ozogamicin","conceptCode":"C71542","definition":"A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Closed","conceptCode":"C49070","definition":"Not affording passage or access; blocked against entry.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E0D9952-C979-32D9-E053-F662850ACCFB","latestVersionIndicator":"Yes","beginDate":"2019-07-19","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-19","modifiedBy":"ONEDATA","dateModified":"2019-07-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E0D9952-C994-32D9-E053-F662850ACCFB","beginDate":"2019-07-19","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-19","modifiedBy":"ONEDATA","dateModified":"2019-07-19","deletedIndicator":"No"},{"value":"266","valueDescription":"Patient did not start Selinexor treatment within 38 days of radiographic diagnosis (for non-biopsied DIPG patients only) or definitive surgery.","ValueMeaning":{"publicId":"6930752","version":"1","preferredName":"Patient did not start Selinexor treatment within 38 days of radiographic diagnosis (for non-biopsied DIPG patients only) or definitive surgery.","longName":"6930752","preferredDefinition":"Patient did not start Selinexor treatment within 38 days of radiographic diagnosis (for non-biopsied DIPG patients only) or definitive surgery.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"924F05B7-01AB-5CEB-E053-F662850A2A9A","latestVersionIndicator":"Yes","beginDate":"2019-09-12","endDate":null,"createdBy":"SHIEHI","dateCreated":"2019-09-12","modifiedBy":"ONEDATA","dateModified":"2019-09-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"924F05B7-01C4-5CEB-E053-F662850A2A9A","beginDate":"2019-09-12","endDate":null,"createdBy":"SHIEHI","dateCreated":"2019-09-12","modifiedBy":"ONEDATA","dateModified":"2019-09-12","deletedIndicator":"No"},{"value":"258","valueDescription":"Relapse as defined in Section 3.3 (B-ALL and MPAL see Section 3.3, B-LLy requires biopsy)","ValueMeaning":{"publicId":"6823866","version":"1","preferredName":"Relapse as defined in Section 3.3 (B-ALL and MPAL see Section 3.3, B-LLy requires biopsy)","longName":"6823866","preferredDefinition":"Relapse as defined in Section 3.3 (B-ALL and MPAL see Section 3.3, B-LLy requires biopsy)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E5FFA52-2A9A-0EBB-E053-F662850A8906","latestVersionIndicator":"Yes","beginDate":"2019-07-23","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-23","modifiedBy":"ONEDATA","dateModified":"2019-07-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E5FFA52-2AB3-0EBB-E053-F662850A8906","beginDate":"2019-07-23","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-23","modifiedBy":"ONEDATA","dateModified":"2019-07-23","deletedIndicator":"No"},{"value":"257","valueDescription":"CD22-negative blasts on central review of diagnostic specimen (HR B-ALL only, off protocol therapy after Consolidation)","ValueMeaning":{"publicId":"6823867","version":"1","preferredName":"CD22-negative blasts on central review of diagnostic specimen (HR B-ALL only, off protocol therapy after Consolidation)","longName":"6823867","preferredDefinition":"CD22-negative blasts on central review of diagnostic specimen (HR B-ALL only, off protocol therapy after Consolidation)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E5FFA52-2ABD-0EBB-E053-F662850A8906","latestVersionIndicator":"Yes","beginDate":"2019-07-23","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-23","modifiedBy":"ONEDATA","dateModified":"2019-07-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E5FFA52-2AD6-0EBB-E053-F662850A8906","beginDate":"2019-07-23","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-23","modifiedBy":"ONEDATA","dateModified":"2019-07-23","deletedIndicator":"No"},{"value":"259","valueDescription":"InO randomization for HR B-ALL temporarily closed due to safety phase analysis","ValueMeaning":{"publicId":"6823865","version":"1","preferredName":"InO randomization for HR B-ALL temporarily closed due to safety phase analysis","longName":"6823865","preferredDefinition":"InO randomization for HR B-ALL temporarily closed due to safety phase analysis","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E5FFA52-2A77-0EBB-E053-F662850A8906","latestVersionIndicator":"Yes","beginDate":"2019-07-23","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-23","modifiedBy":"ONEDATA","dateModified":"2019-07-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E5FFA52-2A90-0EBB-E053-F662850A8906","beginDate":"2019-07-23","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-23","modifiedBy":"ONEDATA","dateModified":"2019-07-23","deletedIndicator":"No"},{"value":"214","valueDescription":"Progressive disease during protocol therapy","ValueMeaning":{"publicId":"6774227","version":"1","preferredName":"Progressive disease during protocol therapy","longName":"6774227","preferredDefinition":"Progressive disease of  20% increase from baseline in tumor size at any time during protocol therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8A722530-1D7D-7D11-E053-F662850A9E19","latestVersionIndicator":"Yes","beginDate":"2019-06-03","endDate":null,"createdBy":"TANGL","dateCreated":"2019-06-03","modifiedBy":"ONEDATA","dateModified":"2019-06-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8A722530-1D96-7D11-E053-F662850A9E19","beginDate":"2019-06-03","endDate":null,"createdBy":"TANGL","dateCreated":"2019-06-03","modifiedBy":"ONEDATA","dateModified":"2019-06-03","deletedIndicator":"No"},{"value":"270","valueDescription":"Excluded constitutional condition or oncologic diagnoses identified after enrollment","ValueMeaning":{"publicId":"7090175","version":"1","preferredName":"Excluded constitutional condition or oncologic diagnoses identified after enrollment","longName":"7090175","preferredDefinition":"Excluded constitutional condition or oncologic diagnoses identified after enrollment","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9973CA76-3971-30AD-E053-F662850A223F","latestVersionIndicator":"Yes","beginDate":"2019-12-11","endDate":null,"createdBy":"LEEW","dateCreated":"2019-12-11","modifiedBy":"ONEDATA","dateModified":"2019-12-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9973CA76-398A-30AD-E053-F662850A223F","beginDate":"2019-12-11","endDate":null,"createdBy":"LEEW","dateCreated":"2019-12-11","modifiedBy":"ONEDATA","dateModified":"2019-12-11","deletedIndicator":"No"},{"value":"269","valueDescription":"Repeat eligibility studies are outside the parameters required for eligibility","ValueMeaning":{"publicId":"5083512","version":"1","preferredName":"Repeat eligibility studies are outside the parameters required for eligibility","longName":"5083512","preferredDefinition":"Repeat eligibility studies are outside the parameters required for eligibility","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"26826FC3-5DD9-AEA2-E050-BB89AD433D3A","latestVersionIndicator":"Yes","beginDate":"2015-12-09","endDate":null,"createdBy":"MIRANDAA","dateCreated":"2015-12-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9973CA76-399E-30AD-E053-F662850A223F","beginDate":"2019-12-11","endDate":null,"createdBy":"LEEW","dateCreated":"2019-12-11","modifiedBy":"ONEDATA","dateModified":"2019-12-11","deletedIndicator":"No"},{"value":"268","valueDescription":"Patient became pregnant","ValueMeaning":{"publicId":"5234436","version":"1","preferredName":"Patient became pregnant","longName":"5234436","preferredDefinition":"Patient became pregnant","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31575AAE-B90D-0F77-E050-BB89AD4319E0","latestVersionIndicator":"Yes","beginDate":"2016-04-25","endDate":null,"createdBy":"HAMMA","dateCreated":"2016-04-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9973CA76-39B2-30AD-E053-F662850A223F","beginDate":"2019-12-11","endDate":null,"createdBy":"LEEW","dateCreated":"2019-12-11","modifiedBy":"ONEDATA","dateModified":"2019-12-11","deletedIndicator":"No"},{"value":"271","valueDescription":"Patient became pregnant","ValueMeaning":{"publicId":"5234436","version":"1","preferredName":"Patient became pregnant","longName":"5234436","preferredDefinition":"Patient became pregnant","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31575AAE-B90D-0F77-E050-BB89AD4319E0","latestVersionIndicator":"Yes","beginDate":"2016-04-25","endDate":null,"createdBy":"HAMMA","dateCreated":"2016-04-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9A624564-7239-44C5-E053-F662850A93DB","beginDate":"2019-12-23","endDate":null,"createdBy":"LEEW","dateCreated":"2019-12-23","modifiedBy":"ONEDATA","dateModified":"2019-12-23","deletedIndicator":"No"},{"value":"226","valueDescription":"A patient with FLT3 ITD AR greater than 0.1 and assigned to the High Risk group who has a suitable donor identified receives HSCT prior to receiving Intensification 1","ValueMeaning":{"publicId":"7090343","version":"1","preferredName":"A patient with FLT3 ITD AR greater than 0.1 and assigned to the High Risk group who has a suitable donor identified receives HSCT prior to receiving Intensification 1","longName":"7090343","preferredDefinition":"A patient with FLT3 ITD AR greater than 0.1 and assigned to the High Risk group who has a suitable donor identified receives HSCT prior to receiving Intensification 1","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9974FB65-4394-6754-E053-F662850AAB30","latestVersionIndicator":"Yes","beginDate":"2019-12-11","endDate":null,"createdBy":"LEEW","dateCreated":"2019-12-11","modifiedBy":"ONEDATA","dateModified":"2019-12-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9974FB65-43AD-6754-E053-F662850AAB30","beginDate":"2019-12-11","endDate":null,"createdBy":"LEEW","dateCreated":"2019-12-11","modifiedBy":"ONEDATA","dateModified":"2019-12-11","deletedIndicator":"No"},{"value":"228","valueDescription":"Patient becomes pregnant during protocol therapy","ValueMeaning":{"publicId":"7090341","version":"1","preferredName":"Patient becomes pregnant during protocol therapy","longName":"7090341","preferredDefinition":"Patient becomes pregnant during protocol therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9974FB65-434E-6754-E053-F662850AAB30","latestVersionIndicator":"Yes","beginDate":"2019-12-11","endDate":null,"createdBy":"LEEW","dateCreated":"2019-12-11","modifiedBy":"ONEDATA","dateModified":"2019-12-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9974FB65-4367-6754-E053-F662850AAB30","beginDate":"2019-12-11","endDate":null,"createdBy":"LEEW","dateCreated":"2019-12-11","modifiedBy":"ONEDATA","dateModified":"2019-12-11","deletedIndicator":"No"},{"value":"227","valueDescription":"Relapse of any site following remission","ValueMeaning":{"publicId":"7090342","version":"1","preferredName":"Relapse of any site following remission","longName":"7090342","preferredDefinition":"Relapse of any site following remission","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9974FB65-4371-6754-E053-F662850AAB30","latestVersionIndicator":"Yes","beginDate":"2019-12-11","endDate":null,"createdBy":"LEEW","dateCreated":"2019-12-11","modifiedBy":"ONEDATA","dateModified":"2019-12-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9974FB65-438A-6754-E053-F662850AAB30","beginDate":"2019-12-11","endDate":null,"createdBy":"LEEW","dateCreated":"2019-12-11","modifiedBy":"ONEDATA","dateModified":"2019-12-11","deletedIndicator":"No"},{"value":"225","valueDescription":"Grade 3 or greater neurotoxicity from HD cytarabine","ValueMeaning":{"publicId":"7090344","version":"1","preferredName":"Grade 3 or greater neurotoxicity from HD cytarabine","longName":"7090344","preferredDefinition":"Grade 3 or greater neurotoxicity from HD cytarabine","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9974FB65-43B7-6754-E053-F662850AAB30","latestVersionIndicator":"Yes","beginDate":"2019-12-11","endDate":null,"createdBy":"LEEW","dateCreated":"2019-12-11","modifiedBy":"ONEDATA","dateModified":"2019-12-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9974FB65-43D0-6754-E053-F662850AAB30","beginDate":"2019-12-11","endDate":null,"createdBy":"LEEW","dateCreated":"2019-12-11","modifiedBy":"ONEDATA","dateModified":"2019-12-11","deletedIndicator":"No"},{"value":"224","valueDescription":"Failure to achieve CNS1 status by the end of Induction 2","ValueMeaning":{"publicId":"7090345","version":"1","preferredName":"Failure to achieve CNS1 status by the end of Induction 2","longName":"7090345","preferredDefinition":"Failure to achieve CNS1 status by the end of Induction 2","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9974FB65-43DA-6754-E053-F662850AAB30","latestVersionIndicator":"Yes","beginDate":"2019-12-11","endDate":null,"createdBy":"LEEW","dateCreated":"2019-12-11","modifiedBy":"ONEDATA","dateModified":"2019-12-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9974FB65-43F3-6754-E053-F662850AAB30","beginDate":"2019-12-11","endDate":null,"createdBy":"LEEW","dateCreated":"2019-12-11","modifiedBy":"ONEDATA","dateModified":"2019-12-11","deletedIndicator":"No"},{"value":"223","valueDescription":"Patient was newly diagnosed with CNS3a or CNS3b at the start of Induction 2","ValueMeaning":{"publicId":"7090346","version":"1","preferredName":"Patient was newly diagnosed with CNS3a or CNS3b at the start of Induction 2","longName":"7090346","preferredDefinition":"Patient was newly diagnosed with CNS3a or CNS3b at the start of Induction 2","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9974FB65-43FD-6754-E053-F662850AAB30","latestVersionIndicator":"Yes","beginDate":"2019-12-11","endDate":null,"createdBy":"LEEW","dateCreated":"2019-12-11","modifiedBy":"ONEDATA","dateModified":"2019-12-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9974FB65-4416-6754-E053-F662850AAB30","beginDate":"2019-12-11","endDate":null,"createdBy":"LEEW","dateCreated":"2019-12-11","modifiedBy":"ONEDATA","dateModified":"2019-12-11","deletedIndicator":"No"},{"value":"222","valueDescription":"Patient with CNS3a or CNS3b status at the end of Induction I","ValueMeaning":{"publicId":"7090347","version":"1","preferredName":"Patient with CNS3a or CNS3b status at the end of Induction I","longName":"7090347","preferredDefinition":"Patient with CNS3a or CNS3b status at the end of Induction I","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9974FB65-4420-6754-E053-F662850AAB30","latestVersionIndicator":"Yes","beginDate":"2019-12-11","endDate":null,"createdBy":"LEEW","dateCreated":"2019-12-11","modifiedBy":"ONEDATA","dateModified":"2019-12-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9974FB65-4439-6754-E053-F662850AAB30","beginDate":"2019-12-11","endDate":null,"createdBy":"LEEW","dateCreated":"2019-12-11","modifiedBy":"ONEDATA","dateModified":"2019-12-11","deletedIndicator":"No"},{"value":"221","valueDescription":"Failure to attain CR at the end of Induction 2","ValueMeaning":{"publicId":"7090348","version":"1","preferredName":"Failure to attain CR at the end of Induction 2","longName":"7090348","preferredDefinition":"Failure to attain CR at the end of Induction 2","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9974FB65-4443-6754-E053-F662850AAB30","latestVersionIndicator":"Yes","beginDate":"2019-12-11","endDate":null,"createdBy":"LEEW","dateCreated":"2019-12-11","modifiedBy":"ONEDATA","dateModified":"2019-12-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9974FB65-445C-6754-E053-F662850AAB30","beginDate":"2019-12-11","endDate":null,"createdBy":"LEEW","dateCreated":"2019-12-11","modifiedBy":"ONEDATA","dateModified":"2019-12-11","deletedIndicator":"No"},{"value":"267","valueDescription":"Patient received concurrent non-protocol anticancer therapy, including chemotherapy,  immunotherapy, or biologic therapy.","ValueMeaning":{"publicId":"7001814","version":"1","preferredName":"Patient received concurrent non-protocol anticancer therapy, including chemotherapy,  immunotherapy, or biologic therapy.","longName":"7001814","preferredDefinition":"Patient received concurrent non-protocol anticancer therapy, including chemotherapy, \r\nimmunotherapy, or biologic therapy.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"950F8C03-81A3-5EE5-E053-F662850AA25C","latestVersionIndicator":"Yes","beginDate":"2019-10-17","endDate":null,"createdBy":"SHIEHI","dateCreated":"2019-10-17","modifiedBy":"ONEDATA","dateModified":"2019-10-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"950F8C03-81BC-5EE5-E053-F662850AA25C","beginDate":"2019-10-17","endDate":null,"createdBy":"SHIEHI","dateCreated":"2019-10-17","modifiedBy":"ONEDATA","dateModified":"2019-10-17","deletedIndicator":"No"},{"value":"272","valueDescription":"Patient found to be HR/IR at the completion of Block 1","ValueMeaning":{"publicId":"7128545","version":"1","preferredName":"Patient found to be HR/IR at the completion of Block 1","longName":"7128545","preferredDefinition":"Patient found to be HR/IR at the completion of Block 1","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9BA80019-A86F-4710-E053-F662850A61F6","latestVersionIndicator":"Yes","beginDate":"2020-01-08","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-01-08","modifiedBy":"ONEDATA","dateModified":"2020-01-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9BA80019-A888-4710-E053-F662850A61F6","beginDate":"2020-01-08","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-01-08","modifiedBy":"ONEDATA","dateModified":"2020-01-08","deletedIndicator":"No"},{"value":"107","valueDescription":"Patient Finish Second Year Clinical Study Participation","ValueMeaning":{"publicId":"7213182","version":"1","preferredName":"Patient Finish Second Year Clinical Study Participation","longName":"7213182","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.: Use up completely.: A suffix denoting the second person having the same complete name (first, middle, and family names).: A period of time that it takes for Earth to make a complete revolution around the sun, approximately 365 days; a specific one year period.: Research conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects; includes development of new technologies, study of mechanisms of human diseases, therapy, clinical trials, epidemiologic, behavior, and health services research.: The act of taking part in an activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Finish","conceptCode":"C64943","definition":"Use up completely.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Second","conceptCode":"C49463","definition":"A suffix denoting the second person having the same complete name (first, middle, and family names).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Year","conceptCode":"C29848","definition":"A period of time that it takes for Earth to make a complete revolution around the sun, approximately 365 days; a specific one year period.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Clinical Study","conceptCode":"C15206","definition":"Research conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects; includes development of new technologies, study of mechanisms of human diseases, therapy, clinical trials, epidemiologic, behavior, and health services research.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Participation","conceptCode":"C25608","definition":"The act of taking part in an activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A12B1985-3751-1AAB-E053-F662850AC0D2","latestVersionIndicator":"Yes","beginDate":"2020-03-18","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-03-18","modifiedBy":"ONEDATA","dateModified":"2020-03-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A12B2597-6DD2-1AAF-E053-F662850AB06F","beginDate":"2020-03-18","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-03-18","modifiedBy":"ONEDATA","dateModified":"2020-03-18","deletedIndicator":"No"},{"value":"229","valueDescription":"Inability to attain and maintain therapeutic immunosuppressive drug levels on the LMP TC arm","ValueMeaning":{"publicId":"7217478","version":"1","preferredName":"Inability to attain and maintain therapeutic immunosuppressive drug levels on the LMP TC arm","longName":"7217478","preferredDefinition":"Inability to attain and maintain therapeutic immunosuppressive drug levels on the LMP TC arm","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A18F18B2-AD19-7C2D-E053-F662850A54A5","latestVersionIndicator":"Yes","beginDate":"2020-03-23","endDate":null,"createdBy":"GALITG","dateCreated":"2020-03-23","modifiedBy":"ONEDATA","dateModified":"2020-03-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A18F18B2-AD32-7C2D-E053-F662850A54A5","beginDate":"2020-03-23","endDate":null,"createdBy":"GALITG","dateCreated":"2020-03-23","modifiedBy":"ONEDATA","dateModified":"2020-03-23","deletedIndicator":"No"},{"value":"215","valueDescription":"Appearance of one or more new lesions or unequivocal progression of non-target lesions (see Section 10.2.5.2) and refer to Section 10.2.1 for exceptions within the first 12 weeks of therapy","ValueMeaning":{"publicId":"7165996","version":"1","preferredName":"Appearance of one or more new lesions or unequivocal progression of non-target lesions (see Section 10.2.5.2) and refer to Section 10.2.1 for exceptions within the first 12 weeks of therapy","longName":"7165996","preferredDefinition":"Appearance of one or more new lesions or unequivocal progression of non-target lesions (see Section 10.2.5.2) and refer to Section 10.2.1 for exceptions within the first 12 weeks of therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9E564FB5-3783-25E0-E053-F662850A9777","latestVersionIndicator":"Yes","beginDate":"2020-02-11","endDate":null,"createdBy":"TANGL","dateCreated":"2020-02-11","modifiedBy":"ONEDATA","dateModified":"2020-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9E564FB5-379C-25E0-E053-F662850A9777","beginDate":"2020-02-11","endDate":null,"createdBy":"TANGL","dateCreated":"2020-02-11","modifiedBy":"ONEDATA","dateModified":"2020-02-11","deletedIndicator":"No"},{"value":"992","valueDescription":"Repeat eligibility studies (if required) are outside the parameters required for eligibility (see Section 3.2)","ValueMeaning":{"publicId":"7331741","version":"1","preferredName":"Repeat eligibility studies (if required) are outside the parameters required for eligibility (see Section 3.2)","longName":"7331741","preferredDefinition":"Repeat eligibility studies (if required) are outside the parameters required for eligibility (see Section 3.2)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A7E8D9FE-E3B2-64B6-E053-4EBD850A0351","latestVersionIndicator":"Yes","beginDate":"2020-06-12","endDate":null,"createdBy":"GALITG","dateCreated":"2020-06-12","modifiedBy":"ONEDATA","dateModified":"2020-06-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A7E8D9FE-E3CB-64B6-E053-4EBD850A0351","beginDate":"2020-06-12","endDate":null,"createdBy":"GALITG","dateCreated":"2020-06-12","modifiedBy":"ONEDATA","dateModified":"2020-06-12","deletedIndicator":"No"},{"value":"300","valueDescription":"Radiation Therapy Receive","ValueMeaning":{"publicId":"7359965","version":"1","preferredName":"Radiation Therapy Receive","longName":"7359965","preferredDefinition":"Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.: To take, accept, or get something offered.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Radiation Therapy","conceptCode":"C15313","definition":"Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Receive","conceptCode":"C25639","definition":"To take, accept, or get something offered.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AAE6966D-79E5-5013-E053-4EBD850AA109","latestVersionIndicator":"Yes","beginDate":"2020-07-20","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-07-20","modifiedBy":"ONEDATA","dateModified":"2020-07-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AAE6966D-7A00-5013-E053-4EBD850AA109","beginDate":"2020-07-20","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-07-20","modifiedBy":"ONEDATA","dateModified":"2020-07-20","deletedIndicator":"No"},{"value":"991","valueDescription":"Rapid central pathologic review (if applicable) does not agree with institutional diagnosis (e.g., suspected relapsed FHWT patients who are found to have anaplasia by central review)","ValueMeaning":{"publicId":"7331421","version":"1","preferredName":"Rapid central pathologic review (if applicable) does not agree with institutional diagnosis (e.g., suspected relapsed FHWT patients who are found to have anaplasia by central review)","longName":"7331421","preferredDefinition":"Rapid central pathologic review (if applicable) does not agree with institutional diagnosis (e.g., suspected relapsed FHWT patients who are found to have anaplasia by central review)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A7D57A4B-1B85-10A5-E053-4EBD850A38A7","latestVersionIndicator":"Yes","beginDate":"2020-06-11","endDate":null,"createdBy":"GALITG","dateCreated":"2020-06-11","modifiedBy":"ONEDATA","dateModified":"2020-06-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A7D57A4B-1B9E-10A5-E053-4EBD850A38A7","beginDate":"2020-06-11","endDate":null,"createdBy":"GALITG","dateCreated":"2020-06-11","modifiedBy":"ONEDATA","dateModified":"2020-06-11","deletedIndicator":"No"},{"value":"275","valueDescription":"Patient enrollment onto another COG anti-cancer therapeutic study (eg, at recurrence).","ValueMeaning":{"publicId":"7406432","version":"1","preferredName":"Patient enrollment onto another COG anti-cancer therapeutic study (eg, at recurrence).","longName":"7406432","preferredDefinition":"Patient enrollment onto another COG anti-cancer therapeutic study (eg, at recurrence).","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ADA3F054-59D9-1DB0-E053-4EBD850A56DB","latestVersionIndicator":"Yes","beginDate":"2020-08-24","endDate":null,"createdBy":"RODELAA","dateCreated":"2020-08-24","modifiedBy":"ONEDATA","dateModified":"2020-08-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ADA3F054-59F2-1DB0-E053-4EBD850A56DB","beginDate":"2020-08-24","endDate":null,"createdBy":"RODELAA","dateCreated":"2020-08-24","modifiedBy":"ONEDATA","dateModified":"2020-08-24","deletedIndicator":"No"},{"value":"274","valueDescription":"Repeat eligibility studies (if required) prior to the initiation of protocol therapy are outside the parameters required for eligibility (see Section 3.3).","ValueMeaning":{"publicId":"7406433","version":"1","preferredName":"Repeat eligibility studies (if required) prior to the initiation of protocol therapy are outside the parameters required for eligibility (see Section 3.3).","longName":"7406433","preferredDefinition":"Repeat eligibility studies (if required) prior to the initiation of protocol therapy are outside the parameters required for eligibility (see Section 3.3).","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ADA3F054-59FC-1DB0-E053-4EBD850A56DB","latestVersionIndicator":"Yes","beginDate":"2020-08-24","endDate":null,"createdBy":"RODELAA","dateCreated":"2020-08-24","modifiedBy":"ONEDATA","dateModified":"2020-08-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ADA3F054-5A15-1DB0-E053-4EBD850A56DB","beginDate":"2020-08-24","endDate":null,"createdBy":"RODELAA","dateCreated":"2020-08-24","modifiedBy":"ONEDATA","dateModified":"2020-08-24","deletedIndicator":"No"},{"value":"993","valueDescription":"Receives other concurrent investigational or desmoid directed therapy","ValueMeaning":{"publicId":"7392668","version":"1","preferredName":"Receives other concurrent investigational or desmoid directed therapy","longName":"7392668","preferredDefinition":"Receives other concurrent investigational or desmoid directed therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACDD2BCB-2568-75FB-E053-4EBD850A360F","latestVersionIndicator":"Yes","beginDate":"2020-08-14","endDate":null,"createdBy":"RODELAA","dateCreated":"2020-08-14","modifiedBy":"ONEDATA","dateModified":"2020-08-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ACDD2BCB-2581-75FB-E053-4EBD850A360F","beginDate":"2020-08-14","endDate":null,"createdBy":"RODELAA","dateCreated":"2020-08-14","modifiedBy":"ONEDATA","dateModified":"2020-08-14","deletedIndicator":"No"},{"value":"302","valueDescription":"Found not to have MPAL by central confirmation of diagnostic specimen or incomplete testing, done as part of APEC14B1","ValueMeaning":{"publicId":"7496251","version":"1","preferredName":"Found not to have MPAL by central confirmation of diagnostic specimen or incomplete testing, done as part of APEC14B1","longName":"7496251","preferredDefinition":"Found not to have MPAL by central confirmation of diagnostic specimen or incomplete testing, done as part of APEC14B1","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B371DC04-097E-5154-E053-4EBD850A6AAE","latestVersionIndicator":"Yes","beginDate":"2020-11-06","endDate":null,"createdBy":"WOODC","dateCreated":"2020-11-06","modifiedBy":"ONEDATA","dateModified":"2020-11-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B371DC04-0997-5154-E053-4EBD850A6AAE","beginDate":"2020-11-06","endDate":null,"createdBy":"WOODC","dateCreated":"2020-11-06","modifiedBy":"ONEDATA","dateModified":"2020-11-06","deletedIndicator":"No"},{"value":"303","valueDescription":"Use of radiation therapy other than cranial and testicular radiation as defined in the protocol.","ValueMeaning":{"publicId":"7496252","version":"1","preferredName":"Use of radiation therapy other than cranial and testicular radiation as defined in the protocol.","longName":"7496252","preferredDefinition":"Use of radiation therapy other than cranial and testicular radiation as defined in the protocol.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3621C69-F982-528C-E053-4EBD850A8905","latestVersionIndicator":"Yes","beginDate":"2020-11-06","endDate":null,"createdBy":"WOODC","dateCreated":"2020-11-06","modifiedBy":"ONEDATA","dateModified":"2020-11-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3621C69-F99B-528C-E053-4EBD850A8905","beginDate":"2020-11-06","endDate":null,"createdBy":"WOODC","dateCreated":"2020-11-06","modifiedBy":"ONEDATA","dateModified":"2020-11-06","deletedIndicator":"No"},{"value":"282","valueDescription":"Patient never received protocol therapy","ValueMeaning":{"publicId":"7457499","version":"1","preferredName":"Patient never received protocol therapy","longName":"7457499","preferredDefinition":"Patient never received protocol therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B0FFAE60-CCDD-0EE9-E053-4EBD850A2967","latestVersionIndicator":"Yes","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B0FFAE60-CCF6-0EE9-E053-4EBD850A2967","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","deletedIndicator":"No"},{"value":"281","valueDescription":"An acute neurological event or condition with an observable change in clinical presentation that would compromise the validity of further cognitive testing","ValueMeaning":{"publicId":"7457500","version":"1","preferredName":"An acute neurological event or condition with an observable change in clinical presentation that would compromise the validity of further cognitive testing","longName":"7457500","preferredDefinition":"An acute neurological event or condition with an observable change in clinical presentation that would compromise the validity of further cognitive testing","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B0FFAE60-CD00-0EE9-E053-4EBD850A2967","latestVersionIndicator":"Yes","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B0FFAE60-CD19-0EE9-E053-4EBD850A2967","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","deletedIndicator":"No"},{"value":"280","valueDescription":"Patient requires emergency unblinding","ValueMeaning":{"publicId":"7457501","version":"1","preferredName":"Patient requires emergency unblinding","longName":"7457501","preferredDefinition":"Patient requires emergency unblinding","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B0FFAE60-CD23-0EE9-E053-4EBD850A2967","latestVersionIndicator":"Yes","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B0FFAE60-CD3C-0EE9-E053-4EBD850A2967","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","deletedIndicator":"No"},{"value":"307","valueDescription":"Withdrawal of consent by patient/family/guardian for any further required observation or data submission","ValueMeaning":{"publicId":"7640476","version":"1","preferredName":"Withdrawal of consent by patient/family/guardian for any further required observation or data submission","longName":"7640476","preferredDefinition":"Withdrawal of consent by patient/family/guardian for any further required observation or data submission","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C0A8FA94-3AE8-5A4F-E053-4EBD850A088A","latestVersionIndicator":"Yes","beginDate":"2021-04-23","endDate":null,"createdBy":"LEEW","dateCreated":"2021-04-23","modifiedBy":"ONEDATA","dateModified":"2021-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C0A8FA94-3B01-5A4F-E053-4EBD850A088A","beginDate":"2021-04-23","endDate":null,"createdBy":"LEEW","dateCreated":"2021-04-23","modifiedBy":"ONEDATA","dateModified":"2021-04-23","deletedIndicator":"No"},{"value":"306","valueDescription":"The fifth anniversary of the most recent date of patient enrollment onto a PedAL or COG therapeutic protocol","ValueMeaning":{"publicId":"7640477","version":"1","preferredName":"The fifth anniversary of the most recent date of patient enrollment onto a PedAL or COG therapeutic protocol","longName":"7640477","preferredDefinition":"The fifth anniversary of the most recent date of patient enrollment onto a PedAL or COG therapeutic protocol","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C0A8FA94-3B0B-5A4F-E053-4EBD850A088A","latestVersionIndicator":"Yes","beginDate":"2021-04-23","endDate":null,"createdBy":"LEEW","dateCreated":"2021-04-23","modifiedBy":"ONEDATA","dateModified":"2021-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C0A8FA94-3B24-5A4F-E053-4EBD850A088A","beginDate":"2021-04-23","endDate":null,"createdBy":"LEEW","dateCreated":"2021-04-23","modifiedBy":"ONEDATA","dateModified":"2021-04-23","deletedIndicator":"No"},{"value":"305","valueDescription":"Three years from the date of patient enrollment onto APAL2020SC if enrolling site failed to obtain an evaluable sample associated with APAL2020SC enrollment with no plans to submit subsequent samples","ValueMeaning":{"publicId":"7640478","version":"1","preferredName":"Three years from the date of patient enrollment onto APAL2020SC if enrolling site failed to obtain an evaluable sample associated with APAL2020SC enrollment with no plans to submit subsequent samples","longName":"7640478","preferredDefinition":"Three years from the date of patient enrollment onto APAL2020SC if enrolling site failed to obtain an evaluable sample associated with APAL2020SC enrollment with no plans to submit subsequent samples","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C0A8FA94-3B2E-5A4F-E053-4EBD850A088A","latestVersionIndicator":"Yes","beginDate":"2021-04-23","endDate":null,"createdBy":"LEEW","dateCreated":"2021-04-23","modifiedBy":"ONEDATA","dateModified":"2021-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C0A8FA94-3B47-5A4F-E053-4EBD850A088A","beginDate":"2021-04-23","endDate":null,"createdBy":"LEEW","dateCreated":"2021-04-23","modifiedBy":"ONEDATA","dateModified":"2021-04-23","deletedIndicator":"No"},{"value":"304","valueDescription":"Five years from the date of patient enrollment onto APAL2020SC if not enrolled onto a sub-protocol","ValueMeaning":{"publicId":"7640479","version":"1","preferredName":"Five years from the date of patient enrollment onto APAL2020SC if not enrolled onto a sub-protocol","longName":"7640479","preferredDefinition":"Five years from the date of patient enrollment onto APAL2020SC if not enrolled onto a sub-protocol","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C0A8FA94-3B51-5A4F-E053-4EBD850A088A","latestVersionIndicator":"Yes","beginDate":"2021-04-23","endDate":null,"createdBy":"LEEW","dateCreated":"2021-04-23","modifiedBy":"ONEDATA","dateModified":"2021-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C0A8FA94-3B6A-5A4F-E053-4EBD850A088A","beginDate":"2021-04-23","endDate":null,"createdBy":"LEEW","dateCreated":"2021-04-23","modifiedBy":"ONEDATA","dateModified":"2021-04-23","deletedIndicator":"No"},{"value":"202","valueDescription":"Less Than Complete Remission Or Partial Remission With Normal Tumor Marker","ValueMeaning":{"publicId":"7589442","version":"1","preferredName":"Less Than Complete Remission Or Partial Remission With Normal Tumor Marker","longName":"7589442","preferredDefinition":"A statement about the relative size or order of two objects specifying that an object of interest is smaller than another object in quantity or measure or value or status.: The disappearance of all signs of cancer in response to treatment.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.: Used to indicate the presence of something or someone.: Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm.: A substance that may be found in tumor tissue or released from a tumor into the blood or other body fluids. A high level of a tumor marker may mean that a certain type of cancer is in the body. Examples of tumor markers include CA 125 (in ovarian cancer), CA 15-3 (in breast cancer), CEA (in ovarian, lung, breast, pancreas, and gastrointestinal tract cancers), and PSA (in prostate cancer).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Less Than","conceptCode":"C61585","definition":"A statement about the relative size or order of two objects specifying that an object of interest is smaller than another object in quantity or measure or value or status.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Complete Remission","conceptCode":"C4870","definition":"The disappearance of all signs of cancer in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Partial Remission","conceptCode":"C18058","definition":"A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"With","conceptCode":"C62355","definition":"Used to indicate the presence of something or someone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Normal","conceptCode":"C14165","definition":"Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Tumor Marker","conceptCode":"C17220","definition":"A substance present in or produced by a tumor or by the host, that can be used for differentiating neoplastic from normal tissue based on measurements in body fluids, secretions, cells, and/or tissues. Markers are used in diagnosis, staging and prognosis of cancer, provide an estimation of tumor burden, and serve for monitoring effects of therapy, detecting recurrence, localization of tumors, and screening in general populations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BCA52952-85EC-05A3-E053-4EBD850A9B06","latestVersionIndicator":"Yes","beginDate":"2021-03-03","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2021-03-03","modifiedBy":"ONEDATA","dateModified":"2021-03-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BCABF94E-83F8-2A72-E053-4EBD850A34DB","beginDate":"2021-03-03","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2021-03-03","modifiedBy":"ONEDATA","dateModified":"2021-03-03","deletedIndicator":"No"},{"value":"308","valueDescription":"Three years from the date of patient enrollment onto APAL2020SC if the diagnosis of relapsed AML, ALL, or MPAL cannot be confirmed","ValueMeaning":{"publicId":"7640493","version":"1","preferredName":"Three years from the date of patient enrollment onto APAL2020SC if the diagnosis of relapsed AML, ALL, or MPAL cannot be confirmed","longName":"7640493","preferredDefinition":"Three years from the date of patient enrollment onto APAL2020SC if the diagnosis of relapsed AML, ALL, or MPAL cannot be confirmed","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C0AA51B9-585F-70DD-E053-4EBD850AC22D","latestVersionIndicator":"Yes","beginDate":"2021-04-23","endDate":null,"createdBy":"LEEW","dateCreated":"2021-04-23","modifiedBy":"KUMMEROA","dateModified":"2023-12-06","changeDescription":null,"administrativeNotes":"2023.9.5 Alt VM Name added per ticket request CADSR0002816. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C0E31572-FC57-2CF6-E053-4EBD850AEECB","beginDate":"2021-04-23","endDate":null,"createdBy":"LEEW","dateCreated":"2021-04-26","modifiedBy":"ONEDATA","dateModified":"2021-04-26","deletedIndicator":"No"},{"value":"88","valueDescription":"Therapeutic Procedure Initiation Timeline Unmet","ValueMeaning":{"publicId":"7582191","version":"1","preferredName":"Therapeutic Procedure Initiation Timeline Unmet","longName":"7582191","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.: The act of starting something; an act that sets in motion some course of events.: A chronological schedule of when activities or events occurred or will occur.: A need or request was not fulfilled.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Initiation","conceptCode":"C47938","definition":"The act of starting something; an act that sets in motion some course of events.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Timeline","conceptCode":"C54576","definition":"A chronological schedule of when activities or events occurred or will occur.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Unmet","conceptCode":"C99757","definition":"A need or request was not fulfilled.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BBB6EA1D-78C2-7768-E053-4EBD850A074A","latestVersionIndicator":"Yes","beginDate":"2021-02-19","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2021-02-19","modifiedBy":"ONEDATA","dateModified":"2021-02-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BBB6EA1D-78DB-7768-E053-4EBD850A074A","beginDate":"2021-02-19","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2021-02-19","modifiedBy":"ONEDATA","dateModified":"2021-02-19","deletedIndicator":"No"},{"value":"203","valueDescription":"Therapeutic Procedure Timing","ValueMeaning":{"publicId":"7595546","version":"1","preferredName":"Therapeutic Procedure Timing","longName":"7595546","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.: The chronological relationship between temporal events.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Timing","conceptCode":"C80484","definition":"The chronological relationship between temporal events.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD5B856B-E9A3-1705-E053-4EBD850ADA4F","latestVersionIndicator":"Yes","beginDate":"2021-03-12","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2021-03-12","modifiedBy":"ONEDATA","dateModified":"2021-03-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BD5B856B-E9BE-1705-E053-4EBD850ADA4F","beginDate":"2021-03-12","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2021-03-12","modifiedBy":"ONEDATA","dateModified":"2021-03-12","deletedIndicator":"No"},{"value":"231","valueDescription":"Patient developed graft failure","ValueMeaning":{"publicId":"7652878","version":"1","preferredName":"Patient developed graft failure","longName":"7652878","preferredDefinition":"Patient developed graft failure","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C1FF6961-E529-743F-E053-4EBD850AED28","latestVersionIndicator":"Yes","beginDate":"2021-05-10","endDate":null,"createdBy":"COOPERJ","dateCreated":"2021-05-10","modifiedBy":"ONEDATA","dateModified":"2021-05-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C1FF6961-E542-743F-E053-4EBD850AED28","beginDate":"2021-05-10","endDate":null,"createdBy":"COOPERJ","dateCreated":"2021-05-10","modifiedBy":"ONEDATA","dateModified":"2021-05-10","deletedIndicator":"No"},{"value":"70","valueDescription":"Diagnosis Criterion Unmet","ValueMeaning":{"publicId":"7582185","version":"1","preferredName":"Diagnosis Criterion Unmet","longName":"7582185","preferredDefinition":"The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.: That which constitutes a standard from which a judgment can be established, a reference point against which other things can be evaluated, or a basis for comparison.: A need or request was not fulfilled.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diagnosis","conceptCode":"C15220","definition":"The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Criterion","conceptCode":"C25466","definition":"That which constitutes a standard from which a judgment can be established, a reference point against which other things can be evaluated, or a basis for comparison.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Unmet","conceptCode":"C99757","definition":"A need or request was not fulfilled.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BBB6C938-4A80-16AF-E053-4EBD850AC77D","latestVersionIndicator":"Yes","beginDate":"2021-02-19","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2021-02-19","modifiedBy":"ONEDATA","dateModified":"2021-02-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BBB6C938-4A99-16AF-E053-4EBD850AC77D","beginDate":"2021-02-19","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2021-02-19","modifiedBy":"ONEDATA","dateModified":"2021-02-19","deletedIndicator":"No"},{"value":"118","valueDescription":"Treating Physician Disagreement With Central Reviewer","ValueMeaning":{"publicId":"7577463","version":"1","preferredName":"Treating Physician Disagreement With Central Reviewer","longName":"7577463","preferredDefinition":"Providing treatment for.: A doctor; a person who has been educated, trained, and licensed to practice the art and science of medicine; a practitioner of medicine, as contrasted with a surgeon.: Inconsistency or lack of agreement between data, facts, claims, or opinions.: Used to indicate the presence of something or someone.: A single person who critically evaluates and reports on laboratory test results, protocols, or other data.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Treating","conceptCode":"C25705","definition":"Providing treatment for.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Physician","conceptCode":"C25741","definition":"A doctor; a person who has been educated, trained, and licensed to practice the art and science of medicine; a practitioner of medicine, as contrasted with a surgeon.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Disagreement","conceptCode":"C54274","definition":"Inconsistency or lack of agreement between data, facts, claims, or opinions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"With","conceptCode":"C62355","definition":"Used to indicate the presence of something or someone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Central Reviewer","conceptCode":"C51807","definition":"A single person who critically evaluates and reports on laboratory test results, protocols, or other data.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BB2B65D6-AC7F-71F0-E053-4EBD850A631D","latestVersionIndicator":"Yes","beginDate":"2021-02-12","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2021-02-12","modifiedBy":"ONEDATA","dateModified":"2021-02-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BB2B65D6-AC98-71F0-E053-4EBD850A631D","beginDate":"2021-02-12","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2021-02-12","modifiedBy":"ONEDATA","dateModified":"2021-02-12","deletedIndicator":"No"},{"value":"Pregnancy","valueDescription":"Pregnancy","ValueMeaning":{"publicId":"2570603","version":"1","preferredName":"Pregnancy","longName":"2570603","preferredDefinition":"Pregnancy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E0D8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-06-21","endDate":null,"createdBy":"SBR","dateCreated":"2004-06-21","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C850CBE7-C7A4-468B-E053-4EBD850AFBCA","beginDate":"2021-07-30","endDate":null,"createdBy":"MACASAC","dateCreated":"2021-07-30","modifiedBy":"ONEDATA","dateModified":"2021-07-30","deletedIndicator":"No"},{"value":"Unacceptable toxicity due to protocol therapy (See Section 5.0)","valueDescription":"Unacceptable toxicity due to protocol therapy","ValueMeaning":{"publicId":"4264211","version":"1","preferredName":"Unacceptable toxicity due to protocol therapy","longName":"4264211","preferredDefinition":"Unacceptable toxicity due to protocol therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F64209E0-D65C-49EF-E040-BB89AD43331D","latestVersionIndicator":"Yes","beginDate":"2014-04-04","endDate":null,"createdBy":"TSANE","dateCreated":"2014-04-04","modifiedBy":"KUMMEROA","dateModified":"2022-11-30","changeDescription":null,"administrativeNotes":"2022.11.30 Alt VM added for ticket request CADSR0001748. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C850CBE7-C7B8-468B-E053-4EBD850AFBCA","beginDate":"2021-07-30","endDate":null,"createdBy":"MACASAC","dateCreated":"2021-07-30","modifiedBy":"ONEDATA","dateModified":"2021-07-30","deletedIndicator":"No"},{"value":"Completion of planned therapy","valueDescription":"Completion of planned therapy","ValueMeaning":{"publicId":"3397022","version":"1","preferredName":"Completion of planned therapy","longName":"3397022","preferredDefinition":"Completion of planned therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA34F3E4-9168-41C1-E040-BB89AD433B93","latestVersionIndicator":"Yes","beginDate":"2012-03-01","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-03-01","modifiedBy":"KUMMEROA","dateModified":"2022-10-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C850CBE7-C7C2-468B-E053-4EBD850AFBCA","beginDate":"2021-07-30","endDate":null,"createdBy":"MACASAC","dateCreated":"2021-07-30","modifiedBy":"ONEDATA","dateModified":"2021-07-30","deletedIndicator":"No"},{"value":"Refusal of further protocol therapy by patient/parent/guardian.","valueDescription":"Refusal of further protocol therapy by patient/parent/guardian.","ValueMeaning":{"publicId":"7751533","version":"1","preferredName":"Refusal of further protocol therapy by patient/parent/guardian","longName":"7751533v1.00","preferredDefinition":"Refusal of further protocol therapy by patient/parent/guardian","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C832A742-DD4E-4049-E053-4EBD850AE448","latestVersionIndicator":"Yes","beginDate":"2021-07-28","endDate":null,"createdBy":"MACASAC","dateCreated":"2021-07-28","modifiedBy":"CLOHNES","dateModified":"2022-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C832A742-DD67-4049-E053-4EBD850AE448","beginDate":"2021-07-28","endDate":null,"createdBy":"MACASAC","dateCreated":"2021-07-28","modifiedBy":"ONEDATA","dateModified":"2021-07-28","deletedIndicator":"No"},{"value":"Patients whose institutional FOXO1 status cannot be confirmed within 4 weeks (28 days) of study entry (See Section 3.3.2)","valueDescription":"Patients whose institutional FOXO1 status cannot be confirmed within 4 weeks (28 days) of study entry (See Section 3.3.2)","ValueMeaning":{"publicId":"7743408","version":"1","preferredName":"Patients whose institutional FOXO1 status cannot be confirmed within 4 weeks (28 days) of study entry (See Section 3.3.2)","longName":"7743408","preferredDefinition":"Patients whose institutional FOXO1 status cannot be confirmed within 4 weeks (28 days) of study entry (See Section 3.3.2)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C78282C7-4FA4-7481-E053-4EBD850A830E","latestVersionIndicator":"Yes","beginDate":"2021-07-19","endDate":null,"createdBy":"MACASAC","dateCreated":"2021-07-19","modifiedBy":"ONEDATA","dateModified":"2021-07-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C78282C7-4FBD-7481-E053-4EBD850A830E","beginDate":"2021-07-19","endDate":null,"createdBy":"MACASAC","dateCreated":"2021-07-19","modifiedBy":"ONEDATA","dateModified":"2021-07-19","deletedIndicator":"No"},{"value":"Patients whose institutions are unable to comply with local fusion testing protocol requirements (See Section 3.3.1)","valueDescription":"Patients whose institutions are unable to comply with local fusion testing protocol requirements (See Section 3.3.1)","ValueMeaning":{"publicId":"7743409","version":"1","preferredName":"Patients whose institutions are unable to comply with local fusion testing protocol requirements (See Section 3.3.1)","longName":"7743409","preferredDefinition":"Patients whose institutions are unable to comply with local fusion testing protocol requirements (See Section 3.3.1)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C78282C7-4FC7-7481-E053-4EBD850A830E","latestVersionIndicator":"Yes","beginDate":"2021-07-19","endDate":null,"createdBy":"MACASAC","dateCreated":"2021-07-19","modifiedBy":"ONEDATA","dateModified":"2021-07-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C78282C7-4FE0-7481-E053-4EBD850A830E","beginDate":"2021-07-19","endDate":null,"createdBy":"MACASAC","dateCreated":"2021-07-19","modifiedBy":"ONEDATA","dateModified":"2021-07-19","deletedIndicator":"No"},{"value":"Patients who are FOXO1 fusion negative and <10 years old (See Section 3.3.3)","valueDescription":"Patients who are FOXO1 fusion negative and <10 years old (See Section 3.3.3)","ValueMeaning":{"publicId":"7743410","version":"1","preferredName":"Patients who are FOXO1 fusion negative and <10 years old (See Section 3.3.3)","longName":"7743410","preferredDefinition":"Patients who are FOXO1 fusion negative and <10 years old (See Section 3.3.3)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C78282C7-4FEA-7481-E053-4EBD850A830E","latestVersionIndicator":"Yes","beginDate":"2021-07-19","endDate":null,"createdBy":"MACASAC","dateCreated":"2021-07-19","modifiedBy":"ONEDATA","dateModified":"2021-07-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C78282C7-5003-7481-E053-4EBD850A830E","beginDate":"2021-07-19","endDate":null,"createdBy":"MACASAC","dateCreated":"2021-07-19","modifiedBy":"ONEDATA","dateModified":"2021-07-19","deletedIndicator":"No"},{"value":"Withdrawal of consent for any further data submissions","valueDescription":"Withdrawal of consent for any further data submissions","ValueMeaning":{"publicId":"3389971","version":"1","preferredName":"Withdrawal of consent for any further data submissions","longName":"3389971","preferredDefinition":"Withdrawal of consent for any further data submissions","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA09DDE8-2B2B-B133-E040-BB89AD431578","latestVersionIndicator":"Yes","beginDate":"2012-02-28","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2012-02-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C7B75DFE-DC9B-2F37-E053-4EBD850A1BA3","beginDate":"2021-07-22","endDate":null,"createdBy":"MACASAC","dateCreated":"2021-07-22","modifiedBy":"ONEDATA","dateModified":"2021-07-22","deletedIndicator":"No"},{"value":"Lost to follow-up","valueDescription":"Lost To Follow-up","ValueMeaning":{"publicId":"2683428","version":"1","preferredName":"Lost To Follow-up","longName":"2683428v1.00","preferredDefinition":"Parted with; no longer held or possessed; incapable of being recovered or regained._Used as a function word to indicate direction, purpose, or movement._The process by which information about the health status of an individual is obtained after a study has officially closed; an activity that continues something that has already begun or that repeats something that has already been done.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lost","conceptCode":"C25560","definition":"Parted with; no longer held or possessed; incapable of being recovered or regained.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"To","conceptCode":"C65107","definition":"Used as a function word to indicate direction, purpose, or movement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Follow-Up","conceptCode":"C16033","definition":"The process by which information about the health status of an individual is obtained after a study has officially closed; an activity that continues something that has already begun or that repeats something that has already been done.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A967466-952B-58A9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-20","endDate":null,"createdBy":"JOSHUAT","dateCreated":"2007-09-20","modifiedBy":"KUMMEROA","dateModified":"2023-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C7B75DFE-DCB9-2F37-E053-4EBD850A1BA3","beginDate":"2021-07-22","endDate":null,"createdBy":"MACASAC","dateCreated":"2021-07-22","modifiedBy":"ONEDATA","dateModified":"2021-07-22","deletedIndicator":"No"},{"value":"Patient enrollment onto another COG study with tumor therapeutic intent (eg, at recurrence)","valueDescription":"Patient enrollment onto another COG study with tumor therapeutic intent (eg, at recurrence)","ValueMeaning":{"publicId":"4854741","version":"1","preferredName":"Patient enrollment onto another COG study with tumor therapeutic intent (eg, at recurrence)","longName":"4854741","preferredDefinition":"Patient enrollment onto another COG study with tumor therapeutic intent (eg, at recurrence)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"17E2BBDF-23FB-BAF3-E050-BB89AD43633F","latestVersionIndicator":"Yes","beginDate":"2015-06-06","endDate":null,"createdBy":"LEEW","dateCreated":"2015-06-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C7B75DFE-DCAF-2F37-E053-4EBD850A1BA3","beginDate":"2021-07-22","endDate":null,"createdBy":"MACASAC","dateCreated":"2021-07-22","modifiedBy":"ONEDATA","dateModified":"2021-07-22","deletedIndicator":"No"},{"value":"Death","valueDescription":"Death","ValueMeaning":{"publicId":"2956827","version":"1","preferredName":"Death","longName":"2956827","preferredDefinition":"The absence of life or state of being dead.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CASP1 Gene","conceptCode":"C26554","definition":"This gene plays a role in apoptosis, inflammation, septic shock, and wound healing.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"77039323-3A1F-00CF-E040-BB89AD43795B","latestVersionIndicator":"Yes","beginDate":"2009-10-28","endDate":null,"createdBy":"MAESKEB","dateCreated":"2009-10-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C7B75DFE-DCC3-2F37-E053-4EBD850A1BA3","beginDate":"2021-07-22","endDate":null,"createdBy":"MACASAC","dateCreated":"2021-07-22","modifiedBy":"ONEDATA","dateModified":"2021-07-22","deletedIndicator":"No"},{"value":"Repeat eligibility studies (if required) prior to the initiation of protocol therapy are outside the parameters required for eligibility (see Section 3.2).","valueDescription":"Repeat eligibility studies (if required) prior to the initiation of protocol therapy are outside the parameters required for eligibility (see Section 3.2).","ValueMeaning":{"publicId":"4844451","version":"1","preferredName":"Repeat eligibility studies (if required) prior to the initiation of protocol therapy are outside the parameters required for eligibility (see Section 3.2).","longName":"4844451","preferredDefinition":"Repeat eligibility studies (if required) prior to the initiation of protocol therapy are outside the parameters required for eligibility (see Section 3.2).","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"178C9BEE-92C0-C0D5-E050-BB89AD433B48","latestVersionIndicator":"Yes","beginDate":"2015-06-02","endDate":null,"createdBy":"LEEW","dateCreated":"2015-06-02","modifiedBy":"KUMMEROA","dateModified":"2022-10-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C7B75DFE-DCD7-2F37-E053-4EBD850A1BA3","beginDate":"2021-07-22","endDate":null,"createdBy":"MACASAC","dateCreated":"2021-07-22","modifiedBy":"ONEDATA","dateModified":"2021-07-22","deletedIndicator":"No"},{"value":"Development of second malignancy","valueDescription":"Development of second malignancy","ValueMeaning":{"publicId":"3389975","version":"1","preferredName":"Development of second malignancy","longName":"3389975v1.00","preferredDefinition":"Processes that involve and promote formation of more mature organs, organ systems, or organisms; general development. (NCI)_Coming next after the first in position in space or time or degree or magnitude._A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Development","conceptCode":"C18732","definition":"Processes that involve and promote formation of more mature organs, organ systems, or organisms; general development. (NCI)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Second","conceptCode":"C25666","definition":"Coming next after the first in position in space or time or degree or magnitude.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Malignant Neoplasm","conceptCode":"C9305","definition":"A neoplasm composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA09DDE8-2BD7-B133-E040-BB89AD431578","latestVersionIndicator":"Yes","beginDate":"2012-02-28","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2012-02-28","modifiedBy":"KUMMEROA","dateModified":"2023-01-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C7B75DFE-DCEB-2F37-E053-4EBD850A1BA3","beginDate":"2021-07-22","endDate":null,"createdBy":"MACASAC","dateCreated":"2021-07-22","modifiedBy":"ONEDATA","dateModified":"2021-07-22","deletedIndicator":"No"},{"value":"Physician determines it is in patient's best interest","valueDescription":"Physician determines it is in patient's best interest","ValueMeaning":{"publicId":"3389976","version":"1","preferredName":"Physician determines it is in patient's best interest","longName":"3389976","preferredDefinition":"Physician determines it is in patient's best interest","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA09DDE8-2BFA-B133-E040-BB89AD431578","latestVersionIndicator":"Yes","beginDate":"2012-02-28","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2012-02-28","modifiedBy":"KUMMEROA","dateModified":"2022-10-05","changeDescription":"inverted quesiton mark changed to apostrophe 03-30-2018 DW","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C7B75DFE-DCFF-2F37-E053-4EBD850A1BA3","beginDate":"2021-07-22","endDate":null,"createdBy":"MACASAC","dateCreated":"2021-07-22","modifiedBy":"ONEDATA","dateModified":"2021-07-22","deletedIndicator":"No"},{"value":"Refusal of further protocol therapy by patient/parent/guardian, including refusal of randomization","valueDescription":"Refusal of further protocol therapy by patient/parent/guardian","ValueMeaning":{"publicId":"3389978","version":"1","preferredName":"Refusal of further protocol therapy by patient/parent/guardian","longName":"3389978","preferredDefinition":"Refusal of further protocol therapy by patient/parent/guardian","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA09DDE8-2C40-B133-E040-BB89AD431578","latestVersionIndicator":"Yes","beginDate":"2012-02-28","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2012-02-28","modifiedBy":"PWEST","dateModified":"2013-09-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C7B75DFE-DD13-2F37-E053-4EBD850A1BA3","beginDate":"2021-07-22","endDate":null,"createdBy":"MACASAC","dateCreated":"2021-07-22","modifiedBy":"ONEDATA","dateModified":"2021-07-22","deletedIndicator":"No"},{"value":"Progressive disease","valueDescription":"Progressive disease","ValueMeaning":{"publicId":"5776731","version":"1","preferredName":"Progressive disease","longName":"5776731","preferredDefinition":"Progressive disease","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D6014CD-4D56-5B57-E053-F662850A6034","latestVersionIndicator":"Yes","beginDate":"2017-04-17","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2017-04-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C7B75DFE-DD1D-2F37-E053-4EBD850A1BA3","beginDate":"2021-07-22","endDate":null,"createdBy":"MACASAC","dateCreated":"2021-07-22","modifiedBy":"ONEDATA","dateModified":"2021-07-22","deletedIndicator":"No"},{"value":"Patient enrollment onto another COG anti-cancer therapeutic study (e.g. at recurrence)","valueDescription":"Patient enrollment onto another COG anti-cancer therapeutic study (e.g. at recurrence)","ValueMeaning":{"publicId":"7751604","version":"1","preferredName":"Patient enrollment onto another COG anti-cancer therapeutic study (e.g. at recurrence)","longName":"7751604","preferredDefinition":"Patient enrollment onto another COG anti-cancer therapeutic study (e.g. at recurrence)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C83CD55D-2546-160E-E053-4EBD850A2453","latestVersionIndicator":"Yes","beginDate":"2021-07-29","endDate":null,"createdBy":"MACASAC","dateCreated":"2021-07-29","modifiedBy":"ONEDATA","dateModified":"2021-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C83CD55D-255F-160E-E053-4EBD850A2453","beginDate":"2021-07-29","endDate":null,"createdBy":"MACASAC","dateCreated":"2021-07-29","modifiedBy":"ONEDATA","dateModified":"2021-07-29","deletedIndicator":"No"},{"value":"Development of a second malignancy.","valueDescription":"Development of a second malignancy.","ValueMeaning":{"publicId":"7751605","version":"1","preferredName":"Development of a second malignancy.","longName":"7751605","preferredDefinition":"Development of a second malignancy.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C83CD55D-2569-160E-E053-4EBD850A2453","latestVersionIndicator":"Yes","beginDate":"2021-07-29","endDate":null,"createdBy":"MACASAC","dateCreated":"2021-07-29","modifiedBy":"KUMMEROA","dateModified":"2022-10-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C83CD55D-2582-160E-E053-4EBD850A2453","beginDate":"2021-07-29","endDate":null,"createdBy":"MACASAC","dateCreated":"2021-07-29","modifiedBy":"ONEDATA","dateModified":"2021-07-29","deletedIndicator":"No"},{"value":"Physician determines it is in the patient's best interest.","valueDescription":"Physician determines it is in the patient's best interest.","ValueMeaning":{"publicId":"7751606","version":"1","preferredName":"Physician determines it is in the patient's best interest.","longName":"7751606","preferredDefinition":"Physician determines it is in the patient's best interest.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C83CD55D-258C-160E-E053-4EBD850A2453","latestVersionIndicator":"Yes","beginDate":"2021-07-29","endDate":null,"createdBy":"MACASAC","dateCreated":"2021-07-29","modifiedBy":"ONEDATA","dateModified":"2021-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C83CD55D-25A5-160E-E053-4EBD850A2453","beginDate":"2021-07-29","endDate":null,"createdBy":"MACASAC","dateCreated":"2021-07-29","modifiedBy":"ONEDATA","dateModified":"2021-07-29","deletedIndicator":"No"},{"value":"Development of a second malignancy","valueDescription":"Development of a second malignancy","ValueMeaning":{"publicId":"5083510","version":"1","preferredName":"Development of a second malignancy","longName":"5083510","preferredDefinition":"Development of a second malignancy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"26826FC3-5D7F-AEA2-E050-BB89AD433D3A","latestVersionIndicator":"Yes","beginDate":"2015-12-09","endDate":null,"createdBy":"MIRANDAA","dateCreated":"2015-12-09","modifiedBy":"CLOHNES","dateModified":"2022-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C83CDF49-4F08-26C8-E053-4EBD850AE1DD","beginDate":"2021-07-29","endDate":null,"createdBy":"MACASAC","dateCreated":"2021-07-29","modifiedBy":"KUMMEROA","dateModified":"2022-08-30","deletedIndicator":"No"},{"value":"309","valueDescription":"Patient never received cranial or craniospinal radiation treatment","ValueMeaning":{"publicId":"7757343","version":"1","preferredName":"Patient never received cranial or craniospinal radiation treatment","longName":"7757343","preferredDefinition":"Patient never received cranial or craniospinal radiation treatment","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C8AB063D-1C3D-6EC8-E053-4EBD850AC4D1","latestVersionIndicator":"Yes","beginDate":"2021-08-03","endDate":null,"createdBy":"COOPERJ","dateCreated":"2021-08-03","modifiedBy":"ONEDATA","dateModified":"2021-08-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C8AB063D-1C56-6EC8-E053-4EBD850AC4D1","beginDate":"2021-08-03","endDate":null,"createdBy":"COOPERJ","dateCreated":"2021-08-03","modifiedBy":"ONEDATA","dateModified":"2021-08-03","deletedIndicator":"No"},{"value":"186","valueDescription":"Patient has received 26 cycles OR two years of protocol therapy","ValueMeaning":{"publicId":"7975292","version":"1","preferredName":"Patient has received 26 cycles OR two years of protocol therapy","longName":"7975292","preferredDefinition":"Patient has received 26 cycles OR two years of protocol therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D2D391A9-03EE-4839-E053-4EBD850AB56B","latestVersionIndicator":"Yes","beginDate":"2021-12-10","endDate":null,"createdBy":"MENARDP","dateCreated":"2021-12-10","modifiedBy":"ONEDATA","dateModified":"2021-12-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D3B084FB-3A7D-259C-E053-4EBD850AB08F","beginDate":"2021-12-21","endDate":null,"createdBy":"MENARDP","dateCreated":"2021-12-21","modifiedBy":"ONEDATA","dateModified":"2021-12-21","deletedIndicator":"No"},{"value":"Patient has received 26 cycles OR two years of protocol therapy","valueDescription":"Patient has received 26 cycles OR two years of protocol therapy","ValueMeaning":{"publicId":"7975292","version":"1","preferredName":"Patient has received 26 cycles OR two years of protocol therapy","longName":"7975292","preferredDefinition":"Patient has received 26 cycles OR two years of protocol therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D2D391A9-03EE-4839-E053-4EBD850AB56B","latestVersionIndicator":"Yes","beginDate":"2021-12-10","endDate":null,"createdBy":"MENARDP","dateCreated":"2021-12-10","modifiedBy":"ONEDATA","dateModified":"2021-12-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D2D391A9-0407-4839-E053-4EBD850AB56B","beginDate":"2021-12-10","endDate":null,"createdBy":"MENARDP","dateCreated":"2021-12-10","modifiedBy":"ONEDATA","dateModified":"2021-12-10","deletedIndicator":"No"},{"value":"Appearance of one or more new lesions or unequivocal progression of non-target lesions (see Section 10.2.5.2) and refer to Section 10.2.1 for exceptions within the first 12 weeks of therapy","valueDescription":"Appearance of one or more new lesions or unequivocal progression of non-target lesions (see Section 10.2.5.2) and refer to Section 10.2.1 for exceptions within the first 12 weeks of therapy","ValueMeaning":{"publicId":"7165996","version":"1","preferredName":"Appearance of one or more new lesions or unequivocal progression of non-target lesions (see Section 10.2.5.2) and refer to Section 10.2.1 for exceptions within the first 12 weeks of therapy","longName":"7165996","preferredDefinition":"Appearance of one or more new lesions or unequivocal progression of non-target lesions (see Section 10.2.5.2) and refer to Section 10.2.1 for exceptions within the first 12 weeks of therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9E564FB5-3783-25E0-E053-F662850A9777","latestVersionIndicator":"Yes","beginDate":"2020-02-11","endDate":null,"createdBy":"TANGL","dateCreated":"2020-02-11","modifiedBy":"ONEDATA","dateModified":"2020-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D33961F5-014F-77CD-E053-4EBD850AE86E","beginDate":"2021-12-15","endDate":null,"createdBy":"MENARDP","dateCreated":"2021-12-15","modifiedBy":"ONEDATA","dateModified":"2021-12-15","deletedIndicator":"No"},{"value":"Resection of any lesions that are increasing in size at any time while on protocol therapy","valueDescription":"Resection of any lesions that are increasing in size at any time while on protocol therapy","ValueMeaning":{"publicId":"7977974","version":"1","preferredName":"Resection of any lesions that are increasing in size at any time while on protocol therapy","longName":"7977974","preferredDefinition":"Resection of any lesions that are increasing in size at any time while on protocol therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D33961F5-0159-77CD-E053-4EBD850AE86E","latestVersionIndicator":"Yes","beginDate":"2021-12-15","endDate":null,"createdBy":"MENARDP","dateCreated":"2021-12-15","modifiedBy":"ONEDATA","dateModified":"2021-12-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D33961F5-0172-77CD-E053-4EBD850AE86E","beginDate":"2021-12-15","endDate":null,"createdBy":"MENARDP","dateCreated":"2021-12-15","modifiedBy":"ONEDATA","dateModified":"2021-12-15","deletedIndicator":"No"},{"value":"Resection of any malignant lesion within the first 12 weeks of protocol therapy","valueDescription":"Resection of any malignant lesion within the first 12 weeks of protocol therapy","ValueMeaning":{"publicId":"7977975","version":"1","preferredName":"Resection of any malignant lesion within the first 12 weeks of protocol therapy","longName":"7977975","preferredDefinition":"Resection of any malignant lesion within the first 12 weeks of protocol therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D33961F5-017C-77CD-E053-4EBD850AE86E","latestVersionIndicator":"Yes","beginDate":"2021-12-15","endDate":null,"createdBy":"MENARDP","dateCreated":"2021-12-15","modifiedBy":"ONEDATA","dateModified":"2021-12-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D33961F5-0195-77CD-E053-4EBD850AE86E","beginDate":"2021-12-15","endDate":null,"createdBy":"MENARDP","dateCreated":"2021-12-15","modifiedBy":"ONEDATA","dateModified":"2021-12-15","deletedIndicator":"No"},{"value":"Response followed by  20% increase in total tumor burden from the nadir at any time during protocol therapy","valueDescription":"Response followed by  20% increase in total tumor burden from the nadir at any time during protocol therapy","ValueMeaning":{"publicId":"7977976","version":"1","preferredName":"Response followed by  20% increase in total tumor burden from the nadir at any time during protocol therapy","longName":"7977976","preferredDefinition":"Response followed by  20% increase in total tumor burden from the nadir at any time during protocol therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D33961F5-019F-77CD-E053-4EBD850AE86E","latestVersionIndicator":"Yes","beginDate":"2021-12-15","endDate":null,"createdBy":"MENARDP","dateCreated":"2021-12-15","modifiedBy":"ONEDATA","dateModified":"2021-12-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D33961F5-01B8-77CD-E053-4EBD850AE86E","beginDate":"2021-12-15","endDate":null,"createdBy":"MENARDP","dateCreated":"2021-12-15","modifiedBy":"ONEDATA","dateModified":"2021-12-15","deletedIndicator":"No"},{"value":"Progressive disease of  20% increase from baseline or nadir in total tumor burden at any time during protocol therapy","valueDescription":"Progressive disease of  20% increase from baseline or nadir in total tumor burden at any time during protocol therapy","ValueMeaning":{"publicId":"7977977","version":"1","preferredName":"Progressive disease of  20% increase from baseline or nadir in total tumor burden at any time during protocol therapy","longName":"7977977","preferredDefinition":"Progressive disease of  20% increase from baseline or nadir in total tumor burden at any time during protocol therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D33961F5-01C2-77CD-E053-4EBD850AE86E","latestVersionIndicator":"Yes","beginDate":"2021-12-15","endDate":null,"createdBy":"MENARDP","dateCreated":"2021-12-15","modifiedBy":"ONEDATA","dateModified":"2021-12-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D33961F5-01DB-77CD-E053-4EBD850AE86E","beginDate":"2021-12-15","endDate":null,"createdBy":"MENARDP","dateCreated":"2021-12-15","modifiedBy":"ONEDATA","dateModified":"2021-12-15","deletedIndicator":"No"},{"value":"277","valueDescription":"Patient never received initial vaccine dose by 3 months after enrollment","ValueMeaning":{"publicId":"8028951","version":"1","preferredName":"Patient never received initial vaccine dose by 3 months after enrollment","longName":"8028951","preferredDefinition":"Patient never received initial vaccine dose by 3 months after enrollment","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D7639432-43EF-6BF8-E053-4EBD850A407D","latestVersionIndicator":"Yes","beginDate":"2022-02-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2022-02-06","modifiedBy":"ONEDATA","dateModified":"2022-02-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D7639432-4408-6BF8-E053-4EBD850A407D","beginDate":"2022-02-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2022-02-06","modifiedBy":"ONEDATA","dateModified":"2022-02-06","deletedIndicator":"No"},{"value":"276","valueDescription":"Repeat eligibility studies (if required) prior to the initiation of vaccination are outside the parameters required for eligibility","ValueMeaning":{"publicId":"8028952","version":"1","preferredName":"Repeat eligibility studies (if required) prior to the initiation of vaccination are outside the parameters required for eligibility","longName":"8028952","preferredDefinition":"Repeat eligibility studies (if required) prior to the initiation of vaccination are outside the parameters required for eligibility","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D7639432-4412-6BF8-E053-4EBD850A407D","latestVersionIndicator":"Yes","beginDate":"2022-02-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2022-02-06","modifiedBy":"ONEDATA","dateModified":"2022-02-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D7639432-442B-6BF8-E053-4EBD850A407D","beginDate":"2022-02-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2022-02-06","modifiedBy":"ONEDATA","dateModified":"2022-02-06","deletedIndicator":"No"},{"value":"Completion of the final QOL assessment or the 3-month post-op Ct scan, whichever is later.","valueDescription":"Completion of the final QOL assessment or the 3-month post-op Ct scan, whichever is later.","ValueMeaning":{"publicId":"7992187","version":"1","preferredName":"Completion of the final QOL assessment or the 3-month post-op Ct scan, whichever is later.","longName":"7992187","preferredDefinition":"Completion of the final QOL assessment or the 3-month post-op Ct scan, whichever is later.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D3D8E738-2689-5542-E053-4EBD850A245B","latestVersionIndicator":"Yes","beginDate":"2021-12-23","endDate":null,"createdBy":"MACASAC","dateCreated":"2021-12-23","modifiedBy":"ONEDATA","dateModified":"2021-12-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D3D8E738-26A2-5542-E053-4EBD850A245B","beginDate":"2021-12-23","endDate":null,"createdBy":"MACASAC","dateCreated":"2021-12-23","modifiedBy":"ONEDATA","dateModified":"2021-12-23","deletedIndicator":"No"},{"value":"Adverse experience after first thoracic intervention of a planned staged procedure that would limit the ability to complete the second staged procedure.","valueDescription":"Adverse experience after first thoracic intervention of a planned staged procedure that would limit the ability to complete the second staged procedure.","ValueMeaning":{"publicId":"7992188","version":"1","preferredName":"Adverse experience after first thoracic intervention of a planned staged procedure that would limit the ability to complete the second staged procedure.","longName":"7992188","preferredDefinition":"Adverse experience after first thoracic intervention of a planned staged procedure that would limit the ability to complete the secoond staged procedure.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D3D8E738-26AC-5542-E053-4EBD850A245B","latestVersionIndicator":"Yes","beginDate":"2021-12-23","endDate":null,"createdBy":"MACASAC","dateCreated":"2021-12-23","modifiedBy":"ONEDATA","dateModified":"2021-12-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D3D8E738-26C5-5542-E053-4EBD850A245B","beginDate":"2021-12-23","endDate":null,"createdBy":"MACASAC","dateCreated":"2021-12-23","modifiedBy":"ONEDATA","dateModified":"2021-12-23","deletedIndicator":"No"},{"value":"Progressive disease at a site outside of the lung between 1st and 2nd procedure of a staged thoracic surgery.","valueDescription":"Progressive disease at a site outside of the lung between 1st and 2nd procedure of a staged thoracic surgery.","ValueMeaning":{"publicId":"7992189","version":"1","preferredName":"Progressive disease at a site outside of the lung between 1st and 2nd procedure of a staged thoracic surgery.","longName":"7992189","preferredDefinition":"Progressive disease at a site outside of the lung between 1st and 2nd procedure of a staged thoracic surgery.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D3D8E738-26CF-5542-E053-4EBD850A245B","latestVersionIndicator":"Yes","beginDate":"2021-12-23","endDate":null,"createdBy":"MACASAC","dateCreated":"2021-12-23","modifiedBy":"ONEDATA","dateModified":"2021-12-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D3D8E738-26E8-5542-E053-4EBD850A245B","beginDate":"2021-12-23","endDate":null,"createdBy":"MACASAC","dateCreated":"2021-12-23","modifiedBy":"ONEDATA","dateModified":"2021-12-23","deletedIndicator":"No"},{"value":"Refusal to accept the assigned surgery post-randomization by physician.","valueDescription":"Refusal to accept the assigned surgery post-randomization by physician.","ValueMeaning":{"publicId":"7992190","version":"1","preferredName":"Refusal to accept the assigned surgery post-randomization by physician.","longName":"7992190","preferredDefinition":"Refusal to accept the assigned surgery post-randomization by physician.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D3D8E738-26F2-5542-E053-4EBD850A245B","latestVersionIndicator":"Yes","beginDate":"2021-12-23","endDate":null,"createdBy":"MACASAC","dateCreated":"2021-12-23","modifiedBy":"ONEDATA","dateModified":"2021-12-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D3D8E738-270B-5542-E053-4EBD850A245B","beginDate":"2021-12-23","endDate":null,"createdBy":"MACASAC","dateCreated":"2021-12-23","modifiedBy":"ONEDATA","dateModified":"2021-12-23","deletedIndicator":"No"},{"value":"Refusal to accept the assigned surgery post-randomization by patient/parent/guardian.","valueDescription":"Refusal to accept the assigned surgery post-randomization by patient/parent/guardian.","ValueMeaning":{"publicId":"7992191","version":"1","preferredName":"Refusal to accept the assigned surgery post-randomization by patient/parent/guardian.","longName":"7992191","preferredDefinition":"Refusal to accept the assigned surgery post-randomization by patient/parent/guardian.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D3D8E738-2715-5542-E053-4EBD850A245B","latestVersionIndicator":"Yes","beginDate":"2021-12-23","endDate":null,"createdBy":"MACASAC","dateCreated":"2021-12-23","modifiedBy":"ONEDATA","dateModified":"2021-12-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D3D8E738-272E-5542-E053-4EBD850A245B","beginDate":"2021-12-23","endDate":null,"createdBy":"MACASAC","dateCreated":"2021-12-23","modifiedBy":"ONEDATA","dateModified":"2021-12-23","deletedIndicator":"No"},{"value":"Rapid central imaging review indicates the patient is not eligible.","valueDescription":"Rapid central imaging review indicates the patient is not eligible.","ValueMeaning":{"publicId":"7992199","version":"1","preferredName":"Rapid central imaging review indicates the patient is not eligible.","longName":"7992199","preferredDefinition":"Rapid central imaging review indicates the patient is not eligible.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D3D5DBCE-67F7-5A5E-E053-4EBD850AA195","latestVersionIndicator":"Yes","beginDate":"2021-12-23","endDate":null,"createdBy":"MACASAC","dateCreated":"2021-12-23","modifiedBy":"ONEDATA","dateModified":"2021-12-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D3D5DBCE-6810-5A5E-E053-4EBD850AA195","beginDate":"2021-12-23","endDate":null,"createdBy":"MACASAC","dateCreated":"2021-12-23","modifiedBy":"ONEDATA","dateModified":"2021-12-23","deletedIndicator":"No"},{"value":"Tenth anniversary of the date the patient was enrolled on this study.","valueDescription":"Tenth anniversary of the date the patient was enrolled on this study.","ValueMeaning":{"publicId":"7992200","version":"1","preferredName":"Tenth anniversary of the date the patient was enrolled on this study.","longName":"7992200","preferredDefinition":"Tent anniversary of the date the patient was enrolled on this study.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D3D5DBCE-681A-5A5E-E053-4EBD850AA195","latestVersionIndicator":"Yes","beginDate":"2021-12-23","endDate":null,"createdBy":"MACASAC","dateCreated":"2021-12-23","modifiedBy":"ONEDATA","dateModified":"2021-12-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D3D5DBCE-6833-5A5E-E053-4EBD850AA195","beginDate":"2021-12-23","endDate":null,"createdBy":"MACASAC","dateCreated":"2021-12-23","modifiedBy":"ONEDATA","dateModified":"2021-12-23","deletedIndicator":"No"},{"value":"History of defined psychiatric co-morbidities in a patient whose tumor is found to have an ALK aberration that would otherwise render the patient eligible for assignment to Arm E","valueDescription":"History of defined psychiatric co-morbidities in a patient whose tumor is found to have an ALK aberration that would otherwise render the patient eligible for assignment to Arm E","ValueMeaning":{"publicId":"8019049","version":"1","preferredName":"History of defined psychiatric co-morbidities in a patient whose tumor is found to have an ALK aberration that would otherwise render the patient eligible for assignment to Arm E","longName":"8019049","preferredDefinition":"History of defined psychiatric co-morbidities in a patient whose tumor is found to have an ALK aberration that would otherwise render the patient eligible for assignment to Arm E","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D6E64B1B-7387-5C30-E053-4EBD850A72DF","latestVersionIndicator":"Yes","beginDate":"2022-01-31","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2022-01-31","modifiedBy":"ONEDATA","dateModified":"2022-01-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D6E64B1B-73A0-5C30-E053-4EBD850A72DF","beginDate":"2022-01-31","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2022-01-31","modifiedBy":"ONEDATA","dateModified":"2022-01-31","deletedIndicator":"No"},{"value":"Refusal of further participation by patient/parent/guardian","valueDescription":"Refusal of further participation by patient/parent/guardian","ValueMeaning":{"publicId":"8040156","version":"1","preferredName":"Refusal of further participation by patient/parent/guardian","longName":"8040156","preferredDefinition":"Refusal of further participation by patient/parent/guardian","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D810D982-0097-6847-E053-4EBD850ADEE3","latestVersionIndicator":"Yes","beginDate":"2022-02-15","endDate":null,"createdBy":"COOPERJ","dateCreated":"2022-02-15","modifiedBy":"KUMMEROA","dateModified":"2022-10-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D810D982-00B0-6847-E053-4EBD850ADEE3","beginDate":"2022-02-15","endDate":null,"createdBy":"COOPERJ","dateCreated":"2022-02-15","modifiedBy":"ONEDATA","dateModified":"2022-02-15","deletedIndicator":"No"},{"value":"Cohort 1 Treatment failure","valueDescription":"Cohort 1 Treatment failure","ValueMeaning":{"publicId":"8119804","version":"1","preferredName":"Cohort 1 Treatment failure","longName":"8119804","preferredDefinition":"Cohort 1 Treatment failure","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DAFD5F66-F62D-554F-E053-4EBD850ABECA","latestVersionIndicator":"Yes","beginDate":"2022-03-24","endDate":null,"createdBy":"LEEW","dateCreated":"2022-03-24","modifiedBy":"ONEDATA","dateModified":"2022-03-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DAFD5F66-F646-554F-E053-4EBD850ABECA","beginDate":"2022-03-24","endDate":null,"createdBy":"LEEW","dateCreated":"2022-03-24","modifiedBy":"ONEDATA","dateModified":"2022-03-24","deletedIndicator":"No"},{"value":"310","valueDescription":"History of defined psychiatric co-morbidities in a patient whose tumor is found to have an ALK aberration that would otherwise render the patient eligible for assignment to Arm E","ValueMeaning":{"publicId":"8019049","version":"1","preferredName":"History of defined psychiatric co-morbidities in a patient whose tumor is found to have an ALK aberration that would otherwise render the patient eligible for assignment to Arm E","longName":"8019049","preferredDefinition":"History of defined psychiatric co-morbidities in a patient whose tumor is found to have an ALK aberration that would otherwise render the patient eligible for assignment to Arm E","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D6E64B1B-7387-5C30-E053-4EBD850A72DF","latestVersionIndicator":"Yes","beginDate":"2022-01-31","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2022-01-31","modifiedBy":"ONEDATA","dateModified":"2022-01-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D916D978-F3F2-04F4-E053-4EBD850A2870","beginDate":"2022-02-28","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2022-02-28","modifiedBy":"ONEDATA","dateModified":"2022-02-28","deletedIndicator":"No"},{"value":"Patients who are FOXO1 fusion positive.","valueDescription":"Patients who are FOXO1 fusion positive.","ValueMeaning":{"publicId":"8093293","version":"1","preferredName":"Patients who are FOXO1 fusion positive.","longName":"8093293","preferredDefinition":"Patients who are FOXO1 fusion positive.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DA783ACF-9EF8-1CA2-E053-4EBD850A8F20","latestVersionIndicator":"Yes","beginDate":"2022-03-18","endDate":null,"createdBy":"MACASAC","dateCreated":"2022-03-18","modifiedBy":"ONEDATA","dateModified":"2022-03-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DA783ACF-9F11-1CA2-E053-4EBD850A8F20","beginDate":"2022-03-18","endDate":null,"createdBy":"MACASAC","dateCreated":"2022-03-18","modifiedBy":"ONEDATA","dateModified":"2022-03-18","deletedIndicator":"No"},{"value":"Repeat eligibility studies (if required) prior to the initiation of protocol therapy are outside the parameters required for eligibility","valueDescription":"Repeat eligibility studies (if required) prior to the initiation of protocol therapy are outside the parameters required for eligibility","ValueMeaning":{"publicId":"6823642","version":"1","preferredName":"Repeat eligibility studies (if required) prior to the initiation of protocol therapy are outside the parameters required for eligibility","longName":"6823642","preferredDefinition":"Repeat eligibility studies (if required) prior to the initiation of protocol therapy are outside the parameters required for eligibility","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E5E3EAB-263B-1144-E053-F662850A9A06","latestVersionIndicator":"Yes","beginDate":"2019-07-23","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-23","modifiedBy":"KUMMEROA","dateModified":"2022-11-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DC25F827-990B-246E-E053-4EBD850A7617","beginDate":"2022-04-08","endDate":null,"createdBy":"LEEW","dateCreated":"2022-04-08","modifiedBy":"ONEDATA","dateModified":"2022-04-08","deletedIndicator":"No"},{"value":"Patient enrollment onto another COG anti-cancer therapy study","valueDescription":"Patient enrollment onto another COG anti-cancer therapy study","ValueMeaning":{"publicId":"8148228","version":"1","preferredName":"Patient enrollment onto another COG anti-cancer therapy study","longName":"8148228","preferredDefinition":"Patient enrollment onto another COG anti-cancer therapy study","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DC04ACBD-8010-15C3-E053-4EBD850AEB0C","latestVersionIndicator":"Yes","beginDate":"2022-04-06","endDate":null,"createdBy":"LEEW","dateCreated":"2022-04-06","modifiedBy":"ONEDATA","dateModified":"2022-04-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DC04ACBD-8029-15C3-E053-4EBD850AEB0C","beginDate":"2022-04-06","endDate":null,"createdBy":"LEEW","dateCreated":"2022-04-06","modifiedBy":"ONEDATA","dateModified":"2022-04-06","deletedIndicator":"No"},{"value":"Relapse or imminent relapse","valueDescription":null,"ValueMeaning":{"publicId":"10497259","version":"1","preferredName":"Relapse or imminent relapse","longName":"10497259v1.00","preferredDefinition":"Relapse or imminent relapse","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E181261B-7EC1-494B-E053-731AD00A555E","latestVersionIndicator":"Yes","beginDate":"2022-06-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-22","modifiedBy":"KUMMEROA","dateModified":"2022-06-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E181261B-7EC5-494B-E053-731AD00A555E","beginDate":"2022-06-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-07-18","modifiedBy":"KUMMEROA","dateModified":"2022-07-18","deletedIndicator":"No"},{"value":"Pregnancy before starting HCT conditioning","valueDescription":null,"ValueMeaning":{"publicId":"10497260","version":"1","preferredName":"Pregnancy before starting HCT conditioning","longName":"10497260v1.00","preferredDefinition":"Pregnancy before starting HCT conditioning","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E181261B-7EC2-494B-E053-731AD00A555E","latestVersionIndicator":"Yes","beginDate":"2022-06-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-22","modifiedBy":"KUMMEROA","dateModified":"2022-07-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E181261B-7EC6-494B-E053-731AD00A555E","beginDate":"2022-06-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-22","modifiedBy":"KUMMEROA","dateModified":"2022-06-22","deletedIndicator":"No"},{"value":"Does not meet criteria to receive HCT within week 12 post randomization","valueDescription":null,"ValueMeaning":{"publicId":"10497261","version":"1","preferredName":"Does not meet criteria to receive HCT within week 12 post randomization","longName":"10497261v1.00","preferredDefinition":"Does not meet criteria to receive HCT within week 12 post randomization","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E181261B-7EC3-494B-E053-731AD00A555E","latestVersionIndicator":"Yes","beginDate":"2022-06-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-22","modifiedBy":"KUMMEROA","dateModified":"2022-06-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E181261B-7EC7-494B-E053-731AD00A555E","beginDate":"2022-06-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-22","modifiedBy":"KUMMEROA","dateModified":"2022-06-22","deletedIndicator":"No"},{"value":"Patient enrollment onto another COG anti-cancer therapeutic study post HCT","valueDescription":null,"ValueMeaning":{"publicId":"10497262","version":"1","preferredName":"Patient enrollment onto another COG anti-cancer therapeutic study post HCT","longName":"10497262v1.00","preferredDefinition":"Patient enrollment onto another COG anti-cancer therapeutic study post HCT","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E181261B-7EC4-494B-E053-731AD00A555E","latestVersionIndicator":"Yes","beginDate":"2022-06-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-22","modifiedBy":"KUMMEROA","dateModified":"2022-06-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E181261B-7EC8-494B-E053-731AD00A555E","beginDate":"2022-06-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-22","modifiedBy":"KUMMEROA","dateModified":"2022-06-22","deletedIndicator":"No"},{"value":"283","valueDescription":null,"ValueMeaning":{"publicId":"10497259","version":"1","preferredName":"Relapse or imminent relapse","longName":"10497259v1.00","preferredDefinition":"Relapse or imminent relapse","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E181261B-7EC1-494B-E053-731AD00A555E","latestVersionIndicator":"Yes","beginDate":"2022-06-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-22","modifiedBy":"KUMMEROA","dateModified":"2022-06-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E4181B4D-6CDB-05DF-E053-731AD00A6D29","beginDate":"2022-07-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-07-18","modifiedBy":"KUMMEROA","dateModified":"2022-07-18","deletedIndicator":"No"},{"value":"236","valueDescription":null,"ValueMeaning":{"publicId":"10497261","version":"1","preferredName":"Does not meet criteria to receive HCT within week 12 post randomization","longName":"10497261v1.00","preferredDefinition":"Does not meet criteria to receive HCT within week 12 post randomization","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E181261B-7EC3-494B-E053-731AD00A555E","latestVersionIndicator":"Yes","beginDate":"2022-06-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-22","modifiedBy":"KUMMEROA","dateModified":"2022-06-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E453C504-D75B-51A5-E053-731AD00A3924","beginDate":"2022-07-21","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-07-21","modifiedBy":"KUMMEROA","dateModified":"2022-07-21","deletedIndicator":"No"},{"value":"311","valueDescription":null,"ValueMeaning":{"publicId":"10939476","version":"1","preferredName":"For suspected relapsed FHWT patients, retrospective central pathology review materials were not submitted within 6 weeks of enrollment on AREN1921","longName":"10939476v1.00","preferredDefinition":"For suspected relapsed FHWT patients, retrospective central pathology review materials were not submitted within 6 weeks of enrollment on AREN1921","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E56F0399-62CC-0F38-E053-731AD00A4684","latestVersionIndicator":"Yes","beginDate":"2022-08-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-08-04","modifiedBy":"KUMMEROA","dateModified":"2022-08-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E56F0399-62CD-0F38-E053-731AD00A4684","beginDate":"2022-08-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-08-04","modifiedBy":"KUMMEROA","dateModified":"2022-09-08","deletedIndicator":"No"},{"value":"402","valueDescription":null,"ValueMeaning":{"publicId":"11160675","version":"1","preferredName":"Receipt of non-protocol anti-cancer therapy (any therapy other than outlined in Section 4.0 and Section 13.0) to the study eye(s), including external beam radiation therapy to study eye or contralateral eye, or enucleation of study eye(s)","longName":"11160675v1.00","preferredDefinition":"Receipt of non-protocol anti-cancer therapy (any therapy other than outlined in Section 4.0 and Section 13.0) to the study eye(s), including external beam radiation therapy to study eye or contralateral eye, or enucleation of study eye(s)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E777ADD9-EE7A-57D1-E053-731AD00A5875","latestVersionIndicator":"Yes","beginDate":"2022-08-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-08-30","modifiedBy":"KUMMEROA","dateModified":"2022-10-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E777ADD9-EE7B-57D1-E053-731AD00A5875","beginDate":"2022-08-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-10-06","modifiedBy":"KUMMEROA","dateModified":"2022-10-06","deletedIndicator":"No"},{"value":"400","valueDescription":null,"ValueMeaning":{"publicId":"11167467","version":"1","preferredName":"Progressive disease in the vitreous seeds (as defined in Section 10.2.2) confirmed by rapid central review.","longName":"11167467v1.00","preferredDefinition":"Progressive disease in the vitreous seeds (as defined in Section 10.2.2) confirmed by rapid central review.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E78DD63D-485E-0B38-E053-731AD00A43E0","latestVersionIndicator":"Yes","beginDate":"2022-08-31","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-08-31","modifiedBy":"KUMMEROA","dateModified":"2022-10-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E78DD63D-4861-0B38-E053-731AD00A43E0","beginDate":"2022-08-31","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-10-06","modifiedBy":"KUMMEROA","dateModified":"2022-10-06","deletedIndicator":"No"},{"value":"401","valueDescription":null,"ValueMeaning":{"publicId":"11167468","version":"1","preferredName":"Progressive disease in subretinal seeds or retinal tumor (as defined in Section 10.2.2.2 and 10.2.2.3)","longName":"11167468v1.00","preferredDefinition":"Progressive disease in subretinal seeds or retinal tumor (as defined in Section 10.2.2.2 and 10.2.2.3)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E78DD63D-485F-0B38-E053-731AD00A43E0","latestVersionIndicator":"Yes","beginDate":"2022-08-31","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-08-31","modifiedBy":"KUMMEROA","dateModified":"2022-10-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E78DD63D-4862-0B38-E053-731AD00A43E0","beginDate":"2022-08-31","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-10-06","modifiedBy":"KUMMEROA","dateModified":"2022-10-06","deletedIndicator":"No"},{"value":"590","valueDescription":null,"ValueMeaning":{"publicId":"11167469","version":"1","preferredName":"Female patient of childbearing potential has a positive pregnancy test while receiving CVE chemotherapy.","longName":"11167469v1.00","preferredDefinition":"Female patient of childbearing potential has a positive pregnancy test while receiving CVE chemotherapy.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E78DD63D-4860-0B38-E053-731AD00A43E0","latestVersionIndicator":"Yes","beginDate":"2022-08-31","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-08-31","modifiedBy":"KUMMEROA","dateModified":"2022-10-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E78DD63D-4863-0B38-E053-731AD00A43E0","beginDate":"2022-08-31","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-08-31","modifiedBy":"KUMMEROA","dateModified":"2022-10-11","deletedIndicator":"No"},{"value":"216","valueDescription":null,"ValueMeaning":{"publicId":"12051857","version":"1","preferredName":"Change to ineligible chemotherapy regimen","longName":"12051857v1.00","preferredDefinition":"Change to ineligible chemotherapy regimen","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ED70866C-BBA0-5939-E053-731AD00A3B7E","latestVersionIndicator":"Yes","beginDate":"2022-11-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-11-14","modifiedBy":"KUMMEROA","dateModified":"2022-11-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ED70866C-BBA3-5939-E053-731AD00A3B7E","beginDate":"2022-11-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-11-14","modifiedBy":"KUMMEROA","dateModified":"2022-11-30","deletedIndicator":"No"},{"value":"217","valueDescription":null,"ValueMeaning":{"publicId":"12051859","version":"1","preferredName":"Patient never received asparaginase chemotherapy","longName":"12051859v1.00","preferredDefinition":"Patient never received asparaginase chemotherapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ED70866C-BBA2-5939-E053-731AD00A3B7E","latestVersionIndicator":"Yes","beginDate":"2022-11-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-11-14","modifiedBy":"KUMMEROA","dateModified":"2022-11-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ED70866C-BBA5-5939-E053-731AD00A3B7E","beginDate":"2022-11-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-11-14","modifiedBy":"KUMMEROA","dateModified":"2022-11-30","deletedIndicator":"No"},{"value":"Repeat eligibility laboratory studies (if required) are outside the parameters required for eligibility","valueDescription":null,"ValueMeaning":{"publicId":"13110850","version":"1","preferredName":"Repeat eligibility laboratory studies (if required) are outside the parameters required for eligibility","longName":"13110850v1.00","preferredDefinition":"Repeat eligibility laboratory studies (if required) are outside the parameters required for eligibility","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67ACE35-8D6A-483F-E053-731AD00A51F3","latestVersionIndicator":"Yes","beginDate":"2023-03-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-09","modifiedBy":"KUMMEROA","dateModified":"2023-03-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67ACE35-8D6B-483F-E053-731AD00A51F3","beginDate":"2023-03-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-09","modifiedBy":"KUMMEROA","dateModified":"2023-03-09","deletedIndicator":"No"},{"value":"New relapse on protocol therapy","valueDescription":null,"ValueMeaning":{"publicId":"13190982","version":"1","preferredName":"New relapse on protocol therapy","longName":"13190982v1.00","preferredDefinition":"New relapse on protocol therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F6E40A86-2D23-7F49-E053-731AD00AAD9E","latestVersionIndicator":"Yes","beginDate":"2023-03-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-14","modifiedBy":"KUMMEROA","dateModified":"2023-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F6E40A86-2D25-7F49-E053-731AD00AAD9E","beginDate":"2023-03-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-14","modifiedBy":"KUMMEROA","dateModified":"2023-03-14","deletedIndicator":"No"},{"value":"Regimen A patient does not complete post-Cycle 1 Callback per protocol (see Section 3.1.6)","valueDescription":null,"ValueMeaning":{"publicId":"13190983","version":"1","preferredName":"Regimen A patient does not complete post-Cycle 1 Callback per protocol (see Section 3.1.6)","longName":"13190983v1.00","preferredDefinition":"Regimen A patient does not complete post-Cycle 1 Callback per protocol (see Section 3.1.6)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F6E40A86-2D24-7F49-E053-731AD00AAD9E","latestVersionIndicator":"Yes","beginDate":"2023-03-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-14","modifiedBy":"KUMMEROA","dateModified":"2023-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F6E40A86-2D26-7F49-E053-731AD00AAD9E","beginDate":"2023-03-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-14","modifiedBy":"KUMMEROA","dateModified":"2023-03-14","deletedIndicator":"No"},{"value":"Start of anti-CMV antiviral medication as pre-emptive therapy","valueDescription":null,"ValueMeaning":{"publicId":"13341059","version":"1","preferredName":"Start of anti-CMV antiviral medication as pre-emptive therapy","longName":"13341059v1.00","preferredDefinition":"Start of anti-CMV antiviral medication as pre-emptive therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F913D3D3-DCA1-3334-E053-731AD00A028E","latestVersionIndicator":"Yes","beginDate":"2023-04-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-04-11","modifiedBy":"KUMMEROA","dateModified":"2023-04-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F913D3D3-DCA6-3334-E053-731AD00A028E","beginDate":"2023-04-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-04-11","modifiedBy":"KUMMEROA","dateModified":"2023-04-11","deletedIndicator":"No"},{"value":"Administration of currently available formulations of the study medication is not feasible","valueDescription":null,"ValueMeaning":{"publicId":"13341060","version":"1","preferredName":"Administration of currently available formulations of the study medication is not feasible","longName":"13341060v1.00","preferredDefinition":"Administration of currently available formulations of the study medication is not feasible","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F913D3D3-DCA2-3334-E053-731AD00A028E","latestVersionIndicator":"Yes","beginDate":"2023-04-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-04-11","modifiedBy":"KUMMEROA","dateModified":"2023-04-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F913D3D3-DCA7-3334-E053-731AD00A028E","beginDate":"2023-04-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-04-11","modifiedBy":"KUMMEROA","dateModified":"2023-04-11","deletedIndicator":"No"},{"value":"Positive plasma CMV PCR","valueDescription":null,"ValueMeaning":{"publicId":"13341061","version":"1","preferredName":"Positive plasma CMV PCR","longName":"13341061v1.00","preferredDefinition":"Positive plasma CMV PCR","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F913D3D3-DCA3-3334-E053-731AD00A028E","latestVersionIndicator":"Yes","beginDate":"2023-04-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-04-11","modifiedBy":"KUMMEROA","dateModified":"2023-04-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F913D3D3-DCA8-3334-E053-731AD00A028E","beginDate":"2023-04-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-04-11","modifiedBy":"KUMMEROA","dateModified":"2023-04-11","deletedIndicator":"No"},{"value":"Patient developed severe renal impairment or severe hepatic impairment","valueDescription":null,"ValueMeaning":{"publicId":"13341062","version":"1","preferredName":"Patient developed severe renal impairment or severe hepatic impairment","longName":"13341062v1.00","preferredDefinition":"Patient developed severe renal impairment or severe hepatic impairment","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F913D3D3-DCA4-3334-E053-731AD00A028E","latestVersionIndicator":"Yes","beginDate":"2023-04-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-04-11","modifiedBy":"GDEEN","dateModified":"2023-04-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F913D3D3-DCA9-3334-E053-731AD00A028E","beginDate":"2023-04-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-04-11","modifiedBy":"KUMMEROA","dateModified":"2023-04-11","deletedIndicator":"No"},{"value":"Patient did not receive transplant","valueDescription":null,"ValueMeaning":{"publicId":"13341063","version":"1","preferredName":"Patient did not receive transplant","longName":"13341063v1.00","preferredDefinition":"Patient did not receive transplant","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F913D3D3-DCA5-3334-E053-731AD00A028E","latestVersionIndicator":"Yes","beginDate":"2023-04-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-04-11","modifiedBy":"KUMMEROA","dateModified":"2023-04-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F913D3D3-DCAA-3334-E053-731AD00A028E","beginDate":"2023-04-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-04-11","modifiedBy":"KUMMEROA","dateModified":"2023-04-11","deletedIndicator":"No"},{"value":"Start of preparative regimen for subsequent transplant","valueDescription":null,"ValueMeaning":{"publicId":"13361717","version":"1","preferredName":"Begin Hematopoietic Cell Transplantation Preparative Regimen","longName":"13361717v1.00","preferredDefinition":"Have a beginning, in a temporal, spatial, or evaluative sense; the point in space or time where something begins._A therapeutic procedure that involves the transplantation of hematopoietic stem cells, either with the patient as their own donor or from a donor to a patient. This can be used for treatment of malignant and non-malignant diseases._The chemotherapy or radiation given prior to blood, marrow, cord blood transplant, or cell infusion to kill diseased cells and make space for the healthy new graft and/or suppress the immune system so rejection does not occur.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Begin","conceptCode":"C25431","definition":"Have a beginning, in a temporal, spatial, or evaluative sense; the point in space or time where something begins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Hematopoietic Cell Transplantation","conceptCode":"C15431","definition":"A therapeutic procedure that involves the transplantation of hematopoietic stem cells, either with the patient as their own donor or from a donor to a patient. This can be used for treatment of malignant and non-malignant diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Preparative Regimen","conceptCode":"C61155","definition":"The chemotherapy or radiation given prior to blood, marrow, cord blood transplant, or cell infusion to kill diseased cells and make space for the healthy new graft and/or suppress the immune system so rejection does not occur.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F94F91DA-E231-3AC4-E053-731AD00AFF87","latestVersionIndicator":"Yes","beginDate":"2023-04-14","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-04-14","modifiedBy":"GDEEN","dateModified":"2023-04-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F94F91DA-E232-3AC4-E053-731AD00AFF87","beginDate":"2023-04-14","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-04-14","modifiedBy":"GDEEN","dateModified":"2023-04-14","deletedIndicator":"No"},{"value":"312","valueDescription":null,"ValueMeaning":{"publicId":"14608597","version":"1","preferredName":"Found not to have MPAL and not be eligible as B-ALL upon by central assessment of a diagnostic specimen, or to have incomplete confirmatory testing, done as part of APEC14B1","longName":"14608597v1.00","preferredDefinition":"Found not to have MPAL and not be eligible as B-ALL upon by central assessment of a diagnostic specimen, or to have incomplete confirmatory testing, done as part of APEC14B1","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0A968BE0-EA43-1202-E063-731AD00A75C5","latestVersionIndicator":"Yes","beginDate":"2023-11-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-11-20","modifiedBy":"KUMMEROA","dateModified":"2023-11-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0A968BE0-EA45-1202-E063-731AD00A75C5","beginDate":"2023-11-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-11-20","modifiedBy":"KUMMEROA","dateModified":"2023-12-07","deletedIndicator":"No"},{"value":"313","valueDescription":null,"ValueMeaning":{"publicId":"14608598","version":"1","preferredName":"HR B-ALL patients randomized to Arm C but unable to receive at least one dose of Inotuzumab Ozogamicin in InO Block 2 due to toxicity","longName":"14608598v1.00","preferredDefinition":"HR B-ALL patients randomized to Arm C but unable to receive at least one dose of Inotuzumab Ozogamicin in InO Block 2 due to toxicity","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0A968BE0-EA44-1202-E063-731AD00A75C5","latestVersionIndicator":"Yes","beginDate":"2023-11-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-11-20","modifiedBy":"KUMMEROA","dateModified":"2023-11-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0A968BE0-EA46-1202-E063-731AD00A75C5","beginDate":"2023-11-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-11-20","modifiedBy":"KUMMEROA","dateModified":"2023-12-07","deletedIndicator":"No"},{"value":"Completion of the 3-month post-op CT scan","valueDescription":null,"ValueMeaning":{"publicId":"14741329","version":"1","preferredName":"Completion of the 3-month post-op CT scan","longName":"14741329v1.00","preferredDefinition":"Completion of the 3-month post-op CT scan","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"106748CF-F428-6673-E063-731AD00AC09A","latestVersionIndicator":"Yes","beginDate":"2024-02-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-02-02","modifiedBy":"KUMMEROA","dateModified":"2024-02-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"106748CF-F429-6673-E063-731AD00AC09A","beginDate":"2024-02-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-02-02","modifiedBy":"KUMMEROA","dateModified":"2024-02-02","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008554","version":"1","preferredName":"Treatment/Off-treatment Reasons","preferredDefinition":"justification for or explanation of the administration or cessation of therapy.","longName":"TX_OTX_RSNS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2C9BE32-8BDB-649C-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2322180","version":"1","preferredName":"Discontinued Reason","preferredDefinition":"Discontinued; stopped permanently or temporarily.:An explanation of the cause of some phenomenon or action.","longName":"C25484:C25638","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Discontinue","conceptCode":"C25484","definition":"To stop or end, permanently or temporarily.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Reason","conceptCode":"C25638","definition":"An explanation of the cause of some phenomenon or action.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD0F852B-04CD-7140-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-08-02","modifiedBy":"ONEDATA","dateModified":"2005-08-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA09DDE8-2B0C-B133-E040-BB89AD431578","latestVersionIndicator":"Yes","beginDate":"2012-02-28","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2012-02-28","modifiedBy":"KUMMEROA","dateModified":"2024-02-02","changeDescription":"Added new values requested by user. Changed from CTEP to COG for by script Thu Jan 2 10:00:57 EST 2014","administrativeNotes":"2024.2.2 PV added per ticket request CADSR0003361. ak 2023.11.20 PVs added per ticket request CADSR0003092. ak 2023.3.9 PV added per ticket request CADSR0002119. ak 2022.8.4 Added PV. ak 2022.8.31 Added PVs for ticket request CADSR0001468. ak. 2022.11.9 Added PV for ticket request CADSR0001670. cjl; 2022.11.14 PVs added for ticket request CADSR0001676. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Reason patient is off study:","type":"Preferred Question Text","description":"Reason patient is off study:","url":null,"context":"COG"},{"name":"COG CRF TEXT 1","type":"Alternate Question Text","description":"Reason off Study","url":null,"context":"COG"},{"name":"COG CRF TEXT 2","type":"Alternate Question Text","description":"If Off Study, Reason patient is off study:","url":null,"context":"COG"},{"name":"COG CRF Text 11","type":"Alternate Question Text","description":"Off Study Reason:","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E7EDB2C8-D25B-672C-E040-BB89AD43143B","latestVersionIndicator":"Yes","beginDate":"2013-10-04","endDate":null,"createdBy":"WONGW","dateCreated":"2013-10-04","modifiedBy":"LEEW","dateModified":"2021-05-04","changeDescription":"Changed from CTEP to COG for by script Thu Jan 2 10:00:57 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}